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Abstract 
 
Aims: To examine the metabolic changes associated with LVH secondary to AS, to 
examine the role of GIK as an adjunct to myocardial protection during AVR, and to 
examine the mechanism of its action. 
 
Methods:  Patients undergoing AVR for AS with evidence of LVH were randomly 
assigned to GIK or placebo. The trial was double blind and conducted at a single 
centre. The primary outcome was the incidence of low cardiac output syndrome. Left 
ventricular biopsies were analysed to assess changes in 5' adenosine 
monophosphate-activated protein kinase (AMPK) and Akt phosphorylation; and 
protein O-linked beta N-acetylglucosamination (O-GlcNAcylation).  217 patients were 
randomised over a four year period (107 control; 110 GIK). 
 
Results: GIK treatment was associated with a significant reduction in the incidence 
of low cardiac output state (OR 0.22, p= 0.0001), and a significant reduction in 
inotrope use 6 to 12 hours postoperatively, (OR 0.30, p=0.0007). These changes 
were associated with a substantial increase in AMPK and Akt phosphorylation and a 
significant increase in the O-GlcNAcylation of selected protein bands. 
 
Conclusions:  Peri-operative treatment with GIK was associated with a significant 
reduction in the incidence of low cardiac output state and the need for inotropic 
support. This benefit was associated with increased signalling protein 
phosphorylation and O-GlcNAcylation.  Multi-centre studies and late follow up will 
determine if routine use of GIK improves patient prognosis  
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1.  Aortic Stenosis 
1.1 Background 
Obstruction to the left ventricular (LV) outflow tract is localised most commonly at the 
aortic valve.  In the developed world the most common acquired cause is 
degenerative calcific aortic stenosis (AS).  The cusps of the aortic valve become 
immobilised by deposits of calcium at their bases as a consequence of years of 
normal mechanical stress on the valve.  This is an active disease process with lipid 
accumulation, inflammation and calcification 1-8.  Degenerative calcification may also 
extend in the direction of the cusps resulting in commissural fusion.   
 
1.2 Pathophysiology 
In degenerative calcific AS there is slow and progressive LV outflow tract obstruction.  
Left ventricular output is maintained by the development of left ventricular 
hypertrophy which may sustain a large pressure gradient across the aortic valve for 
many years without a reduction in cardiac output, left ventricular dilatation or the 
development of symptoms.   The increased systolic wall stress induced by AS leads 
to a parallel replication of sarcomeres and concentric hypertrophy and the increase in 
left ventricular wall thickness is often sufficient to counterbalance the increased 
pressure so that peak systolic wall tension returns to normal 1-3.  An inverse 
correlation between wall stress and ejection fraction exists suggesting that the 
depressed ejection fraction found in some patients is a consequence of inadequate 
wall thickening 4 resulting in afterload mismatch 5.  Patients with AS and 
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compensated pressure overload may have normal interventricular stress (dσ/dt) and 
pressure (dP/dt) development indicative of normal contractility 6. 
 
Although LV hypertrophy is a key adaptive mechanism to the pressure load imposed 
by AS, it has an adverse pathophysiological consequence by increasing diastolic 
stiffness.  This leads to an increased intracavity filling pressure 7, 8.  In some this 
increase in stiffness is directly related to muscle mass but with no alteration in 
diastolic properties of each unit of myocardium, in others its is due to increases in 
both chamber and muscle stiffness which contribute toward the elevation of 
ventricular diastolic filling pressure at any level of ventricular diastolic volume 9, 10.  A 
raised left ventricular end diastolic pressure is therefore reflective of diastolic 
dysfunction rather than systolic dysfunction.  Forceful atrial contraction that 
contributes to an elevated end-diastolic pressure plays an important role in 
ventricular filling without increasing mean left atrial or pulmonary venous pressure 11 
and therefore loss of atrial transport with atrial fibrillation often results in significant 
clinical deterioration. 
 
Left ventricular hypertrophy in severe AS is associated with a variety of changes in 
the myocardial ultrastructure including large nuclei, loss of myofibrils, accumulation of 
mitochondria, large cytoplasmic areas devoid of contractile material and proliferation 
of fibroblasts and collagen fibres in the interstitial space 12.  The depression of 
cardiac function that occurs late in the course of aortic stenosis may well be related 
to these morphological alterations.  
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Although coronary flow in LVH is elevated in absolute terms, it is normal when 
corrected for myocardial mass 13, myocardial oxygenation in severe AS may be 
inadequate, even in the absence of coronary artery disease.  The hypertrophied left 
ventricular muscle mass, the increased systolic pressure and the prolongation of 
ejection all elevate myocardial oxygen consumption 14.  The abnormally high diastolic 
pressure compressing the intramuscular coronary arteries exceeds the coronary 
perfusion pressure thereby interfering with coronary blood flow 15  thus leading to a 
potential imbalance between myocardial oxygen supply and demand.  Myocardial 
perfusion is also impaired by the relative decrease in myocardial capillary density and 
the elevation of left ventricular end-diastolic pressure which lowers the aortic-left 
ventricular end-diastolic pressure gradient in diastole.  The subendocardium in 
severe AS in particular is susceptible to ischaemia and this malperfusion may be 
responsible in part for the development of subendocardial ischaemia 15.  Recent work 
combining cardiac magnetic resonance to measure LV mass and PET to quantify 
resting and hyperaemic (dipyridamole) myocardial blood flow and coronary 
vasodilator reserve (CVR) in patients with severe LVH secondary to AS with 
angiographically normal coronary arteries and non-hypertrophied controls 
demonstrated that patients with severe LVH manifested significantly lower 
subendocardial CVR (1.43 ± 0.17) than subepicardial CVR (1.78 ± 0.35; p=0.01), 
with a further reduction in subendocardial CVR with hyperaemia (0.92 ± 0.17; 
p=0.05) 16.  Quantitative analysis of high energy phosphate levels in patients with 
severe LVH secondary to aortic stenosis with angiographically normal coronary 
arteries has also demonstrated a significant reduction in ATP concentration in the 
subendocardium (25.9 ± 1.7 µmoles.g protein-1) compared to the subepicardium 
(31.5 ± 1.6; p=0.01)17 .  Hypertrophied hearts also exhibit an increased sensitivity to 
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ischaemic injury with larger infarcts and higher mortality rates than are seen in the 
absence of hypertrophy 16-18 .  Elderly patients, particularly women, often develop 
excessive concentric hypertrophy resulting in a reduced end systolic volume and 
increased ejection fraction a combination associated with increased peri-operative 
morbidity and mortality 18, 19. 
 
1.3 Grading the degree of stenosis 
The American Heart Association guidelines grade the severity of stenosis on the 
basis of a number of haemodynamic and natural history data 20. 
Indicator Mild Moderate  Severe 
Jet Velocity ms-1 <3.0 3.0-4.0 >4.0 
Mean Gradient (mmHg)   6o 
Valve area (cm 2) >1.5 1.0-1.5 <1.0 
Table 1.  The grading of severity of aortic stenosis 20. 
1.4 Natural History 
 
Aortic stenosis is associated with a prolonged latent period during which there is no 
increased risk of cardiac morbidity or mortality.  Once the stenosis is moderate the 
average rate of progression is an increase in jet velocity of 0.3 ms-1 per year, an 
increase in mean gradient of 7mmHg per year and a decrease in valve area of 
0.1cm2 per year 19-25 but individuals may manifest marked variability in 
haemodynamic progression. 
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Following the long latent period, symptoms of angina, syncope or heart failure 
develop and the clinical prognosis changes significantly.  After the onset of 
symptoms mean survival is 2-3 years 19-23 with a significantly higher risk of sudden 
death (Fig 1.2).  The onset of symptoms is therefore the key step in considering 
surgical intervention for aortic stenosis. 
 
1.5 Echocardiographic assessment  
Echocardiographic assessment is indicated when there is a systolic murmur that is 
grade 3/6 or greater, a single S2, or symptoms that might be due to AS.  The 2D 
echocardiogram is valuable for interrogation of valve anatomy and function and 
determining the LV response to pressure overload 20. 
1.6 Indications for Surgery 
In adults with severe symptomatic calcific AS, AVR is the only effective treatment 
improving both symptoms and survival 19-23.  The outcome is similar in patients with 
preserved and with moderately impaired LV contractility21.  The ejection fraction in 
patients with severely impaired function caused by excessive afterload improves after 
AVR but if the ventricular dysfunction is not caused by afterload mismatch then 
improvement in ventricular function and performance status is reduced.  In the 
absence of severe co-morbidity AVR is therefore indicated in virtually all symptomatic 
patients.  In 1998, a joint task force of the American College of Cardiology (ACC) and 
the American Heart Association (AHA) developed evidence-based consensus 
guidelines for management of valvular heart disease which were updated in 2006 20.  
These indications for AVR are listed in Appendix A. 
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Figure 1 Survival in untreated patient vs surgically treated patients  with severe Aortic Stenosis     
2. Myocardial Metabolism  
2.1 Overview 
Cardiomyocytes oxidise fatty acids derived from both the plasma and the breakdown 
of intracellular triacylglycerol stores, while pyruvate is derived from either lactate 
dehydrogenase or glycolysis.  The rates of these metabolic pathways are tightly 
coupled to the rate of contractile work, and conversely, contractile work is coupled to 
the supply of oxygen and the rate of oxidative phosphorylation. 
 
The fasted heart extracts free fatty acids (FFAs), lactate and glucose from the blood, 
and assuming complete oxidation of extracted substrates, fatty acid oxidation 
accounts for 60-80% of the oxygen consumption with a lesser contribution from 
lactate and glucose, each accounting for 10-20%. 
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2.2 Glycolysis and Glycogen metabolism 
The uptake of extracellular glucose is regulated by the transmembrane glucose 
gradient and the concentration and activity of glucose transporters. The two isoforms 
GLUT 1 and GLUT 4 22, 23 are located in the sarcolemmal membrane and in 
intracellular microsomal vesicles 22-24.  Insulin and ischaemia result in translocation 
from the intracellular site into the plasma membrane resulting in an increase in the 
capacitance for glucose transport 24-26.  On entering the cell glucose is rapidly 
phosphorylated by hexokinase rendering it impermeable to the cell membrane27.  
Insulin activates hexokinase, and cell culture data suggest that glucose 
phosphorylation by hexokinase is the rate limiting step in insulin stimulated glucose 
utilisation 28.  Glucose 6-phosphate (G 6-P) can be used for either glycogen synthesis 
or it can proceed down the glycolytic pathway to form pyruvate 27 (Fig 1).  The 
glycolytic pathway produces two molecules of ATP and two molecules of pyruvate 
per molecule of glucose. Under aerobic conditions pyruvate enters the mitochondria 
and is decarboxylated to actetyl coenzyme a (CoA) whereas during anaerobic 
conditions pyruvate is reduced in the cytosol to lactate27.  If the concentration of G 6-
P is constant the primary regulators of glycolytic rate are the activity of 
phosphofructokinase (PFK) and the ability to form reduced NADH 29-32.  The activity 
of PFK is inhibited by  H+ , citrate and ATP and is stimulated by ADP, Ca2+, and 
fructose 2,6-biphosphate from F 6-P.  NAD+ is reduced to NADH and cytosolic NADH 
can be converted back to NAD+ through the conversion of pyruvate to lactate by 
lactate dehydrogenase or the reducing equivalents can be shuttled into the 
mitochondria via the malate-aspartate shuttle27.  Glyceraldehyde 3-phosphate 
dehydrogenase would appear to be a rate limiting step for glycolysis with either high 
rate of contractile work 32 or during ischaemia 33. 
  
Page 1-28 
 
 
Figure 2 The Glycolytic pathway. 
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It has been hypothesised that glycolytically derived ATP is preferentially used for 
Ca2+ re-uptake into the sarcoplasmic reticulum and that it is essential for optimal 
diastolic relaxation 34-36.  This evidence comes from studies in isolated tissue that 
demonstrated that inhibition of glycolysis resulted in impaired relaxation especially in 
ischaemic or reperfused myocardium 35.  It has also been demonstrated that key 
glycolytic enzymes are associated with the cardiac ATP-sensitive K+ channels and 
that glycolytically derived ATP preferentially inhibits these channels 37.  Glycolysis is 
also important for optimal function of the Na+ /K+ ATPase and prevention of 
intracellular Na+ accumulation during ischaemia 38. 
 
The rate of glycogen synthesis is regulated by the concentration of G 6-P and the 
activity of glycogen synthase.  Glycogen synthase activity and glycogen storage are 
both increased by insulin 39-41.  Glycogenolysis results in the formation of G 6-P and 
is regulated by the activity of glycogen phosphorylase.  Glycogen phosphorylase is 
activated when phosphorylated by phosphorylase kinase which is activated by Ca2+.   
This is regulated by protein kinase a, and thus activated by cAMP 39.  Glycogen 
phosphorylase activity is therefore controlled by both hormonal stimulation including 
β-adrenergic receptor stimulation resulting in increased cAMP and Ca2+, and 
metabolic feedback from AMP, Pi and Ca2+.  In vivo there is simultaneous synthetase 
and phosphorylase activity 41-44. 
 
The overall rates of glucose uptake, glycogen synthesis and breakdown and the rate 
of glycolysis are controlled by multiple steps distributed along these pathways and 
are not subject to control at discrete steps 29. 
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2.3 Pyruvate and Lactate Oxidation 
 
Under well perfused conditions in vivo lactate is a major source of pyruvate 
formation, and under some conditions lactate uptake can exceed glycolysis as a 
source of pyruvate 45, 46.  Studies with carbon labelled lactate tracers in humans have 
shown that 80-100% of the lactate taken up by the heart in health is immediately 
released as labelled CO2 into the coronary effluent suggesting that extracted lactate 
is rapidly oxidised by lactate dehydrogenase, decarboxylated by pyruvate 
dehydrogenase (PDH) and oxidised to CO2 in the TCA cycle 46. 
 
Pyruvate decarboxylation is the key irreversible step in carbohydrate oxidation and is 
catalysed by PDH 47.  The activity of PDH is regulated by a variety of mechanisms.  It 
is inactivated by phosphorylation by PDH kinase and is activated by 
dephosphorylation by PDH phosphatase.48-50.  The rate of pyruvate oxidation is 
strongly dependent on the degree of phosphorylation of PDH and on the 
concentrations of its substrates and products in the mitochondria.   The activity of 
PDH phosphatase is increased by Ca2+ and Mg2+, while PDH kinase is inhibited by 
pyruvate and ADP and activated by increases in AcylCoA /CoA and NADH / NAD+ 47, 
51
. 
 
Pyruvate oxidation and the activity of PDH in the heart are decreased by elevated 
rates of fatty acid oxidation and caused by increased plasma levels of FFA and are 
enhanced by suppression of FFA oxidation induced by a decrease in plasma FFA 
levels 47. Positive inotropic agents also increase the amount of active enzyme by a 
Ca 2+ dependent activation of PDH phosphatase 52. 
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2.4 Fatty acid metabolism 
Although the energy yield from complete oxidation of fatty acids is more than that of 
carbohydrates, providing 130 molecules ATP per mole FFA versus 38 molecules 
ATP per mole of glucose, it is more oxygen dependent.  The ATP yield using FFA per 
mole of oxygen is 2.83 compared to 3.17 for glucose 27. 
 
Fatty acids are stored as triacylglycerols (TAGs).  Oxidation of free fatty acids in the 
mitochondria can only occur after a series of essential steps.  It has been 
hypothesised that during ischaemia accumulation of these metabolites due to 
inhibition of mitochondrial metabolism contributes towards cellular dysfunction 53. 
 
Hydrolysis of TAGs by hormone sensitive lipases generates glycerol and FFAs.  
Glycerol is then converted to glyceraldehyde-3-phosphate which is then converted to 
either pyruvate or glucose by the liver.  The mitochondrial membrane is impermeable 
to fatty acids therefore long chain acyl groups from fatty acids are transported into 
the mitochondrial matrix by carnitine so that they can undergo β-oxidation 27. On the 
outer mitochondrial membrane fatty acids are attached with a thioester bond to 
coenzyme A (CoA), a reaction catalysed by fatty-acyl-CoA synthetase 27.  Acyl CoA 
is conjugated to carnitine by carnitine palmitoyltransferase I (CPT-I) on the outer 
mitochondrial membrane and it is then shuttled inside by carnitine-acylcarnitine 
translocase.  Acyl-carnitine is then converted to acyl-CoA by CPT-II on the inner 
mitochondrial membrane where it can then undergo β-oxidation 27. 
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CPT-I undergoes allosteric inhibition as a result of malonyl-CoA an intermediate in 
fatty acid biosynthesis, in order to prevent futile cycling between β-oxidation and fatty 
acid synthesis 47. 
 
 
Figure 3 Acyl CoA degradation pathway 
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2.5 TCA Cycle and Oxidative phosphorylation 
The tricarboxylic acid cycle (TCA) operates only under aerobic conditions requiring a 
constant supply of NAD+ and FAD.  The enzymes involved are located in the 
mitochondrial matrix or attached to the inner surface of the mitochondrial membrane. 
This facilitates the transfer of reducing equivalents to the enzymes of the electron 
transport chain.  There are four oxidation-reduction reactions that occur in the cycle 
and these donate four pairs of electrons, three to NAD+ and one to FAD 27.  These 
reduced electron carriers are subsequently oxidised by the electron transport chain 
leading to the generation of 11 molecules of ATP, an additional high energy 
phosphate bond in the formation of succinate means a total of 12 molecules of ATP 
are produced for each Acyl CoA that is completely oxidised 27. 
 
Figure 4 The TCA Cycle 27 
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The NADH and FADH2 formed by glycolysis and the TCA cycle are energy rich 
molecules due to a pair of electrons with a high transfer potential. The transfer of 
electrons from NADH and FADH2 to oxygen leads to protons being pumped out of 
the mitochondrial matrix. This process generates a pH and transmembrane electric 
potential gradient.  Flow of protons back to the mitochondrial matrix via ATP 
synthase leads to ATP synthesis. This process of oxidative phosphorylation is highly 
efficient generating 32 of the 36 molecules of ATP generated from complete 
oxidation of glucose to carbon dioxide and water  27.  The ATP yield is shown below: 
 
 
Glycolysis:  Glucose into pyruvate (in the cytosol) ATP Yield per glucose 
Phosphorylation of glucose       -1 
Phosphorylation of fructose-6-phosphate     -1 
Dephosphorylation of 2 molecules of 1,3 BPG    +2 
Dephosphorylation 2 molecules phosphoenolpyruvtae   +2 
 
Conversion of pyruvate into acetyl CoA (inside mitochondria) 
2 NAD are formed 
 
Citric Acid cycle 
2 molecules of guanine triphosphate formed from 2 of succinyl CoA 
6 NADH from oxidation of 2 each of isocitrate, ketoglutarate, malate +2  
2 FADH formed in oxidation of 2 molecules succinate  
 
Oxidative Phosphorylation 
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2 NADH formed in glycolysis each yield 2 ATP    +4 
2 NADH from oxidative decarboxylation of pyruvate    +6 
2 FADH2 formed incitric acid cycle each yields 2 ATP   +4 
6 NADH formed in citric acid cycle each yields 3 ATP   +18 
 
Net yield of Glucose        +36 
 
ATP yield from the complete oxidation of glucose  
 
 
The rate of oxidative phosphorylation is closely related to the work of the heart. 
Electrons do not flow through the electron transport chain unless ADP is 
simultaneously phosphorylated to ATP.  This regulation of oxidative phosphorylation 
by ADP is termed respiratory control.  The level of ADP also affects the rate of the 
TCA cycle because of its need for NAD+ and FAD therefore as ATP is consumed 
ADP levels increase therefore oxidative phosphorylation is coupled to ATP utilisation. 
 
2.6 Phosphocreatine and Hypertrophy 
Myocardial energetic demands are met primarily through mitochondrial ATP 
production via oxidative phosphorylation.  Phosphocreatine (PCr) is an important 
short term energy source which maintains a high phosphorylation potential under 
conditions of increased energy demand.  The transfer of a phosphoryl group from 
PCr to ADP by the enzyme creatine kinase (CK) rapidly and reversibly generates 
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ATP and creatine, approximately 10 times faster than the maximum rate of ATP 
generation by oxidative phosphorylation 54. 
 
The PCr/ATP ratio is an indicator of the energetic state of the myocardium.  Studies 
in animals in both hypertrophy and failure have demonstrated a progressive 
reduction in the creatine pool of 60% largely due to a reduced number of creatine 
transporters 55, 56.  In heart failure in man studies with 31P NMR spectroscopy have 
demonstrated a reduced PCr/ATP with the magnitude of this reduction being 
predictive of late mortality 57 58 .  This reduction is partly due to a reduced creatine 
pool and partly to reduced CK isoenzyme expression, particularly mitochondrial CK. 
2.7 Control of Metabolism 
Central to the role of regulating energy homeostasis is the trimeric enzyme AMP-
activated protein kinase (AMPK) 59.  AMPK induces a cascade of events within the 
cell in response to the ever changing energy charge of the cell 60, 61.  Once activated, 
AMPK-mediated phosphorylation events switch cells from net active ATP 
consumption to activate ATP production 59.  These events are rapidly initiated and 
referred to as short-term regulatory processes.  AMPK is activated by 
phosphorylation by one or more upstream AMPK kinases (AMPKKs), and in the 
absence of phosphorylation, there is no detectable activity of AMPK towards any 
substrates 59, 62. 
 
AMPK is also regulated by AMP.  The effects of AMP are twofold.  Direct allosteric 
activation makes AMPK a poorer substrate for dephosphorylation, and because AMP 
affects both the rate of AMPK phosphorylation in the positive direction, and 
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dephosphorylation in the negative direction, the cascade is ultrasensitive59.  This 
means that a very small rise in AMP levels can induce a dramatic rise in the activity 
of AMPK.  Negative allosteric regulation of AMPK also occurs and this effect is 
exerted by phosphocreatine with a high glycogen content suppressing AMPK activity 
60
. 
The signalling cascade initiated by the activation of AMPK exerts effects on glucose 
and lipid metabolism, gene expression and protein synthesis61.  During myocardial 
ischaemia, AMPK activation leads to the phosphorylation and activation of 
phosphofructo-kinase 2, one of the most important regulators of the rate of flux 
through glyolysis and gluconeogenesis63.  AMPK activation also leads to 
phosphorylation and inhibition of acetyl-CoA carboxylase (ACC)61.  This inhibition 
results in a decrease in the level of malonyl-CoA which itself is an inhibitor of 
carnitine palmitoyltransferase 1 (CPT-1)61.  In addition, AMPK has been 
demonstrated to phosphorylate and thus regulate the activity of HMG-CoA reductase, 
malonyl CoA decarboxylase, glycogen synthase and creatine kinase thus regulating 
the spectrum of fatty acid, cholesterol, glucose, glycogen, and phosphocreatine 
metabolism 60, 64, 65 
2.8 Metabolism in hypertrophy 
The hypertrophic response of the heart enables it to meet the demands of chronically 
elevated haemodynamic workload.  Whilst initially compensatory, LVH is ultimately a 
maladaptive response, associated with markedly increased cardiovascular mortality 
and a substantial increase in the development of heart failure 66 initiated through two 
mechanisms. Firstly, pathological LVH is associated with activation of the circulating 
and tissue renin-angiotensin-aldosterone systems coupled with local up-regulation of 
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NADPH oxidase which both lead to progressive cardiac fibrosis and impaired 
function67.  Secondly, there is increasing evidence that the hypertrophied heart is 
relatively energy starved and that energy deficiency may play a key role in the 
transition from LVH to HF 68-70. 
 
Animal models of hypertrophy and failure suggest that the loss of ATP in the 
myocardium is slow and progressive ~0.35% of the ATP pool per day.  This low rate, 
whilst not necessarily immediately translatable to man, means that a decrease in 
ATP content would be difficult to detect until the heart was in severe failure thus 
explaining the conflicting literature on this topic 71, 72. The loss of ATP in the failing 
heart is caused by loss in the total adenine nucleotide (TAN) pool 73.  The 
combination of a fall in ATP and TAN had previously been observed in the context of 
ischaemia 54. Whether the fall in this case is due to a failure of de novo purine 
synthesis or failure to increase synthesis to support the hypertrophied myocyte mass 
or because reactions converting adenine nucleotides to diffuse purine nucleosides 
and bases are accelerated remains unknown. 
 
Analysis of biopsies in patients with LVH secondary to severe AS showed that before 
the decrease in ATP level becomes significant the total creatine pool falls by over 
60% 74.  This finding has been confirmed more recently non-invasively using MR 
spectroscopy, and further extended by relating the magnitude of the depletion to the 
severity of heart failure 56.  The observation that the PCr to ATP ratio and the PCr 
concentration are lower in both compensated LVH as well as failing hearts suggests 
that the loss of creatine cannot be a specific marker of the failing heart. Instead it has 
been hypothesised that loss of PCr is a more general marker of a mismatch in the 
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integration of the pathways maintaining sufficient ATP supply to meet the demand for 
ATP utilisation 74. 
 
The mechanisms responsible for energy starvation in LVH are controversial and 
include both tissue ischaemia as a consequence of increased myocardial oxygen 
demand, increased LVEDP resulting in a reduced trans-coronary perfusion gradient 
and increased capillary-myocyte diffusion distance 67 and altered metabolism and 
substrate utilisation. FFA account for the majority (~70%) of energy production in the 
healthy adult heart, with the remainder accounted for by carbohydrates, ketone 
bodies and amino acids via anaplerosis 75.  Under certain circumstances this balance 
may change, for example during ischaemia a shift to relatively greater carbohydrate 
utilisation occurs 70.  Teleologically this shift results from the lower oxygen 
requirement for ATP production when using carbohydrates vs FFA 65, 69. This shift 
away from FFA recapitulates the metabolism of the fetal heart which is relatively 
oxygen starved 76.  
 
On the basis of stoichiometry, a shift from oleate (FFA) to carbohydrate metabolism 
would render the heart only ~12% more efficient with respect to oxygen 65, 69 but in 
animal models where substrate utilisation is acutely shifted from FFA to glucose, 
there is an ~40% increase in oxygen efficiency 77-80 . Two principal explanations have 
been proposed for this apparent discrepancy between stoichiometry and empirical 
observations. Firstly, FFA may undergo wasteful “futile” intracellular cycles 65 and 
secondly, mitochondrial uncoupling may be increased with dominant FFA utilisation 
81
.  Uncoupling proteins (UCPs) are present in the mitochondrial membrane of 
several tissues including cardiac and skeletal muscle 82.  The principal role of UCPs 
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is to export lipid peroxides out of the mitochondrion as they accumulate, protecting 
the mitochondrial DNA from damage 83.  However, the concomitant dissipation of 
mitochondrial electrochemical gradient results in a reduced efficiency of ATP 
production.  Uncoupling protein expression is increased by FFA excess within the 
cytosol, acting via the PPARα receptor 83. 
 
 A large number of studies have examined substrate utilisation in animal models of 
LVH. Although a source of persistent controversy, these studies broadly suggest that 
in LVH, there is a shift away from FFA utilisation 65.  Furthermore, gene expression 
studies have shown a shift towards a foetal pattern of myocardial gene expression 
with down regulation of genes involved in FFA metabolism 75. There has also been 
considerable debate as to whether this shift in substrate utilisation is an adaptive 
response (to reduced tissue oxygen) or a maladaptive response, predisposing to the 
development of HF 65. 
 
Recent studies in other animal models of LVH have shown that while glucose uptake 
and glycolysis are maintained or even increased, glucose oxidation is reduced 84 . 
This uncoupling of glycolysis from glucose  oxidation was not due to reduced activity 
of the pyruvate  dehydrogenase complex 84, 85 but it is unknown whether the reduced 
pyruvate oxidation described in animal models of LVH occurs in human LVH.  In 
patients with LVH due to aortic stenosis cardiac insulin resistance has also been 
demonstrated with normal basal glucose uptake but a marked reduction in insulin 
stimulated uptake 86.  In summary, the data in animal models of LVH suggests a 
down regulation of all metabolic pathways (i.e. FFA and carbohydrate oxidation). This 
maladaptive down regulation of all metabolic pathways would render the heart 
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energetically vulnerable. Furthermore if down regulation of FA β-oxidation is greater 
than down regulation of FA uptake, accumulation of LCFA’s might increase 
uncoupling of the mitochondrial electron transport chain further aggravating energetic 
impairment. 
2.9 Genomic control of metabolism 
Analysis of gene expression during the induction of cardiac hypertrophy has 
identified a specific transcription pattern 87.  Early mediators of the hypertrophic 
pattern include the immediate early genes (e.g., c-fos, c-myc, c-jun and Egr1), 
followed by a cascade of mitogen activated protein kinases.  These changes result in 
substantial alterations to the expression and organisation of sarcomeric and 
structural proteins 87. 
 
Although many of the differentially expressed genes identified in initial studies are 
involved in cytoskeletal and matrix remodelling, myosin isoform switching (MHCα to 
MHCβ) and TGFβ signalling, downregulation of components of the fatty acid 
oxidation pathway has also been note.  This distinct change in transcription has been 
described as a general reactivation of the fetal gene programme 88 
 
From a metabolic point of view, further genome wide expression profiling has 
however contradicted this initial work.  Rather than an isolated downregulation of 
fatty acid and a switch to carbohydrate metabolism, LV hypertrophy has additionally 
been demonstrated to manifest a downregulation of the genes for oxidative 
phosphorylation.  Over 40 genes associated with complexes I-V of the mitochondrial 
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oxidative phosphorylation and respiratory chain machinery have been identified as 
downregulated, with an additional seven TCA genes also downregulated 89. 
 
In addition to the individual genes of any specific pathway, it is also now accepted 
that a number of master regulators control the regulation of such pathways.  In 
controlling metabolism 2 master regulators have been identified Peroxisome 
proliferator activated receptor alpha (PPAR α), peroxisome proliferator activated γ 
coactivator alpha (PGC1α) and Oestrogen recepetor alpha (EERα). 
 
PPARs regulate a wide variety of target genes involved in cellular lipid catabolism 
and storage.  In the heart, activation of PPARα increases the expression of genes 
involved in three major steps in the cellular fatty acid utilization pathway: (i) fatty acid 
transport and esterification (via FATP / FAT/CD36, FABP and ACS), (ii) fatty acid 
mitochondrial import (via M-CPY I/CPT1β) and (iii) mitochondrial (MCAD, LCAD) and 
peroxisomal (ACO) β-oxidation, and recent evidence has linked PPARα to the known 
alterations in cardiac energy substrate utilisation during pathological LVH including 
reduced FAO rates and increase glycolysis.  PGC-1α is a transcriptional co-activator, 
i.e., it increases the probability of a gene being transcribed by interacting with 
transcription factors, but it does not itself bind to DNA in a sequence specific manner.  
PGC-1α is involved in a wide variety of biological responses including mitochondrial 
biogenesis, glucose / fatty acid metabolism and heart development.  When the heart 
undergoes hypertrophy PGC-1α expression is markedly decreased, and this has 
been associated with a conversion of fatty acid oxidation to glycolytic metabolism. 
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2.10 Effects of ischaemia 
Myocardial substrate metabolism during ischaemia is highly dependent on the 
severity of ischaemia 22, 33, 90, 91.  At normothermia and at a normal workload complete 
elimination of coronary flow quickly results in depletion of high energy phosphates, 
lactate accumulation and contractile akinesis which with time evolves into tissue 
necrosis and myocardial infarction.   
 
In animal models mild to moderate ischaemia results in a rapid decrease in 
mechanical work associated with a decrease in ATP and creatine phosphate 
concentrations and a transient net output of lactate by the myocardium.  With time 
there is partial restoration of ATP 92 and lactate output decreases but contractile 
function does not return to normal.   Following reperfusion there is a return to normal 
contractile function.  More severe ischaemia results in greater rates of lactate 
accumulation and glycogen breakdown, and more severe contractile dysfunction or if 
the ischaemia is of sufficient duration, myocardial necrosis and infarction. 
 
Complete cessation of coronary flow differs from partial reductions in flow in that 
there is no residual re-synthesis of ATP by oxidative phosphorylation and there is 
total dependence upon anaerobic metabolism with endogenous substrates.  The sole 
source of glycolytic substrate under these conditions becomes glycogen since there 
is no blood flow to deliver glucose to the tissue 93.  There is also no washout of 
lactate and therefore intracellular pH decreases, and eventually a reduction in the 
rate of glycolysis occurs due to H+ inhibition of phosphofructokinase.  Additionally, 
the flux through glyceraldehyde 3-phosphate dehydrogenase may also become rate 
limiting due to low cytosolic NAD+/NADH ratio 33. 
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Myocardial ischaemia results in a decrease in flux through pyruvate dehydrogenase 
(PDH) as seen by a decreased rate of glucose oxidation and a switch from net 
lactate uptake to net production.  In vivo studies have demonstrated no inhibition of 
PDH with a 60% reduction in coronary flow despite increased lactate production 94 
and therefore it has hypothesised that the decreased flux through PDH is due to a 
build up of NADH and acetyl CoA in the mitochondria independent of the 
phosphorylation state 93 
 
Reductions in coronary flow result in non-uniform distribution of blood flow across the 
left ventricular wall 95 with a relatively modest decrease in subepicardial flow but a 
more profound decrease in subendocardial flow 90, 96 .  Therefore during ischaemia 
there are lower ATP, creatine phosphate and glycogen levels and higher lactate 
content in the subendocardium than in the subepicardium 95.  Some reports have 
suggested a small but significant increase in the capacity for glycolysis in the 
subendocardium relative to the subepicardium 97, and this has led to the hypothesis 
that the subendocardium may be inherently better suited to withstand ischaemia 
because of higher glycogen levels, and a greater activity of key glycolytic enzymes. 
However there is not a consistent transmural gradient in these parameters and 
therefore any transmural difference in metabolism would appear to be due to 
differences in blood flow and contractile work and not to the inherent capacity for 
glycolysis 95, 97, 98. 
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2.11 Effects of reperfusion 
During ischaemia anaerobic glycolysis becomes an important source of ATP 
production but this leads to H+ production which is a major contributor to the acidosis 
that occurs in the myocardium 99.  Whilst the sodium-hydrogen exchanger NHE1 
provides an important mechanism whereby myocardial intracellular pH is restored, 
this in itself can contribute towards further cellular damage and dysfunction.  
Although intracellular pH is restored, the intracellular concentration of Na+ increases, 
and is further exacerbated by ischaemia-induced depression of sodium-potassium 
pump 100.  This results in reduced calcium efflux and even calcium influx 101 leading to 
intra-cellular calcium overload. 
 
 Continued production of H+ during the critical early period of reperfusion has the 
potential to further exacerbate myocardial injury 102.  Animal studies have 
demonstrated that during reperfusion there is an increase in the rate of fatty acid 
oxidation 103-108, impaired pyruvate oxidation and accelerated anaerobic glycolysis 109.  
High rates of fatty acid β-oxidation dramatically inhibit glucose oxidation resulting in 
an imbalance between glycolysis and glucose oxidation 108, 110.  This uncoupling is a 
major source of H+ production.  When glycolysis is uncoupled from glucose oxidation 
and pyruvate derived from glycolysis is converted to lactate there is a net production 
of two H+ from each glucose molecule which results from the hydrolysis of 
glycolytically derived ATP 111.  Pyruvate oxidation is also inhibited by the high plasma 
FFAs which result in low tissue malonyl CoA levels and subsequently less inhibition 
of CPT-1 and fatty acid oxidation 111. 
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2.12 Cell signalling in myocardial ischaemia reperfusion 
Myocardial ischaemia results in a dramatic activation of AMPK 61, 112.  This activation 
restores myocyte ATP levels, primarily by turning on ATP generating pathways 
through both glucose and fatty acid metabolism in the ischaemic heart.  
 
AMPK increases cardiac glucose utilisation by a number of different mechanisms.  
AMPK activation promotes the translocation of GLUT-4 to the sarcolemma of the 
myocytes promoting glucose uptake 112.  AMPK also phosphorylates and activates 
phosphofructokinase 2 (PFK-2) producing fructose-2,6-bisphosphate, a potent 
promoter of glycolysis.  AMPK activation during ischaemia may therefore be 
beneficial to the heart in terms of increasing glucose utilisation and subsequent 
anaerobic ATP production.   
 
A second major metabolic consequence of AMPK activation during ischaemia and 
reperfusion, is a stimulation of fatty acid oxidation 61 via phosphorylated and therefore 
inhibition of  Acetyl-CoA Carboxylase (ACC), the enzyme that converts acetyl CoA to 
malonyl-CoA, an inhibitor of CPT-1 62.  Inactivation therefore of ACC results in 
increase in fatty acid transport into the mitochondria and subsequent oxidation. 
 
Fatty acid oxidation can be dramatically accelerated during ischaemia reperfusion 
such that 95% of acetyl CoA derived ATP originates from fatty acids 61.  These high 
rates of fatty acid oxidation are in part due to an increase in the circulating levels of 
free fatty acids that occur during ischaemia.  The combination of AMPK activation 
and high circulating levels of free fatty acids can lead to high rates of fatty acid 
oxidation via the Randle cycle 47.  Fatty acid derived acetyl CoA decreases the 
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production of glucose derived acetyl CoA via inhibition of pyruvate dehydrogenase 
(PDH), resulting in a continued low rate of glucose oxidation, an uncoupling of 
glucose oxidation and a decrease in cardiac efficiency during this critical period of 
reperfusion.   
 
The question therefore of whether or not AMPK activation is beneficial during 
reperfusion remains to be fully elucidated.  The majority of studies examining AMPK 
activation in the ischaemic heart suggest that AMPK activation is an adaptive 
response that allows the heart to generate ATP and thereby protect cardiac tissue in 
the presence of oxygen deprivation 113 but there remains a paucity of data on the 
effect of AMPK activation on cardiac function.   
 
To analyse the effect of AMPK activation during reperfusion, initial work was carried 
out using AMPK knock-out mice.  These experiments were conducted using isolated 
hearts perfused with low levels of fatty acids (0.14mM oleate). AMPK activity, 
glucose uptake and lactate production were all increased in wild-type mice but not in 
knock-out mice.  AMPK knock-out mice also demonstrated worse function during and 
after ischaemia, an increase in creatine kinase and lactate dehydrogenase 
production, and an increase in the pro-apoptotic caspase-3 and TUNEL positive cells 
112
.  These hearts also demonstrated significant increases in myocardial necrosis 
after ischaemia suggesting that AMPK activation is cardioprotective in isolated hearts 
undergoing ischaemia reperfusion and important in allowing myocytes to function 
following a period of ischaemia 112.  It was also noted that during ischaemia and 
reperfusion, both rates of fatty acid oxidation and glucose oxidation were similar 
between wild-type and AMPK knock-out mice112. 
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Recently it has also been shown that activation of the survival pathways associated 
with ischaemic preconditioning is also associated with significant activation of AMPK 
114
.  This activation is associated with up-regulation of GLUT-4 expression, which 
occurs in a protein kinase C-dependent manner 115.  The activation of H11 kinase 
that occurs in preconditioned hearts is also associated with an activation of AMPK to 
the nucleus, therefore resulting in an increase in the transcription of metabolic 
enzymes such as GLUT-4.  Although the activation of AMPK and increases in 
glucose uptake has the potential to benefit the heart, it has yet to be directly 
determined whether this activation of AMPK is associated with cardioprotection in the 
setting of ischaemic preconditioning 115. 
 
AMPK activation itself has also been shown to induce preconditioning in isolated 
cardiomyocytes and to prevent hypoxic injury 116, although the degree to which 
AMPK activation is either required or sufficient to induce preconditioning is uncertain.  
The molecular mechanism behind which AMPK activation might induce 
preconditioning are complex but may include activation of ATP-sensitive potassium 
channels 116.  Activation stimulates the movement of these channels from storage 
membranes to cell surface membranes where they are physiologically active and can 
shorten the action potential and therefore potentially reduce calcium overload during 
reperfusion 116. 
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3. Myocardial Protection 
3.1 Damage from Myocardial ischaemia 
Immediately after the onset of ischaemia contractile force and pH rapidly decline as 
lactate and protons accumulate in the myocardial cytoplasm. High energy 
phosphates and glycogen reserves diminish whilst adenosine, inosine and other 
nucleotide products of ATP catabolism leave the cell.   The ultrastructural changes in 
early ischaemia are limited to loss of glycogen granules and a degree of intracellular 
and organelle swelling. 
 
If the period of ischaemia continues, further accumulation of fatty acids within the cell 
leads to diastolic arrest.  Within fifteen minutes of ischaemia the control of 
sarcolemmal permeability is lost 117  resulting in further loss of adenosine, lactate, 
cytoplasmic proteins and enzymes.  Macromolecules in the cell are converted to 
smaller more osmotically active molecules further exacerbating cell swelling.   
Cellular metabolism and ATP production cease and glycogen stores are eventually 
depleted.  As glycolysis and mitochondrial function are totally lost, cellular autolysis 
begins and cell contents leak more extensively into the interstitial space.  Myocardial 
contracture begins when ATP levels reach critically low levels developing firstly in the 
subendocardium and more rapidly with myocardial hypertrophy 118. 
 
3.2 Damage from Myocardial Reperfusion 
The response of myocardial cells to reperfusion depends upon the damage the cell 
has sustained during ischaemia.  The critical point in the pathway to cell death at 
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which reperfusion results in explosive cellular response remains unknown.  The 
spectrum of reperfusion injury ranges from myocardial stunning to more severe injury 
including cell death and necrosis.  The histological features of some of these more 
advanced forms of reperfusion injury include myofibrillar disruption and contraction 
bands 119. 
 
Oxygen derived free radicals generated during reperfusion are the fundamental 
cause of reperfusion injury and are characterised by the presence of unpaired 
electrons, including superoxide, hydrogen peroxide and hydroxyl radicals.  In normal 
physiological states myocardial cells are exposed to low levels of oxygen free 
radicals which are well controlled.  Superoxide dismutase catalyzes the reduction of 
superoxide anions to hydrogen peroxide and water. Hydrogen peroxide is then 
further reduced to water and oxygen by catalase and glutathione peroxidise.  
ischaemia progressively reduces the level of superoxide dismutase and increases 
the metabolic end-products of ATP catabolism such as hypoxanthine and xanthine 
which can then supply oxygen free radicals to xanthine oxidase.  Reperfusion leads 
to a chain reaction producing overwhelming amounts of free radicals. Iron converts 
the superoxide radical into hydroxyl radicals which results in peroxidation of 
membrane lipids leading to an increase in membrane permeability, decreased 
calcium transport into the sarcoplasmic reticulum and altered mitochondrial function 
120
 leading to myocardial stunning or necrosis. 
 
Reperfusion-induced elevation in cytotoxic reactive oxygen species (ROS), can 
trigger opening of the mitochondrial permeability pore (mPTP) resulting in immediate 
dissipation of the mitochondrial membrane potential 121, and it is ROS rather than 
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calcium overload that would appear to be the more important trigger for mPTP 
opening 122.  It has further been demonstrated in isolated cell culture that ROS-
induced mPTP opening is followed by an additional ROS burst that occurs 
simultaneously with mitochondrial membrane potential dissipation 122-124.  This ROS-
induced ROS release (RIRR) would appear to be responsible for a large fraction of 
the oxidative damage detected in cells after reperfusion 124.  Additionally, RIRR-
induced mitochondrial depolarisation can propagate to neighbouring cardiomyocytes 
resulting in regional pathological disturbance in excitability 122, 124-126.  .  
 
The most significant consequence of mPTP opening is loss of the mitochondrial 
membrane electrochemical gradient, critical to the synthesis of ATP.  This can result 
in further membrane instability as ATP levels become inadequate to fuel activity of 
the Na+/K+ ion channels 127.  The mPTP can also allow leakage of components of the 
electron transport chain, notably cytochrome c which may lead to further production 
of free radicals.  The mPTP also causes the mitochondria to become permeable to 
small osmotically active molecules resulting swelling and membrane rupture further 
releasing cytochrome c.  Cytochrome c can cause further cellular injury by activating 
the pro-apoptotic caspase cascade 127. Unless pore closure occurs, these changes 
will cause irreversible cell damage resulting in necrosis.  Even if closure occurs, the 
mitochondrial swelling and outer membrane rupture may be sufficient to set the 
apoptotic cascade in motion 
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3.3 Cardioprotection from ischaemia-Reperfusion Injury 
3.3.1 Cardioprotective Signalling Pathways and the mPTP 
Cardiomyocyte survival after reperfusion has been negatively correlated to the 
fraction of cellular mitochondria that undergo mPTP induction 122.  Activation of a 
number of complex sets of cell signalling pathways which increase the mPTP-ROS 
threshold can provide the cardiomyocyte with increased protection. These signalling 
pathways have been employed clinically through pre- and post- ischaemic 
conditioning and by various pharmacological agents 128-131.  Activation at a variety of 
points along the various signalling pathways will result in comparable levels of 
protection of cardiomyocytes from reperfusion injury and it has therefore been 
hypothesised that there exists a common final mechanism to integrate these diverse 
signals to the end effecter, the mPTP 122. 
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3.3.2 GSK -3β mediated cardioprotection 
Recently it has been proposed that GSK-3β is the most likely candidate for this point 
of convergence 122.  GSK-3 is a serine/threonine kinase that phosphorylates and 
down regulates glycogen synthase, the rate limiting step of glycogen synthase 132.  It 
has also been implicated in many other critical regulatory roles; it regulates multiple 
transcription factors, apoptosis, cell cycle progression, cell migration and cell 
survival.  Unlike most kinases, GSK-3 is highly active in the basal state and exerts a 
tonic-negative inhibitory effect on down-stream pathways.  Phosphorylation results in 
enzyme inactivation and therefore relief of its tonic inhibition and activation of 
downstream targets 131.  Two isoforms exist, α and β.  They have similar biochemical 
properties and substrate recognition, but they are often but not always functionally 
identical and interchangeable 122 and it is GSK-3β not GSK-3α that is involved in 
cardioprotection 122. 
 
Extensive evidence has now accumulated that GSK-3β is critical to the role of 
cardioprotection 133-136.  It has been demonstrated that both pre-conditioning 133, 134 
and post-conditioning136 involve inhibition of GSK-3β.  Moreover, substantial 
evidence implicates GSK-3β as the critical mediator of pharmacological conditioning 
triggered by numerous agents including opioid antagonists 137, 138, erythropoietin 135, 
anaesthetics such as propofol and isoflurane139.  It has also been demonstrated that 
a number of agents thought to function specifically by free radical scavenging 
compounds also activate prosurvival kinases acting through GSK-3β inhibition by its 
phosphorylation 140 . 
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It has been suggested that protection signalling should be separated into two main 
mechanistic categories; memory-associated signalling, which results in 
preconditioning that persists for several hours, and memory-lacking signalling, which 
results in relatively short-lived cell protection once the triggering agent, and therefore 
the phosphorylation state of one or more key proteins, is removed from the system.  
It has been suggested that both memory-associated and memory-lacking protection 
requires GSK-3β and that this enzyme is located proximally to the mPTP complex 122. 
Furthermore it has been hypothesised that it acts as a master switch to convey 
multiplicity of protective signals to their final point the mPTP 122.  Whether or not other 
kinase signalling pathways can bypass this intersection remains unknown. 
 
Memory-lacking signalling can be induced by insulin, insulin-like growth factor, 
glucagon like peptide-1 and, β2-adrenoreceptor activation, resulting in activation of 
one or more of the multiple signalling transduction pathways including P13K, PKA, 
PKB/AKT, PKG, PKC and their down-stream targets including GSK-3β 122. 
 
Recent evidence supports a direct functional role of the Bcl-2 protein family in GSK-
3β related cardioprotection against mPTP induction by ROS.  A direct link between 
the induction of pre-conditioning to protect against ischaemia-reperfusion injury and 
GSK-3β phosphorylation-dependent modulation of mitochondrial Bcl-2 protein levels 
has been demonstrated 141.  In addition to a direct modulation of the mitochondrial 
voltage-dependent anion channels (VDAC), activity may be regulated by binding of 
Bcl-2 proteins to VDAC; and in a model of isolated cardiomyocytes, infusion of a 
peptide comprised of the BH4 domain of BcL-XL, increased the ROS threshold for 
mPTP induction 122.  Recently it has also been demonstrated that cardioprotection 
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induced by GSK-3β inhibition results in a significant decrease in VDAC 
phosphorylation with  increased levels of Bcl-2 in mitochondria and specifically, 
increased Bcl-2 affinity for VDAC 141. 
 
In summary, it has been proposed that in the basal (active) state a GSK-3β 
subdomain pool relevant to mitochondrial signalling is active and binds ANT forming 
a dynamic complex with phosphorylated VDAC.  In this basal state the Bcl-2 BH4 
domain-containing proteins would be inhibited by the BH3 proteins.   Cardioprotective 
signalling deactivates GSK-3β by phosphorylation and leads either directly or 
indirectly by involving de-phosphorylation of VDAC and the release of VDAC from the 
GSK-3β-bound pool of ANT, to a shift in balance within the Bcl-2 family of proteins.  
The resultant de-phosphorylation of VDAC may then increase the ROS threshold for 
mPTP induction 141 thus improving myocardial protection. 
 
3.3.4 Protein O-GlcNAcylation and Cardiac Protection 
Post-translational modification (PTM) of proteins is a common mechanism for the 
modulation of protein function, location and turnover.  Protein phosphorylation is the 
most widely studied form, but there are many other forms of PTM including acylation, 
methylation and glycoslylation. Protein O-GlcNAcylation refers to the PTM of serine 
and threonine residues of nuclear and cytoplasmic proteins by the O-linked 
attachment of the monosaccharide β-N-acetylglucosamine (O-GlcNAc).  However in 
contrast to the hundreds of kinases and phosphatases that regulate protein 
phosphorylation, to date, only one enzyme has been identified that catalyses the 
formation of O-GlcNAc and one enzyme that catalyses its removal.  It has been 
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estimated that approximately 5% of total glucose entering the cell is metabolised via 
the hexosamine biosynthesis pathway (HBP) 142. 
 
Glucose entry into the HBP is controlled by GFAT (L-glutamate-D-fructose 6-
phosphate amidotransferase) which is glutamine dependent.  Two isoforms exist: 
GFAT-1 and GFAT-2.  GFAT-1 is subject to phosphorylation by cAMP dependent 
protein kinase and AMPK phosphorylates GFAT-1.  AMPK activity is stimulated by 
increased HBP flux and therefore GFAT may represent a key regulatory point 
between HBP and AMPK signalling 103. 
 
The attachment of a single β-N-acetylglucosamine molecule via a O-linkage to 
specific serine-threonine residues of nuclear and cytoplasmic proteins is catalysed by 
O-GlcNAc transferase (OGT).  The rate of protein O- GlcNAcylation is strongly 
regulated by HBP flux since OGT catalytic activity is highly sensitive to changes in 
UDP-GlcNAc concentrations 143.  In addition, insulin has been shown to increase both 
tyrosine phosphorylation and O-GlcNAcylation of OGT leading to increased activity 
and transient translocation from the nucleus to the cytoplasm 144, 145. 
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Figure 5.  The Hexosamine biosynthesis pathway (HBP) and protein Protein O-GlcNAcylation 142.  
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Protein O-GlcNAcylation is emerging as a key regulator of a number of critical 
biological processes including nuclear transport, translation and transcription, signal 
transduction and apoptosis 146.  Although chronic activation of O-GlcNAc would 
appear to be deleterious in a variety of settings, acute activation appears to be an 
endogenous stress response designed to enhance cell survival 146.  Overall O-
GlcNAc levels have been shown to be significantly increased in response to multiple 
experimental stress stimuli in several mammalian cell lines 147.  
 
In the isolated perfused heart, ischaemia has been shown to increase both UDP-
GlcNAc and overall O-GlcNAc levels 148 indicating that this endogenous stress-
activated pathway is active in the heart.  Activation of the HBP either by glucosamine 
or glutamine prior to the induction of ischaemia significantly increased O-GlcNAc 
levels 146, improved contractile function and decreased tissue injury after reperfusion 
149
.  Additionally, perfusion with the GFAT inhibitor Azaserine and the OGT inhibitor 
Alloxan prevented the increase in O-GlcNAc levels, decreased functional recovery, 
and exacerbated tissue injury after ischaemia-reperfusion.  There was also significant 
correlation between increased O-GlcNAc levels and cTnI release 149. 
 
Several putative mechanisms have been suggested to explain the increased 
tolerance to ischaemic stress associated with increased O-GlcNAc levels 146.  
Increasing O-GlcNAc levels have been associated with increased transcription of 
heat shock proteins (HSP) including HSP40 and HSP70 147. In particular HSP70 has 
been identified as a target for GlcNAcylation 150.  Activation of O-GlcNAc formation 
has also been shown to attenuate mPTP opening, a critical step in oxygen free 
radical-induced apoptosis and necrosis 151, 152.  One of the O-GlcNAc modified 
  
Page 1-59 
 
proteins identified as a potential O-GlcNAc target is VDAC, and it has been 
hypothesised that VDAC may preserve mitochondrial integrity by interfering with 
mPTP formation 151. 
 
A number of other pathways may also contribute to O-GlcNAc-mediated 
cardioprotection.  Increasing O-GlcNAc levels with glucosamine attenuated the 
ischaemia-induced p38 MAPK phosphorylation, decreased ischaemic contracture 
and reduced the incidence of reperfusion arrhythmias 146, 148.  Paradoxically, at the 
end of reperfusion, phosphorylated p38 levels were increased in response to 
glucosamine treatment which could lead to activation of pro-survival pathways 
through downstream effectors such as αβ-crystallin and HSP27, both of which have 
been shown to play a role in ischaemic protection and are also targets for 
GlcNAclyation 153.  It has been shown that ischaemia-reperfusion alters the level of 
O-GlcNAc modification of glycogen phosphorylase b, mitochondrial aconitase 2 and 
the cytoskeletal protein vinculin 154 all of which have been hypothesised to improve 
functional response to ischaemia-reperfusion injury 154.  Increased levels of O-
GlcNAc have also been reported to inhibit protein degradation 147 most likely due to 
inhibition of the proteasome 147 and this could also contribute to improved cell 
survival.  In addition there is also some experimental evidence that increasing O-
GlcNAc levels inhibit Ca 2+ overload during reperfusion 155. 
 
Cellular stress leads to an increase in ROS production and one consequence of this 
is increased flux through HBP and an increase in O-GlcNAc synthesis 156 which in 
turn leads to increase in O-GlcNAcylation of mitochondrial proteins and increased 
tolerance of mitochondria to stress 151.  Furthermore, there is some experimental data 
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suggesting that inhibition of GADPH by mitochondrial superoxide is an important 
factor leading to increased O-GlcNAcylation 156 and taken together these studies 
suggest that ROS and mitochondria may contribute towards the regulation of O-
GlcNAc synthesis which could in turn modulate the response to oxidative stress. 
 
Nitric oxide is one of the most widely recognised reactive species in redox signalling 
and nitric oxide synthase (NOS) is subject to both phosphorylation and O-
GlcNAcylation and therefore is a potent target for O-GlcNAc signalling 146.  eNOS is 
activated by Akt-mediated phosphorylation thereby increasing NO production.  This 
Akt phosphorylation site is also subject to O-GlcNAcylation leading to lower activity 
and decreased NO production 156.  Therefore the modulation of NO production by O-
GlcNAc demonstrates a convergence between redox signalling and O-GlcNAc 
protein modification 146. 
 
 
 
Figure 6.  Phosphorylation of endothelial nitric oxide synthetase (eNOS) results in increased 
eNOS activity and NO production, whereas O-GlcNAcylation at the same site leads to decreased 
enzyme activity and NO production146. 
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The intersection of redox and O-GlcNAc signalling may apply not only to specific 
proteins such as eNOS but may be involved in the regulation of entire signalling 
pathway146;  the insulin pathway is such a proposed pathway.  A number of 
components of insulin signalling include IR-β, IRS-1/2, PI3K, Akt and GSK-3β have 
all been reported to be O-GlcNAcylated and the result is lowered activity and an 
attenuated response to insulin 157.  Insulin signalling is also regulated by NO, the 
production of which may be regulated by direct O-GlcNAcylation of NOS.  Thus 
increasing flux through OGT is envisaged to decrease NO production not only by 
direct modification of NOS but also by reducing NOS phosphorylation via O-
GlcNAcylation of the IR complex and Akt. 
 
 
 
Figure 7  O-GlcNAc modification of eNOS decreases its activity and NO production.  At the same 
site Akt-mediated phosphorylation and activation of eNOS decreases its activity and NO 
production.  However, Akt is also subject to O-GlcNAcylation which reduces its activity thereby 
inhibiting eNOS phosphorylation and NO production 146. 
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3.4 Myocardial Protection for Aortic Valve Surgery 
Protective strategies are employed during cardiac surgery to produce a motionless 
bloodless operating field enabling access to the aortic valve to facilitate precise 
surgical repair whilst preserving myocardial function by limiting ischaemia and 
controlling reperfusion.   
 
Establishing cardiopulmonary bypass alone results in a significant reduction in 
cardiac work.  It reduces ATP requirements from a resting level ~85µmol/g/min to 
50µmol/g/min 158.  This requirement can be reduced to less than 10µmol/g/min by 
preventing myocardial depolarisation 158.  The resting membrane potential is defined 
by the ion concentration differences between the intracellular and extracellular areas, 
and by the permeability of the membrane to each type of ion.  The interactions 
between ions that generate the resting potential are modelled by the Goldman-
Hodgkin-Katz voltage equation which in the ventricular myocardium is between -
85mV to -95mV.  The maintenance of this gradient is due to the Na+/K+ ion exchange 
pump as well as the Na+/Ca2+ exchanger current and the inwardly rectifying K+ 
current.  Excitation in the resting phase (Phase 4) results in opening of fast Na+ 
channels resulting in a rapid influx of Na + ions  
 
 
This can be achieved with the use of cardioplegia, a solution containing a high 
concentration of potassium.   
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Initial work by Melrose 159 and then by Sealy160 demonstrated proof of concept in the 
1950s but clinical application was limited by the development of myocardial necrosis.  
Further refinements to the composition of crystalloid cardioplegia solutions by Gay 
and Ebert 161 led to the development of the first clinically accepted St Thomas’ 
cardioplegia solutions by Hearse in 1973 162.  This concept was taken further by 
Buckberg who reported use of blood based cardioplegia in 1978 with the theoretical 
advantages of improved buffering, endogenous oxygen free radical scavenging and 
superior oxygen transport 163, 164. 
 
3.5 Special considerations with LVH  
The hypertrophied left ventricle is particularly vulnerable to ischaemia-reperfusion 
injury 165-167.  Hypertrophy is accompanied by distinct quantitative and qualitative 
changes including a switch of contractile proteins to a foetal isoform and a 
reintroduction of fetal isoforms for numerous enzymes including lactate 
dehydrogenase and creatine kinase 111, 168, changes in calcium handling34, impaired 
insulin signalling 169 as well as the metabolic changes discussed earlier in  in this 
chapter 65, 170, 171. 
 
These adaptive changes should render the heart less susceptible to ischaemic injury 
as anaerobic glycolysis becomes the main source of energy production but 
paradoxically glucose uptake and metabolism is impaired during ischaemia and early 
reperfusion.  Hypertrophied hearts use both exogenous carbohydrates such as 
glucose and lactate, and endogenous stores of glucose from glycogen 110.  During 
myocardial ischaemia hypertrophied hearts exhibit accelerated loss of high energy 
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phosphates 102, greater accumulation of tissue lactate and hydrogen ions, earlier 
onset of ischaemic contracture and accelerated calcium overloading during early 
reperfusion 110.  This increased vulnerability is due to a combination of morphological, 
metabolic and physiological changes that occur in the hypertrophied myocardium. 
 
4. Glucose-Insulin-Potassium Therapy 
4.1 History 
The use of Glucose-insulin-potassium (GIK) as a metabolic intervention to treat 
myocardial ischaemia was first reported by Sodi-Pallares in 1962 172.  He 
demonstrated in animals and then patients with acute myocardial infarction that GIK 
reduced electrocardiographic signs of ischaemia, reduced infarct size and improved 
survival.  However, a trial by the Medical Research Council, UK found that patients 
with acute myocardial infarction treated with GIK had no positive survival benefits. 
The combination of this and the introduction of thrombolysis for the primary treatment 
of acute myocardial infarction tempered its further use.   
 
The potential benefit of this therapy to improve contractile function in patients with 
myocardial stunning following cardiac surgery was demonstrated by Baimbridge in 
1969, and in the early days of cardiac surgery GIK was used for both 
cardioprotection and weaning from cardiopulmonary bypass. Its use was then 
abandoned due to the introduction of St Thomas’ cardioplegia, the development of 
hypothermic cardiopulmonary bypass and the introduction of positive inotropic agents 
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such as dopamine and dobutamine alongside less cardiodepressant anaesthetic 
agents.   
 
In the 1980s there was an increase in the number of patients with unstable coronary 
artery syndromes presenting for emergency surgical revascularisation. In addition 
elderly patients and patients with a history of severe coronary artery disease, 
ventricular hypertrophy and chronic heart failure were referred for surgery.  These 
patients required more complex surgery and frequently developed significant 
myocardial stunning.  Poor outcomes in these patients using contemporary 
myocardial protection strategies led to further interest in protective adjuncts such as 
GIK. 
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4.2 Proposed Mechanisms of Action 
The potential beneficial mechanisms of action of GIK therapy can be broken down by 
the timing of ischaemia.  Prior to ischaemia GIK may increase myocardial glycogen 
stores resulting in improved ischaemic tolerance 173. During ischaemia when 
oxidative metabolism is reduced, GIK may augment anaerobic glycolysis, the 
predominant source of ATP production 174.  In reperfusion GIK can limit the high 
plasma concentrations of fatty acids high levels which result in an increase in the rate 
of myocardial fatty acid uptake and oxidation 104, 107, 175, and therefore lead to a 
reduction in glucose utilisation by the myocardium and suppression of glucose 
oxidation to a greater extent than glycolysis resulting in an uncoupling of glycolysis 
from glucose oxidation 102. 
 
4.2.1 Glucose uptake & glycogenesis prior to ischaemia 
Insulin and ischaemia both stimulate the translocation of GLUT-1 and GLUT-4 to the 
sarcolemma 24 and therefore increase the capacity of the myocardium to take up 
glucose.  Importantly, these effects have been shown to be additive in terms of 
glucose transporter translocation and glucose uptake 25.  Insulin also increases 
glycogen synthetase activity and promotes glycogen storage 40.  Studies have 
demonstrated a 50-70% increase in cardiac glycogen concentration with overnight 
treatment with GIK prior to surgery with associated improved clinical outcomes 173, 176.  
However it is unknown whether the improved outcome was related to a greater rate 
of carbohydrate oxidation due to lower FFA levels and higher rates of glycolysis and 
pyruvate oxidation or due to glycolytically derived ATP. 
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4.2.2 Glucose uptake and glycolysis during ischaemia 
Myocardial substrate metabolism during ischaemia is highly dependent on the 
severity of ischaemia 70.  During ischaemia mitochondrial oxidative metabolism is 
suppressed and anaerobic glycolysis becomes an important source of ATP 
production 174. Some of the beneficial effects of GIK may be due to an increase in 
glycolytically derived ATP, a decrease in PDH activity due to decreased plasma FFA 
concentration and increased insulin levels.  
 
Animal studies of GIK during periods of low-flow ischaemia have demonstrated an 
increase anaerobic glycolytic flux and therefore a decrease in ATP depletion 93 
resulting in improvements in systolic and diastolic function.  Preservation of high 
energy phosphates during ischaemia is beneficial as it may help to maintain critical 
membrane function including sodium and calcium ion homeostasis and ultimately, 
the enhanced production of energy may delay or reduce the extent of ischaemic 
necrosis. 
 
4.2.3 Glucose and fatty acid oxidation during reperfusion 
The recovery of myocardial oxidative metabolism is rapid following reperfusion 104.  
During this period fatty acid metabolism dominates as a source of oxygen 
consumption for a number of reasons 104.  Circulating fatty acid levels rise as a result 
of heparin and of elevated endogenous catecholamines 102 and high plasma FFA 
levels result in an increase in the rate of myocardial fatty acid uptake. High cytosolic 
concentrations of FFA result in both stimulation of fatty acid oxidation and an 
accumulation of fatty acid intermediates such as acyl-carnitine which contributes 
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towards cell membrane damage 61. Incomplete oxidation of FFA during periods of 
ischaemia also leads to peroxide formation which impairs cellular function. ischaemia 
reperfusion also results in phosphorylation of AMPK which reduces malonyl 
coenzyme (CoA) to inactive ACC therefore reducing inhibition of CPT-1 mediated 
fatty acid uptake into the mitochondria 175. 
 
The dominance of fatty acid oxidation during reperfusion leads to a reduction in 
glucose utilisation by the myocardium.  Importantly glucose oxidation is suppressed 
to a much greater extent than glycolysis.  This results in a far greater uncoupling of 
glycolysis from glucose oxidation than normal.  This increased uncoupling leads to 
accelerated proton production that is an important contributor to the myocardial 
dysfunction and decreased contractile efficiency observed during reperfusion 98, 177.  
Thus high levels of fatty acid oxidation contribute towards myocardial dysfunction and 
contractile inefficiency during oxidation by decreasing rates of glucose oxidation and 
increasing proton production from glucose metabolism 53, 104, 175. 
 
GIK therapy during reperfusion results in high insulin levels which inhibit hormone 
sensitive lipase in adipose tissue.  This leads to a significant reduction in circulating 
fatty acid levels resulting in reduced myocardial fatty acid uptake and oxidation 93.  
This concept has been supported by the observation that the greatest clinical benefit 
of GIK therapy occurs with therapeutic regimens that maximally suppress circulating 
fatty acid levels 178.  Fatty acid oxidation may also be directly reduced by the action of 
insulin on AMPK 179. 
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GIK infusion during the reperfusion period may also directly stimulate glucose 
uptake, again via GLUT translocation 25, 26, and this combined with the reduction in 
fatty acid oxidation results in an increase in myocardial glucose oxidation 104.  This 
may lead to improved coupling of glycolysis to glucose oxidation 103, decreased 
proton production 99 and therefore an increase in myocardial contractile efficiency. 
4.2.4 Anapleurosis via pyruvate during reperfusion 
Depletion of Krebs cycle intermediates during reperfusion has been hypothesised to 
be a significant cause of impaired energy production during reperfusion 90.  
Anapleurosis refers to the pathways which are involved in the replenishing of 
intermediate substrates of metabolic cycles.  There are 4 major anapleurotic 
reactions including carboxylation of pyruvate to oxaloacetate; transamination of 
aspartate to oxaloacetate; glutamate-dehydrogenase of glutamate to α-ketoglutarate 
and β-oxidation of fatty acids to succinyl-CoA.  Of these reactions, carboxylation of 
pyruvate is the major mechanism of aneuplorosis in the heart 178. GIK has been 
proposed to increase pyruvate production by increasing glucose uptake and 
glycolytic flux.  Therefore an additional benefit of GIK therapy may be rapid 
replenishment of the depleted citric acid cycle intermediate pool. 
4.2.5 Direct Insulin activation of AKT signalling  
Recent work by Yellon has demonstrated that insulin administered at the onset of 
reperfusion attenuated infarct size by more than 45% in an isolated perfused rat 
heart subjected to 35 minutes of regional ischaemia and 2 hours of perfusion 180.  
Perfusing the heart with either glucose or pyruvate showed no significant differences 
in the degree of cardioprotection suggesting that the effects of GIK are predominantly 
due to insulin.  It was also found that administration of insulin directly at the onset of 
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reperfusion was crucial in mediating cardioprotection.  A delay of 15 minutes after 
reperfusion negated any cardioprotective effect of insulin administration. 
 
Insulin is known to activate the prosurvival kinase Akt. Akt is activated in the 
proximity of the cell membrane with subsequent translocation to the cytosol.  
ischaemia alone induces Akt phosphorylation >4 fold in the absence of insulin.  On 
the basis of the cardioprotective effect of insulin being independent of glucose 
administration it was proposed that it was achieved via Akt-mediated cell survival 
signalling.  The administration of insulin at the onset of reperfusion maintained 
activated/phosphorylated Akt in both the cytosolic and membrane fraction of the 
myocardium compared to placebo treated hearts.  Addition of an Akt inhibitor such as 
the PI3-kinase inhibitor wortmannin, completely abolished the cardioprotective effect 
of insulin180. 
 
The conclusion of this paper was that the classic tyrosine kinase and Akt-mediated 
cell survival programmes are activated by insulin when administered at the moment 
of reperfusion.   
 
4.3 Studies of GIK in Acute Myocardial ischaemia 
Interpreting the results of GIK as a therapeutic strategy in the treatment of acute 
myocardial infarction (AMI) have been complicated by the study designs which have 
differed significantly in terms of composition of the GIK solutions and in the timing 
and duration of therapy.  A meta-analysis by Ordoubardi in 1997 identified 15 
randomised control trials of GIK versus placebo therapy in the treatment of AMI 181.  
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Six trials were excluded leaving a total of 9 trials containing 1932 randomised 
patients.  The hospital mortality in the GIK group was 16.1% versus 21% in the 
placebo group, a relative reduction of 23% resulting in a number needed to treat to 
prevent one death of 20 patients. 
 
Since this meta-analysis there have been four further randomised controlled trials of 
GIK. The Diabetes Mellitus Insulin Glucose Infusion in Acute Myocardial Infarction 
(DIGAMI) trial 182, the Polish GIK trial (Pol-GIK) 183, the Dutch Glucose Insulin 
Potassium Study (GIPS) 184 and the Estudios Cardiolgicos Latinoamerica (ECLA) 
study 185. 
 
The DIGAMI study was a multi-centre European study which examined the effects of 
in-hospital glucose-insulin infusions and subsequent tight glycaemic control with 
subcutaneous insulin in diabetic patients with AMI.  620 diabetic patients were 
randomised to either conventional treatment or an infusion of 5% glucose with 80 IU 
L-1 of actrapid insulin. Although they did not demonstrate a reduction in in-hospital 
mortality, late follow up demonstrated an absolute risk reduction in mortality of 11% 
182
. 
 
A second DIAGMI 2 study recruited a further 1253 non-insulin dependent diabetic 
patients with AMI 186.  They were randomised to either glucose-insulin infusion 
followed by insulin, glucose-insulin followed by clinician led management or routine 
glucose management but this trial failed to detect a significant difference in mortality 
at 2 year follow up. In the original DIGAMI trial all patients recruited had a blood 
glucose of >11.0mmoll-1 182 but in DIGAMI 2 blood glucose was not part of the 
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inclusion criteria 186. DIGAMI patients therefore had a higher baseline level of blood 
glucose with a greater initial reduction than patients recruited in DIAGMI 2.  
 
The Pol-GIK trial was a prospective randomised multi-centre trial examining the 
effects of low dose GIK (10% dextrose;20-32 IU Insulin l-1, KCl 80mmoll-1) versus 
placebo in non-diabetic patients presenting with AMI for a 24 hour period 183. 954 
patients were randomised but this trial was terminated early after the interim analysis 
found no difference in mortality or specific cardiac events.  The lack of effect may 
have been due to a large number of low risk patients recruited with a lower than 
predicted overall mortality.  In addition, the GIK regimen employed may not have 
been adequate to suppress FFA plasma levels and the investigators proposed further 
work using a higher dose of GIK 183. 
 
The GIPS trial randomised 490 patients who were suitable for PCI to either GIK or 
placebo 187.  There was no statistical difference in 30 day survival overall but a sub-
group analysis demonstrated a reduction in mortality for those without heart failure.  
This led to the design of GIPS-2 which examined the outcome of GIK as an adjunct 
in patients without heart failure undergoing primary PCI 184.  The trial was halted early 
after an interim analysis reported no difference between groups 188.  At one year 
follow up there was no difference in mortality, recurrent MI or need for repeat 
intervention between groups. 
 
The multi-centre CREATE-ECLA study randomised 20,201 patients with AMI 
presenting within 12 hours to receive either GIK (25% glucose, 50IUl-1 Insulin, 
Potassium 80mmoll-1 at 1.5.ml/kg-1h-1) for 24 hours or standard care 185, 189.  74.1% of 
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patients received thrombolytic therapy and 9.1% underwent primary PCI.  The trial 
had a 99% and 95% power to detect a 20% and 15% relative risk reduction 
respectively with the use of GIK.  The trial demonstrated no significant differences 
between groups on the primary outcome of 30 day all-cause mortality or any of the 
secondary endpoints which included a composite endpoint of death or non-fatal 
cardiac arrest, death or cardiogenic shock, death or re-infarction and each of these 
individually.  There were also no differences in any of the pre-specified subgroup 
analysis which included diabetes status, heart failure, time to presentation, 
reperfusion strategy. 
 
4.4 Studies of GIK in Cardiac Surgery  
Interpreting the trials of GIK in cardiac surgery has been complicated by the same 
heterogeneity of dosage regimens, timing of treatment, length of treatment and route 
of administration as in the trials of GIK in AMI.  The majority of these studies have 
been carried out in patient undergoing coronary bypass grafting (CABG) using 
cardiopulmonary bypass and cardioplegia based myocardial protection 190-195.  
Although they have consistently demonstrated improvements in post operative 
haemodynamics, they have been less clear on the effect of GIK on reducing 
myocardial injury. 
 
Bothe et al conducted a meta-analysis of the randomised trials examining the effects 
of GIK in cardiac surgery 190.  35 trials were included, the majority performed in 
patients undergoing CABG with cardiopulmonary bypass.  This meta-analysis 
demonstrated an 11% improvement in post-operative cardiac index.  When trials 
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were split into peri-operative versus post-operative infusion strategies the calculated 
improvement was 6.1% versus 19.5% respectively.  The meta-analysis also 
demonstrated a consistent reduction in inotrope usage. 
 
4.4.1 The MESSAGE Trials 
Between January 2000 and September 2004, two consecutive randomised double-
blind prospective placebo controlled trials were performed at University Hospital 
Birmingham examining the effects of GIK versus placebo in non-diabetic patients 
undergoing isolated coronary artery bypass grafting 196-198.  This trial also contained a 
third arm examining the effect of thyroid hormone in addition to or separate from GIK. 
160 patients were randomised to placebo and 157 to GIK198. 
 
The main clinical findings of these studies were that GIK improved haemodynamics 
in the post-operative period during the period of GIK infusion.  In addition, the 
incidence of low cardiac output episode as defined by a cardiac index of <2.2lmin-1m-
2
 was lower in the GIK group although after post hoc testing this did not reach 
significance.  In the GIK arm 33 / 157 patients (21%) required inotropic support for 
LCOE compared to 50 / 160 (31.3%) in the control arm 197.  However, GIK was 
associated with a consistent reduction in systemic vascular resistance and hence a 
parallel increase in vasopressor requirements.  In the GIK arm 108 / 157 (69%) of 
patients required vasoconstrictor therapy compared with 73 / 160 (46%) in the control 
group, p=0.0001. 
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The MESSAGE studies also examined myocardial injury at the time of surgery by 
analysing serial Troponin I plasma levels and serial ECGS.  There was no statistical 
difference in the incidence of new peri-operative myocardial infarction as defined by 
the presence of new Q-waves or new LBBB on serial ECGs and in the second no 
significant difference in Troponin release between the two treatment groups 197, 198.  
 
4.4.2 Previous studies of GIK in ventricular hypertrophy 
The majority of clinical trials in cardiac surgery have examined the effect of GIK in 
patients undergoing isolated coronary artery bypass grafting.  Although some of 
these patients will have had significant left ventricular hypertrophy secondary to 
hypertension, this is not detailed in any of the trials nor in the meta-analysis 
discussed above. 
 
A study from Finland by Koskenkari and colleagues randomised 40 patients 
undergoing combined AVR and CABG randomised 1:1 to GIK or control 199.  
Although they did not examine the degree of hypotrophy in these patients, the trial 
demonstrated a reduction in LCOE from 17 / 20 (85%) in the control arm to 13 / 20 
(65%) in the GIK arm with similar vasopressor requirements.  One patient in the GIK 
arm had a peri-operative myocardial infarction defined by peak Troponin I >60µgl-1 
compared to two patients in the control arm (N/S).  No other studies have examined 
the effects of peri-operative GIK administration on patients with demonstrable 
hypertrophy undergoing cardiac surgery. 
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5. Metabolomics 
Whilst it has been consistently demonstrated that LVH is associated with changes in 
the PCr:ATP ratio there is an appreciation that this may well be the end point of a 
down regulation of multiple metabolic pathways.  Such a down regulation may result 
in differing concentrations of multiple intermediary metabolites. 
 
Metabolomics is a novel field of investigation that attempts to analyse the small 
changes in metabolites, that individually, may be insignificant, but when compared 
together may demonstrate significant changes in the metabolome.  The metabolome 
represents the collection of all metabolites in a biological cell thus giving an instant 
snapshot of the physiology of that cell. It spans a variety of chemical compound 
classes, including those that are anionic versus cationic, and lipophilic versus 
lipophobic.  Metabolites in tissue are present across a broad range of concentration 
and no individual analytical method is capable of analysing all metabolites. 
 
5.1 Techniques for Metabolomic Analysis 
 
Metabolites can be measures by several available analytical methods.  
Chromatographic procedures such as gas chromatography (GC), high performance 
liquid chromatography (HP-LC) and capillary electrophoresis have all been used to 
identify and quantify metabolite subsets e.g., purine metabolites but are best used for 
initial separation in combination with other detection techniques 200, 201.  Recently, two 
high-throughput techniques have been used for profiling large numbers of 
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metabolites simultaneously: nuclear magnetic resonance (NMR) spectroscopy and 
mass spectrometry (MS).  NMR spectroscopy uses magnetic properties of nuclei to 
determine the number and type of molecular entities in a molecule whereas MS 
distinguishes metabolites on the basis of mass/charge ratio (m/z).  It requires a 
separation of the metabolite components but offers far greater sensitivity than NMR 
and has been used to resolve compounds in the femtomole / litre range. 
 
Fourier transform ion cyclotron resonance (FT-ICR) mass spectrometry ionizes 
compounds to generate charged molecules and then measures their mass-to-charge 
(m/z) ratio.  FT-ICR measures mass by detecting the image current produced by ions 
cyclotroning in the presence of a magnetic field.  Cyclotroning is the method of using 
a perpendicular magnetic field to accelerate charged particles to spiral almost in a 
circle so that they re-encounter the accelerating voltage many times.  Instead of 
measuring the deflection of ions within a detector such as an electron multiplier, the 
ions are injected into a static electric/magnetic ion trap (Penning trap) where they 
effectively form part of a circuit.  Detectors at fixed positions measure the electrical 
signal of ions which mass near them over time, producing a periodic signal.  Since 
the frequency of an ion’s cycling is determined by its mass to charge ratio, the m/z 
ratio can be calculated by a process of deconvoluting by performing a Fourier 
transform on the signal. Fourier transform is a mathematical algorithm which converts 
the wave form function into a secondary mathematical function 202. 
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5.2 Statistical Approaches to Metabolomic Data Reduction and Pathway Analysis 
High-throughput metabolomics risks generating false-positive associations due to 
multiple testing and over-fitting of data.  However, traditional statistical techniques to 
correct for such errors e.g. Bonferroni correction, result in an insurmountable 
statistical penalty, and even newer statistical techniques such as re-sampling 
methods, or control of false discovery rate do not really adequately address the 
fundamental problem of how to detect subtle but important changes in multiple 
variables identified in an ‘omics’ approach 203. 
 
For metabolites participating in set biological pathways, a bioinformatics approach 
using pathway analysis can instead be employed.  Although measurement error in 
the marker discovery phase often prevents high confidence in any individual 
metabolite’s correlation, the observation that multiple metabolites in a particular 
biological pathway are moving in a related fashion allows the correlation of changes 
in the biomarkers of that pathway to be made. 
 
There are a number of data reduction strategies that have been validated for 
processing high-throughput data including supervised learning multivariate analysis, 
cluster based discriminant analysis, partial least squares linear regression analysis 
and principal component analysis (PCA) 204. 
 
  
Page 1-79 
 
6. Hypotheses 
Symptomatic aortic stenosis is associated with a poor natural history with almost 
universal progression to heart failure and death if left untreated.  Animal models 
suggest that pathological hypertrophy is associated with impaired cardiac energetics 
secondary to maladaptive changes in metabolism.  Human data from patients in 
heart failure also suggests that impaired cardiac energetics as defined by a reduced 
PCr:ATP ratio is also highly predictive of survival.  Patients with significant 
hypertrophy undergoing cardiac surgery are known to be at increased risk of 
inadequate myocardial protection due to a number of morphological and functional 
abnormalities.  In addition significantly impaired energetics due to maladaptive 
changes in metabolism may further jeopardise their myocardial protection. 
 
Glucose-insulin-potassium has the potential to improve myocardial protection in 
these patients via a number of mechanisms.  High levels of glucose and insulin in the 
immediate pre-ischaemic period may improve myocardial glycogen storage.  
Switching substrate to more efficient glucose oxidation during reperfusion should 
improve aerobic ATP production and therefore also reduce the production of oxygen 
free radical species.  Insulin itself has also been linked to “memory-lacking” 
cardioprotection through the conditioning pathways.  This may therefore also 
decrease mPTP susceptibility to ROS through GSK-3β signalling pathway. 
 
1. Myocardial protection in patients undergoing aortic valve replacement for 
aortic stenosis may be improved by metabolic manipulation in the immediate 
peri-operative period. 
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2. Left ventricular hypertrophy in man secondary to aortic stenosis is associated 
with significant impaired energetics due to down-regulation of cardiac 
metabolic pathways as demonstrated by an abnormal metabolome. 
3. Glucose-insulin-potassium improves myocardial protection by suppressing 
plasma free fatty acid levels and up-regulating glucose transport in the early 
reperfusion period thus driving more efficient glucose metabolism. 
4. Insulin also exerts a direct cardio-protective effect on the cardiomyocyte via 
Akt / AMPK signalling.   
5. Insulin also increases protein O-GlcNAcylation and therefore decreasing the 
susceptibility of the mitochondria to oxidative stress and improving myocardial 
function following ischaemia reperfusion.  
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7.  Trial Design  
7.1 Patient Selection 
The aim of this study was to assess the impact of GIK on patients with with 
echocardiographic evidence of LVH as defined by a left ventricular mass index 
greater than 134 g.m-2 for men, or 100 g.m-2 for women 205, 206, undergoing AVR for 
AS ± CABG.  It was decided to include patients undergoing concomitant coronary 
artery revascularisation as this effects over 30% of patients undergoing AVR for AS 
and indeed patients with a combination of LVH and coronary artery disease may be 
at further risk from significant ischaemia-reperfusion injury.  To select a relatively 
homogenous patient group patients undergoing ascending aortic replacement were 
included but not those undergoing root or arch procedures.  Aortic root procedures 
are uncommon in patients with AS, and patients with arch pathology represent a 
different disease pathology, and tend to require more extensive surgery including 
circulatory arrest. 
 
Patients with isolated aortic regurgitation AVR were excluded.  These patients 
demonstrate eccentric remodelling with compensatory larger stroke volumes and 
therefore haemodynamically behave very differently. Patients with other significant 
valvular lesions were also excluded due to the impact of this haemodynamic 
pathology on ventricular function.  
 
Patients with atrial fibrillation, or those in sinus rhythm maintained with Amiodarone 
were also excluded.  Patients with significant LVH have a greater dependence on 
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active atrial contractility to maintain cardiac output, and the presence of AF can result 
in difficulties in measuring cardiac output using a thermodilution technique.  
 
7.2 Endpoint Selection and Power Calculation 
In 2003 when this trial was being designed, the mortality for isolated AVR was ~3%, 
and for patients undergoing AVR + CABG ~6% 207.  The operative mortality has 
continued to improve and the mortality until the year ending 2008 in the UK was 2 
and 4.5% respectively 208.  Powering a study designed to analyse survival in a single 
centre is therefore not possible.  We therefore examined potential surrogate markers 
of outcome. 
 
The incidence of LOCS following surgery in the UK however remains approximately 
30%.  This is thought to represent a type of myocardial stunning, and although most 
patients develop no permanent myocardial injury 209, some patients require prolonged 
or high dose inotropic support which may be associated with permanent injury 
resulting in further remodelling and fibrosis 210.  Additionally, of the patients that do 
not survive cardiac surgery, LCOE is implicated in 30% of deaths, and late outcome 
may be jeopardised 211, 212 
 
In previous trials of GIK in the department, the use of GIK was associated with a 
reduction in LCOE from 31% to 21% 198  The incidence of LCOE in patients 
undergoing AVR as recorded by the department PATS database is approximately 
35%. Based upon the assumption that GIK might offer similar benefits in patients 
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undergoing AVR, 220 patients randomised 1:1 to GIK or control would give the trial a 
90% power with 5% sensitivity. 
 
On this basis it was decided that LCOE would be both a feasible and clinically 
relevant primary endpoint.  To allow for comparison with previous work in the 
department, LCOE was defined as CI<2.2 lmin-1m-2.in the presence of adequate 
filling pressures (CVP 8-12mmHg or PAWP 12-16mmHg) and adequate heart rate, 
(80-110bpm) where systolic BP <90mmHg and/or inotropic support +- IABP for >60 
minutes to maintain such a clinical picture within six hours of cross clamp removal.  
Any patient meeting any of these criteria was to be presented to a blinded end-points 
committee where a diagnosis of LCOE was to be adjudicated. 
 
Secondary endpoints were pre-defined as need for inotrope therapy and total dose of 
inotrope therapy administered, post operative haemodynamics as defined by the 
cardiac index at 6 hours following AXC removal, stratified for surgeon and intent to 
perform CABG and new peri-operative myocardial infarction.  There is a paucity of 
data on which to define myocardial infarction following aortic valve surgery.  It was 
therefore decided to compare mean TnT at six hours post AXC removal, again 
stratified by surgeon and intent to perform CABG.  Additionally, a significant Troponin 
rise for patients undergoing isolated AVR was defined >0.8 µl-1 and in patients 
undergoing AVR + CABG >1.3 µl-1.  Safety outcome measures including length of 
stay, glucose control and wound infection rates. 
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7.3 Clinical Protocols 
To allow for appropriate comparison between groups pre-determined surgical and 
anaesthetic protocols were agreed by all trialists.  The management of potential 
LCOE episodes was also standardised.  Dopamine was selected as the first line 
inotrope as per standard clinical practice in our department. The first choice 
vasopressor however was changed from norepinephrine to phenylephrine.  Although 
in clinical practice norepinepherine is considered primarily an α-agonist it also has 
significant β1 effects resulting in an increase in contractility.  In contrast, 
phenylephrine is a pure α-agonist with no β effects. 
 
7.4 Haemodynamic monitoring 
Haemodynamic measurements were obtained in all cases with a Pulmonary artery 
flotation catheter (PAFC).  The cardiac output was measured using thermodilution. 
Three successive injections of 10 ml cold (6–10°C) dextrose 5% in water at end-
expiration were made. The recorded value was the mean of three individual 
measurements. Recorded values for pulmonary artery pressure, pulmonary artery 
wedge pressure (PWP) and CVP were obtained at end-expiration from graphic 
recordings. 
 
The indices of LV function used in this trial as a surrogate of LV function are both 
load and afterload dependent.  Therefore, in all patients, it was attempted to manage 
these parameters with appropriate filling to achieve a PAWP of 8-14mmHg and via 
the use of vasoactive drugs to achieve a SVR of 800-1200 dyne.cm-1.sec-5. 
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7.5 GIK Administration 
Previous studies with GIK in our department had infused GIK from the induction of 
anaesthesia until six hours post aortic-cross clamp removal.  The data from these 
previous studies had shown that this approach had resulted in a median infusion time 
of 85 minutes until the onset of global ischemia secondary to aortic cross-clamping.  
Animal data from GIK experiments had previously demonstrated maximal glycogen 
loading within one hour of administration.  Following aortic cross clamp removal, the 
nadir of ventricular function has been demonstrated to occur within six hours of aortic 
cross clamp removal 213,214.  Unless the myocardium is subjected to further ischemia, 
systolic function starts to improve although diastolic function may continue to decline 
213
.  To allow comparison of our results with these previous trials which were 
designed with the above rationale, it was elected to continue to infuse GIK from 
induction to six hours post aortic cross clamping.  Although overnight administration 
of GIK pre-operatively has been hypothesised to improve myocardial protection by 
increasing glycogen storage, due to staffing and logistical reasons it was agreed that 
this approach would not be appropriate in the current setting. 
 
7.6 Data Collection 
All data were prospectively collected and stored on a custom designed data sheet. 
Once data acquisition was complete for a patient the data were entered into a 
custom designed Microsoft™ Access© Database.  All data was anonymised and 
stored securely in compliance with Caldicott principles and the Data Protection Act. 
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7.7 Statistical Analysis 
Continuous data was assessed for normality and are presented as mean (standard 
error mean) or median (interquartile range).  Normally distributed data was analysed 
by Student’s t-test or by analysis of variance (ANOVA) with a post hoc Bonferroni test 
to allow for multiple comparisons.  Skewed data were analysed with Mann-Whitney 
u-test.  Categorical data was analysed by Fisher's exact test.  Main outcome 
analyses were pre-specified and conducted according to the intention-to-treat 
principle with the use of SAS software (version 9.1, SAS Institute, Ca USA). p values 
other than for the primary end point are nominal. Dichotomous outcomes were 
analysed with the use of nonlinear mixed models, which included CABG as a patient-
level covariate and Consultant as a random effects. Continuous data were analysed 
with the use of mixed models, which included CABG as a patient-level covariate and 
Consultant as random effects.  215. The rates of adverse events were compared 
between groups by means of Fisher's exact test.  
 
8. Experimental Design 
8.1 Left Ventricular biopsies 
To allow analysis of the cellular changes that occur in LVH, and the effect of GIK on 
ischemia/reperfusion it was elected to take biopsies of the anterior wall of the left 
ventricle between the LAD and its first diagonal branch.  Ethical approval was 
obtained to take biopsies in patients under the age of 80 years.  The upper age limit 
was chosen in light of surgical concerns in a potentially frail and high risk patient 
group.  Additionally, in some frail patients, biopsies were not taken at Consultant 
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request.  To preserve high energy phosphates, protein and RNA intact at the point of 
biopsy, samples were immediately snap-frozen in liquid nitrogen.  With these caveats 
in place, complete biopsies were collected on 124 patients enrolled in the trial. 
 
Full thickness left ventricular biopsies were taken with a tru-cut needle.  This method 
allowed a minimum of tissue (sometimes as little as 8mg) that could be processed for 
analysis.  It is accepted, particularly in patients with severe LVH, that cellular 
conditions may not be comparable between the epi- and endo-cardium.  There are a 
number of reasons why it was decided that this was acceptable and no further 
manipulation was required.  When comparing between LVH and non-LVH samples,  
whilst accepting the known differences in the sub-endocardium, it is not known to 
what level these differences reach, nor of how this is influenced by the degree of 
hypertrophy.  It was therefore decided that crude estimates of sub-endocardium 
would have been unhelpful.  When comparing between patients with LVH, because 
the echocardiographic markers of LVH were similar between groups, it was agreed 
that full thickness biopsy would therefore have been equally representative between 
groups. 
 
To date a number of experiments have been completed on the biopsies and a further 
set are planned.  A total of 26 patient samples were used in the metabolomics 
experiments, 42 in the western blotting of Akt, AMPK and Protein O-GlcNAcylation.  
Protein O-GlcNAcylation in particular is recognised as being very difficult to blot, and 
many samples were analysed before satisfactory blots could be obtained.  32 
samples were used in other experiments that are beyond the scope of this thesis.  
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The remaining samples have undergone metabolomic extraction and further work is 
ongoing as detailed in the final chapter. 
8.2 Metabolism in Left Ventricular Hypertrophy 
 
To assess changes in genotype expression, mRNA of the major transcription 
regulators of carbohydrate, fatty acid metabolism were compared using Taqman 
PCR.   
 
Following successful pilot experiments with mass spectroscopy, it was decided to 
develop this novel technique not previously reported in LV hypertrophy in man to 
analyse the many thousands of metabolites that construct the myocardial 
metabolome.  Metabolomics is a powerful technique in terms of high-throughput 
sampling, processing and analysis, however, it has a number of limitations.  There is 
a lack of systemised method for metabolite analysis, a bias to the only the most 
abundant or processable chemical metabolites, the lability of metabolites that require 
stringent extraction; and multiple confounding variables including age, gender and 
pharmacotherapy.   
 
To compare the metabolome and the transcription of master regulators of 
metabolism a control group needed to be identified.  This group must be of a similar 
age of the hypertrophy group because changes in the cellular phenotype with ageing 
have been demonstrated.  The control group clearly must have no evidence of 
hypertrophy or infarction nor of diabetes, insulin resistance or the metabolic 
syndrome.  More importantly, LV tissue samples needed to be obtained from this 
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group.  After much discussion, it was elected to use LV samples from patients with 
stable coronary artery disease undergoing elective CABG with no evidence of 
previous infarction, or echocardiographic evidence of hypertrophy. 
 
8.3 Cardioprotection and GIK 
Cardioprotective conditioning signalling pathways have been proposed as an 
important mechanism of the myocyte protecting itself against ischemia-reperfusion.  
It has been hypothesised that the protective effects of GIK is via a direct memory 
lacking cardioprotective effect, and animal data has suggested it is mediated via Akt 
and GSK-3β signalling pathway.  Ischemia is also known to up-regulate this 
pathways but not to the same extent.  Therefore to assess whether GIK upregulates 
these signalling pathways, biopsies of the left ventricle taken prior to the onset of 
ischemia in patients treated with GIK were compared to matched patients in the 
control arm.  Following protein extraction western blotting was used to quantify the 
total expression of both ACC and GSK-3β and the phosphorylated forms.  The ratio 
between the total expression and phosphorylated expression were then compared to 
give a marker of activation. 
 
8.4 GIK and Protein O-GlcNAcylation 
Recently it has been demonstrated that increased O-GlcNAc levels are associated 
with an increased tolerance to ischaemic stress increased transcription of HSPs 146 
147
, and activation of O-GlcNAc formation has also been shown to attenuate mPTP 
opening, a critical step in oxygen free radical-induced apoptosis and necrosis 151, 152.  
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To examine whether GIK therapy is associated with increased O-GlcNAc levels 
through both an increase in glucose substrate for the HBP and also increased flux via 
a direct action of insulin, left ventricular biopsies in patients treated with GIK were 
compared to matched patients in the control arm prior to the onset of ischaemia.  
Following protein extraction western blotting was used to quantify the total 
expression of protein O-GlcNAc. 
 
8.5 Metabolism and GIK 
To attempt to analyse the effect of GIK on metabolism, plasma glucose, free fatty 
acid and insulin levels were measured at pre-specified intervals during ischaemia 
and reperfusion.  Left ventricular biopsies in patients treated with GIK were compared 
to matched patients in the control arm after 10 minutes of reperfusion.  AMPK activity 
was analysed by comparing active phosphorylated-AMPK to total AMPK levels.  In 
the presence of suppressed free fatty acid levels, a significant increase in AMPK 
phosphorylation has been hypothesised to imply increased glucose oxidation which 
may improve recovery of high energy phosphates and therefore reduce the severity 
of injury secondary to reactive oxygen species during reperfusion ultimately leading 
to improved contractile function. 
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9. Trial Protocol 
9.1 Patient Selection 
All patients undergoing elective or urgent first time aortic valve replacement for aortic 
stenosis in the context of echocardiographic or magnetic resonance quantification of 
LVH were considered for recruitment to this study.  The patient inclusion and 
exclusion criteria used in this trial is detailed in Table 2.0.   
 
Inclusion criteria Exclusion criteria 
Aortic valve replacement for aortic 
stenosis +- concomitant coronary artery 
bypass grafting 
Left Ventricular Hypertrophy 
 
Other procedures required in addition 
to coronary artery bypass grafting 
Diabetes mellitus 
Atrial fibrillation or Amiodarone  
Renal failure (creatinine>200mmol.l-1) 
Liver failure 
Previous cardiac surgery 
Pregnancy 
Age <18 years 
Table 2 Inclusion and exclusion criteria 
 
9.2 Patient Recruitment 
Suitable patients were approached prior to surgery and counselled as to the nature of 
the trial. A patient information sheet was then made available to the patients. After 
having given the patients and relatives time to read and discuss the information sheet 
  
Page 2-93 
 
the patient was then approached again and if agreeable written informed consent 
was obtained for participation in the trial.  The patient information leaflet and consent 
form please see appendix B and C. 
 
9.3 Randomisation 
The allocation of treatment or placebo is randomly determined in a blinded fashion 
and includes stratification need for concomitant CABG. The randomisation schedule 
for the allocation of treatment or placebo uses a blinded minimisation procedure 
designed by Professor Nick Freemantle, Health Care Evaluation Group, University of 
Birmingham. 
 
9.4 Treatment Groups 
The treatment arm received a central GIK infusion consisting of 500ml of 40% 
glucose, 35IU Actrapid insulin (Novo Nordisk A/S, Bagsvaerd, Denmark) 50mmol of 
potassium chloride (KCl)) run at 0.75ml.kg-1.h-1 rounded to the nearest 10ml.h-1 
starting at sternotomy and finishing six hours following release of the AXC.  The 
control group received 5% dextrose run at 0.75ml.kg-1.h-1 rounded to the nearest 
10ml.h-1 starting at sternotomy and finishing six hours following release of the aortic 
cross clamp (AXC).  To ensure blinding of investigators, trial solution bags of 
placebo/GIK were wrapped in opaque tape to conceal the identity of the solution and 
simply labelled as “trial solution”.  
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9.5 Anaesthetic Protocols 
9.5.1 Premedication, induction and maintenance of anaesthesia 
Pre-medications were administered 90 minutes prior to surgery and consisted of 
temazepam (maximum dose of 30mg), ranitidine 150mg and metoclopramide 10mg. 
Anaesthetic induction was with fentanyl 10-15µg.kg-1 or alfentanyl 15µg.kg-1 
(anaesthetist choice), etomidate 0.1-0.2mg.kg-1 and pancuronium 0.1mg.kg-1  
Anaesthesia was maintained by a propofol based anaesthetic with either propofol (1-
2% neat strength at the discretion of the anaesthetist) infused at 4-8mg.kg-1.h-1 or 
using target controlled rate at 2-4µg.ml-1 and alfentanyl 25mg in 50ml (neat) infused 
at 50µg.kg-1.h-1. enflurane was used to supplement propofol-based anaesthesia but 
was not mandatory. Other volatile anaesthesia were not permitted.  All patients 
received a quadruple lumen central venous (CVP) line and a pulmonary artery 
flotation catheter (PAFC) fully floated into the pulmonary artery prior to sternotomy. 
 
9.5.2 Other medication 
Mannitol (20%) as an osmotic diuretic (0.5ml.kg-1) was administered via the CVP line 
prior to institution of CPB. Phenylephrine (0.1mg.ml-1) was administered in aliquots to 
maintain a MAP 60-70mmHg. Aprotinin was administered at full-dose with a test 
dose of 1 000 000 units, followed by an iv bolus dose of 2 000 000 units with 2 000 
000 units given into the CPB circuit followed by a continuous infusion of 500 000 
units.hr-1 in all cases.  Heparin was administered prior to the institution of bypass and 
after the termination of bypass was reversed by Protamine at a dose of 1mg per 
100iu of heparin. 
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9.6 Perfusion Protocol 
All patients underwent surgery utilising CPB. For all cases a roller pump with a 2l  
Hartman’s prime with 8000U heparin and a Capiox SX oxygenator were used. 
Intermittent antegrade cold blood cardioplegia was administered via the aortic root 
and directly into the coronary ostia following aortotomy using St Thomas A for 
induction at 12ml.kg-1 and St Thomas B for maintenance at 6ml.kg-1 diluted 4:1 with 
blood (see Table 5.2 for composition) at a rate of 300ml.min-1 or a pressure of 120-
150mmHg. Maintenance doses of cardioplegia were administered after 20 minutes or 
at earlier intervals at the discretion of the surgeon. Supplemental retrograde 
cardioplegia and “hot shots” were not permitted. All patients were actively cooled to 
32oC. A target mean radial artery perfusion pressure of 50-60mmHg was maintained 
using phenylephrine (0.1mg.ml-1). For all cooling and re-warming, blood/water 
temperature gradients were ≤ 7oC. On re-warming once the nasopharyngeal 
temperature reached 35oC, the heater/ chiller temperature was set to 37oC. 
 
St Thomas A Solution St Thomas B Solution 
898ml Ringers compound NaCl 
102ml Cardioplegia solution containing 
   16.6g Magnesium Chloride 
    6.1g Potassium Chloride 
    1.4g Procaine Hydrochloride 
 
966ml Ringer’s compound NaCl 
34ml Cardioplegia containing 
   5.2g Magnesium chloride 
   1.9g Potassium chloride 
   0.4g Procaine hydrochloride 
Table 3 Composition of Cardioplegia 
 
  
Page 2-96 
 
9.6 Surgical Protocol 
9.7.1. Conduct of Operation 
 
After transfer to the operating theatre the patient was prepped and draped as 
standard. If concomitant bypass grafting were to be performed then the internal 
mammary artery and saphenous vein/radial artery were harvested synchronously. 
After harvest of conduit CPB was instituted in a standard fashion with venous 
drainage from the right atrium using a two-stage cannula, with single arterial return to 
the ascending aorta. An AXC was applied proximal to the aortic cannula and 
cardioplegia solution delivered into the aortic root as previously detailed. 
 
For patients undergoing concomitant revascularisation, the distal anastomoses of all 
free grafts were first performed.  The aorta was then opened, the valve explanted, 
the annulus sized and the valve replaced in a manner of the surgeons choosing.  
Supplemental doses of cardioplegia were delivered by direct ostial cannulation.  The 
heart was vented either through a direct left ventricular vent or left superior 
pulmonary vein vent.  The heart was then de-aired and the aortotomy closed.  If 
pedicled coronary artery grafts were to be placed then the distal anastomes were 
then performed.  The aortic cross clamp was then removed and all proximal aorto-
spahenous anastomses performed during a period of partial aortic occlusion. 
 
In cases of severe ascending aortic calcification instead of a standard cross clamp, a 
22 Fr TRIUMPH aortic occlusion arterial cannula was introduced directly into the 
ascending aorta.   If aortic calcification made application of a side biting clamp 
perilous, proximal anastomses were performed using a period of single aortic cross 
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clamping.  If the ascending aorta was dilated then it was replace an interposition graft 
(Gelweave, Vasctex Terumo, Scotland). 
  
Right atrial and ventricular pacing wires were placed prior to separation from CPB. 
Patients were separated from CPB with a heart rate of 70-110bpm (native or paced) 
without inotropic support if possible. Drains were placed to the mediastinum and 
open pleural cavities and closure was performed in a standard fashion with sternal 
wires and layers of Vicryl. 
 
9.7.2. Myocardial Biopsy 
 
Biopsies were full thickness and taken from the left ventricular (LV) free wall. LV 
biopsies were obtained using a Trucut biopsy needle (Allegiance Healthcare, McGaw 
Park, IL). LV biopsies were taken prior to application of the AXC (pre-ischaemia), 
immediately before removal of the AXC (ischaemia) and approximately 10 minutes 
after removal of the AXC (reperfusion). Biopsies were immediately snap frozen in 
liquid nitrogen and subsequently stored at -80oC. Biopsy sites were oversewn with 
5’O’ prolene to ensure haemostasis. 
 
9.8 Assessment and management of hypotension 
 
For the purposes of this study hypotension was defined as MAP< 60mmHg. Prior to 
institution of any inotrope or vasoconstrictor therapy the following were assessed: the 
accuracy and calibration of the arterial line; heart rate and rhythm and right and left 
sided filling pressures. If any therapy could be instituted at this stage e.g. pacing rate, 
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fluid challenge, then these were performed. Finally a set of cardiac output studies 
was performed. If the CI was less than 2.2l.min-1.m-2 with a normal SVR 9800-
1200dyne.cm-1.sec-5) and adequate filling and heart rate, the protocol for 
management of LCOE was followed (section 8.9). In the event of a CI greater than 
3.0l.min-1.m-2 with a low SVR (< 800dyne.cm-1.sec-5) vasoconstrictor therapy with 
phenylephrine (10mg in 50ml of dextrose 5% at 0-0.2µg.kg-1.h-1) titrated to the 
response of the MAP was instituted. If the ceiling dose of 0.2µg.kg-1.h-1 of 
phenylephrine was reached without the MABP returning to the range 65-85mmHg 
then vasopressin (20U in 40 ml of 5% dextrose) at 5 U.h-1 was started. Further 
treatment above these levels was at the discretion of the patient’s clinical team 
 
9.9 Management of suspected low cardiac output episode 
 
For the purpose of this study a LCOE was defined as a CI of less than 2.2l.min-1.m-2 
refractory to appropriate intra-vascular volume expansion following correction or 
attempted correction of any dysrhythmias. In the case of inotropic support being 
instituted due to a LCOE, all data were analysed by a blinded endpoints comprising 
at least two consultant surgeons.  In order to qualify as a LCOE episode a 
unanimous verdict was sought but in the event of disagreement, contentious cases 
were discussed and a consensus opinion agreed. 
 
9.9.1 Inotrope Therapy 
 
In the event of a LCOE inotropic therapy was instituted. Dopamine was used as the 
first line inotropic agent in this study (200mg in 50ml 5% dextrose). and instituted at a 
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dose of 5-10 µg.kg.-1.min-1 according to a prepared nomogram. Thereafter, all 
management considered necessary above and beyond dopamine 10µg.kg.-1.min-1 
was at the discretion of the clinical team. 
 
9.9.2 Low cardiac output episode in theatres and anticipatory treatment 
Whenever possible cardiac output studies were performed and recorded prior to 
institution of inotropic support. In the case of an anticipated LCOE based on 
subjective and objective features of cardiac performance before and during surgery, 
confirmatory cardiac output studies were performed if possible. Otherwise inotropic 
therapy was started at the discretion of the clinical team and charts underwent review 
by the endpoint committee. 
 
9.10 Biochemical monitoring 
After initiating the trial solutions in theatre serial arterial blood gases (ABGs) were 
performed every 30 minutes until institution of CPB, every 20 minutes during CPB 
and hourly for the first 12 hours following removal of the AXC. Thereafter ABGs were 
performed at the discretion of the clinical team. 
 
During the trial, blood samples were taken from all patients at baseline, during 
reperfusion and then at 6 and 12 hours following cross clamp removal.  Plasma 
glucose was measured in fluoride oxalate samples using a Yellow Springs analyzer 
(YSI2300; Yellow springs instruments Aldershot, UK), plasma insulin levels were 
measured by radioimmunossay (Pharmacia, Uppsala, Sweden) and FFA by a 
commercial enzymatic system (NEFA-C, Wako, Neuss, Germany).  The area under 
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the curve for the mean plasma levels was calculated and compared between GIK 
and control using Mann-Whitney u-test. 
 
9.11 Blood glucose management  
The aim of glycaemic control in this study was to maintain a blood glucose level 
within a target range of 4.1-10.0mmol.l-1. Levels of blood glucose greater than 
10.0mmol.l-1 were treated with an insulin actrapid sliding scale (50 units actrapid in 
50ml normal saline – see Appendix C for sliding scales). Supplemental boluses of 
insulin were permitted to obtain glycaemic control. Regardless of blood glucose 
readings actrapid infusions were terminated one hour prior to termination of trial 
solutions to prevent rebound hypoglycaemia. 
 
Hypoglycaemia for the purposes of this study was defined as blood glucose less than 
4.0mmol.l-1. In the event of hypoglycaemia, treatment was given as a bolus of 25mls 
of 50% dextrose. Blood glucose measurement was then repeated after 30 minutes 
and supplemental boluses of 50% dextrose administered as required. 
 
9.12 Potassium Management   
Serum potassium levels were maintained in the range of 4.5-5.5mmol.l-1. Prior to and 
during cardiopulmonary bypass supplemental potassium was not administered 
unless clinically indicated. After cardiopulmonary bypass intravenous potassium 
chloride was administered to maintain potassium levels within the range 4.5-
5.5mmol.l-1 during the first 12 hours. 
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10. Laboratory Protocols 
10.1 RNA and Protein Extraction 
Biopsies were initially homogenised using Ultraturax homogeniser at 10,000 rpm for 
30-60 seconds in the presence of 1ml Tri Reagent©.  The samples were allowed to 
stand at room temperature for 5 minutes. 0.2ml chloroform per ml of TRI Reagent© 
was then added and thoroughly mixed.  This was then allowed to stand for a further 
10 minutes at room temperature. 
 
Samples were centrifuged at 12000g for 15 minutes at 4 oC separating into an upper 
colourless aqueous phase containing RNA, a middle layer of protein and a lower 
layer of DNA.   
 
10.1.2 Isolation of RNA 
The RNA phase was transferred to a clean eppendorf tube adding 0.5ml of 
isopropanol per ml of Tri Reagent©.  This was thoroughly mixed and left to stand at 
room temperature for 10 minutes. 
 
Samples were centrifuged at 12000g for 10 minutes at 4oC to precipitate a pellet of 
RNA.  The supernatant was removed and discarded and the RNA pellet washed with 
1ml 75% ethanol per ml TRI Reagent©.  Samples were vortexed and then 
centrifuged at 12000g for 5 minutes at 4oC. 
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Samples were air-dried to remove all residual ethanol.  The RNA was then dissolved 
in 50 µl nuclease free water by repeat pipetting at room temperature. 
 
10.1.3 Isolation of Protein 
Following removal of the aqueous phase containing RNA, the DNA was precipitated 
with 0.3ml of 100% ethanol per 1ml TRI Reagent© used for the initial 
homogenisation.  The samples were thoroughly mixed and incubated at room 
temperature for 2-3 minutes.  The sample was centrifuged at 2000g for 5 minutes at 
4 oC to sediment the DNA. 
 
300 µl of the supernatant (phenol/ethanol phase) was transferred to a clean 
eppendorf and the DNA destroyed.  Proteins were precipitated by adding three 
volumes of acetone.  The sample was thoroughly mixed for 10-15 seconds to obtain 
a homogenous solution and stored at room temperature for 10 minutes at room 
temperature before being centrifuged at 2000g for 10 minutes at 4o C to sediment the 
protein. 
 
The supernatant was then discarded and the protein pellet re-suspended in 0.5mk of 
0.3M guanidine HCl in 95% ethanol 2.5% glycerol (1:1).  Following dispersion a 
further 0.5ml of guanidine HCL in 95% ethanol 2.5%glycerol (1:1) wash solution was 
added and the sample incubated at room temperature for a further 10 minutes.  The 
protein was sedimented by centrifugation at 8000g for 5 minutes at room 
temperature.   
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The wash solution was then decanted and two further washes with incubations and 
spins in 1 ml of guanidine HCL in 95% ethanol 2.5%glycerol (1:1) were made.  After 
each wash the sample was vortexed to disperse the pellet and remove residual 
phenol. 
 
The final wash was made in 1ml ethanol containing 2.5% glycerol (v:v) and the 
sample was then incubated for 10 minutes at room temperature. The proteins were 
sedimented by centrifuging at 8000g for 5 minutes at room temperature.  The alcohol 
was decanted and the samples air dried for 30 minutes at room temperature.  The 
proteins were solubilised by adding 200µl 1% SDS and gently dispersed and 
supplemented with 0.025% Tween 80.  The proteins were stored at -80oC until 
required.  
 
10.2 Reverse Transcription and Quantitative PCR 
RNA was reverse transcribed using avian myeloblastosis virus (AMV) reverse 
transcriptase (Promega, Madison, WI) in a total reaction of 20 µl, with 1 µl of total 
RNA, 30pmol random hexamer primers, 4 µl of 5x AMV reverse transcriptase buffer 
2 µl of deoxynucleotide triphosphate (dNTP) mix (200 µM each), 20U ribonuclease 
inhibitor (RNain; Promega) and 15U of AMV reverse transcriptase. 
 
Expression of specific mRNA was determined using the ABI PRISM 7500 sequence 
detection system.  RT-PCR was carried out in 25 µl volumes on 96 well plates in a 
reaction buffer containing 1x TaqMan Universal PCR Master Mix, 0.75 µl TaqMan 
probe per reaction and 4.5 µl forward and reverse primer per reaction.  All reactions 
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were multiplexed with a pre-optimised control probe for 18s RNA (ABI, Warrington, 
UK).  As per the manufacturer’s guidelines, data were expressed as cycle threshold 
(Ct) values and used to determine the ∆Ct value.  This was calculated by the Ct of 
the housekeeping gene from the Ct of the target gene.   
 
Statistical comparison was made between the ∆Ct values to exclude potential bias 
caused by averaging data that had been transformed through the equation 2-∆∆Ct to 
give the fold changes in gene expression. 
 
Target genes were labelled with FAM and housekeeping genes with VIC.  All 
measurements were carried out twice on each sample.  Reactions were at 50 oC for 
2 minutes and at 95 oC for 10 minutes followed by 40 cycles. 
 
10.3 Western Blotting 
Resolving gels of varying concentrations were prepared depending upon the 
intended target.  Resolving gel preparations are shown in Appendix E.  The gel was 
pipetted into clean gel plate and 1000 µl of isopropranol was added.  The gel was 
allowed to set and then the isopropranol removed. 
 
A stacking gel of 5% acylamide, 0.2M Tris-HCl pH 6.87, 7mM SDS, 0.2% v/v TEMED 
and 8.8mM APS was prepared and layered on top of the resolving gel.  Protein 
samples were loaded alongside Bio-rad Precision Plus Protein Prestained Dual 
Colour standards.  Gels were then run using the Mini-Protean III electrophoresis cell 
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(Bio-Rad) and electrophoresed at 200 V through the resolving gel in SDS running 
buffer (25mM Trizma base, 192 mM glycine, 3.5 mM SDS) for 50 minutes. 
 
Two pieces of 3mm filter paper (Whatmann, Kent, UK), a 10 cm x 8 cm sheet of 
PVDF membrane (Hybond-P, Amersham Biosciences, Amersham, UK) pre-soaked 
in 100% methanol, and two fibre pads were equilibrated in transfer buffer (25mM 
Trizma base, 192mM glycine, 20% methanol), and the electrophoresed SDS-PAGE 
gel was sandwiched in a transfer cassette of the Mini Protean III transfer apparatus 
(Bio-Rad, Hemel Hempstead, UK).   
 
Protein was transferred onto the PVDF membrane at 250 mAmp for ninety minutes.  
Following transfer, the membrane was blocked with 5% (w/v) Marvel dried skimmed 
milk in TBS-T (Tris-buffered saline containing 20mM Tris-HCl pH 7.6, 140mM NaCl 
and supplemental with 0.025% Tween 80) for at least one hour on a rocker bed at 
room temperature. 
 
Membranes were probed overnight with the primary antibodies diluted in 5% (w/v) 
milk-TBS-T at 4 oC on a rocker bed.  Primary antibodies are detailed in Appendix F.  
Membranes were then washed four times in TBS-T with fifteen minute incubations on 
a rocker bed between each wash. 
 
The membrane was incubated with the appropriate secondary antibody diluted in 5% 
milk TBS-T for one hour on a rocker bed.  The membranes were further washed for 
one hour with TBS-T at room temperature changing the wash solution every ten 
minutes. Excess wash buffer was then discarded and the membranes incubated with 
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ECL (Enhanced Chemiluminesence Plus (Amersham Biosciences) at 5 minutes at 
room temperature.  The excess detection reagent was drained off, the blots covered 
and then placed protein side up in an X-Ray film cassette.  A sheet of 
autoradiography film (Hyperfilm© ECL, Amersham Biosciences) was placed on top of 
the membrane, the cassette closed and exposed for 10 seconds and developed.  On 
the basis of the appearance of this film, the exposure time for further films was 
adjusted to give optimal results. 
 
The limitations of western blotting are widely accepted.  It is a slow, complex and 
cumbersome technique which is very operator dependent.  Only one protein can be 
analysed at time, and repeated stripping and re-probing may result in protein loss 
and incorrect results.  It is however a robust and reproducible method of protein 
analysis and recent advances in digital image processing have made analysis of the 
final photographic results increasingly accurate. 
 
10.4 Mass Spectroscopy 
Metabolites were extracted from 10 non-LVH and 10 LVH cardiac tissue biopsies 
using a two-step methanol:water:chloroform protocol.  Samples were initially 
homogenised using a 24 bead-based homogeniser (Stretton Scientific, Stretton, UK) 
320µl methanol and 128µl water.  The homogenate was removed into a 1.8ml glass 
vial and all of the remaining solvents were added (320µl chloroform 128µl water).  
Samples were then vortexed for 60 seconds and left on ice for 10 minutes to allow 
partition.  The samples were centrifuged at 2000g at 4oC for 5 minutes.  
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The polar fraction from each biphasic mixture was removed, split into two equal 
volumes, and then dried in a centrifugal concentrator. An “extract blank” was also 
prepared using identical methods except that no biological material was added to the 
solvents.  These were then stored at -80°C until analysis.  
 
Following resuspension of the dried polar extracts in 80:20 methanol:water, 
containing 0.25% formic acid or 20 mM ammonium acetate for positive and negative 
ion analysis respectively, Fourier transform ion cyclotron resonance (FT-ICR) mass 
spectrometry-based metabolomics was conducted using a hybrid 7-T LTQ FT 
(Thermo Scientific, Bremen, Germany) equipped with a chip-based direct infusion 
nanoelectrospray ion source (Triversa, Advion Biosciences, Ithaca, NY).  
 
The nanoelectrospray conditions comprised of a 200nl/min flow rate, 0.3psi backing 
pressure and +1.7 or -1.7 kV electrospray voltage respectively for positive and 
negative ion analysis controlled by ChipSoft software (version 8.1.0 Advion 
Biosciences, UK).  
 
Each sample was analysed in triplicate with Fourier transform ion cyclotron mass 
spectroscopy (FT-ICR MS) collecting multiple adjacent selected ion monitoring (SIM) 
windows which are stitched together from m/z 70 to 500 with each window 
overlapping by m/z 10 (3) with automatic gain control (AGC) target of 1 x 105 charges 
and a mass resolution of 100,000.  Data was recorded for 5.5 minutes per replicate 
analysis using Xcalibur software version 2.0, (Thermo Scientific, USA).   
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Transient data from the FT-ICR detector were processed using averaging of 
transients, Hanning apodisation and application of a fast Fourier transformation all 
using custom written code in MATLAB Version 7.0 (The MathWorks, MA USA).  
 
Next the SIM-stitching algorithm was applied (Custom written code, MATLAB, 
Version 7.0 The MathWorks) 216 which stitched together multiple SIM windows, 
rejected all peaks with a signal-to-noise ratio (SNR) <3.5, and then internally 
calibrated each mass spectrum using a pre-defined calibrant list of metabolites (3).   
 
The data were normalised using probabilistic quotient normalisation (PQN) to 
minimise the effects of particularly high and low intensity peaks 96.  They were then 
subject to generalised log transformation 217 to stabilise the variance across the 
several thousands of detected peaks in order to avoid the highest intensity peaks 
dominating in the multivariate analysis. Principal components analysis (PCA) was 
used to assess the metabolic differences between the sample groups in an unbiased 
manner, using the PLS_Toolbox (version 3.53, Eigenvector Research, Manson, WA, 
USA) within Matlab (version 7.1; The MathsWorks, Natick, MA, USA), and confirmed 
using Student’s t-tests (MS Excel, Seattle, USA). To determine empirical formulae 
and putative metabolite identities of key peaks in the mass spectra, the strategy of 
Taylor et al., 218 was followed, and Student’s t-tests with appropriate correction for 
multiple hypothesis testing were conducted to assess the significance of these 
metabolic changes between groups. 
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10.5 Principal component analysis  
Principal component analysis (PCA) is a mathematical reduction strategy that has 
been validated for processing high-throughput data.  It attempts to transform a 
number of possibly correlated variables into a smaller number of uncorrelated 
variables called principal components.  The aim is for the first principal component to 
account for as much variability in the data as possible, and each following component 
to account for as much of the remaining variability as possible.  Although this is a 
highly complex mathematical technique, it is actually one of the simplest available 
tools for this type of data processing.  In the multivariable metabolomic dataset 
produced by our FT-ICR MS analysis, the PCA plots each individual dataset as a set 
of co-ordinates. 
 
This technique has accepted limitations including assumptions on linearity, and on 
the importance of mean and covariance, but a detailed description of this 
computational technique and its limitations is beyond the scope of this work. 
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Chapter 3.  An integrative systems biology study 
of the metabolic profile in ventricular hypertrophy 
secondary to aortic stenosis in man. 
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11.  Introduction 
Integrative systems biology is the attempt to explain biological phenomenon not only 
by the delineation of genes and molecules but by reconstructing biochemical 
supramolecular networks that represent various cellular functions.  The process 
leading to integrative systems biology consists of combining elements of the genome, 
transcriptome, proteome and the metabolome. 
 
To perform such a study of the overall metabolic pathway changes LVH in man, we 
combined analysis of key parts of the metabolic transcriptome, the transcription of 
the master transcriptional regulators PGC-1α, PPARα and ERRα, the key fatty acid 
transport protein CPT1 and the glucose uptake transporter GLUT-4, and the enzyme 
controlling the crux of the glycolytic pathway via inhibition of PDH, the kinase PDK-4, 
with the resultant metabolome, and compared this to that of a non hypertrophied 
control. 
 
There are a number of master transcriptional regulators.  PGC1α was chosen 
because it is a transcriptional co activator that regulates the genes involved in energy 
metabolism, interacting with PPARα.  It is also thought to be a master integrator of 
external signals and is known to be activated by a number of factors including 
reactive oxygen species, reactive nitrogen species, cAMP and the Akt pro-survival G-
protein signals.  PPARα was chosen as it is a controls the transcription of factors 
regulating cellular differentiation and metabolism, controlling carbohydrate, lipid and 
protein metabolism, and ERRα is a nuclear receptor widely expressed in tissue that 
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preferentially uses fatty acids as a predominant energy source.  It is involved in 
regulating mitochondrial biogenesis, gluconeogenesis, oxidative phosphorylation and 
fatty acid metabolism.   
 
There are a number of critical steps in fatty acid oxidation, however one of the crucial 
and rate limiting step is the transport of long chain acyl groups from fatty acids across 
the impermeable mitochondrial membrane by carnitine so that they can undergo β-
oxidation 27.  On the outer mitochondrial membrane fatty acids are attached with a 
thioester bond to coenzyme A (CoA), a reaction catalysed by fatty-acyl-CoA 
synthetase 27.  Acyl CoA is conjugated to carnitine by carnitine palmitoyltransferase I 
(CPT-I) on the outer mitochondrial membrane and it is then shuttled inside by 
carnitine-acylcarnitine translocase.  Acyl-carnitine is then converted to acyl-CoA by 
CPT-II on the inner mitochondrial membrane where it can then undergo β-oxidation 
27
.  Similarly, there are a number of crucial steps involved in glycolysis.  The uptake 
of extracellular glucose is regulated by the transmembrane glucose gradient and the 
concentration and activity of glucose transporters including GLUT 4 22, 23.   
 
The metabolome represents the collection of all metabolites within the cell.  These 
represent not just the end products of cellular metabolism but all the individual 
intermediate and by-products as well as all the proteins and enzymes.  Using 
principal component analysis it is possible to possibly correlated variables into a 
smaller number of uncorrelated variables called principal components.  The first 
principal component will account for as much of the variability in the data as possible.  
This means that in a complex system of interconnected reactions, small changes in 
the concentration of each individual intermediate, which individually may not be 
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significant, when analysed as a whole system can allow the differences to be 
identified. 
 
12. Methods 
12.1 Patients 
Following local ethics approval, age and sex matched patients with LVH secondary to 
AS undergoing AVR with no significant coronary artery disease in the placebo group 
of the HINGE trial were compared to age and sex matched patients undergoing 
elective CABG without both echocardiographic evidence of hypertrophy and clinical 
evidence of hypertension, previous infarction or ongoing ischemia were studied as a 
control group. 
 
12.2 Echocardiographic Assessment of LV Function 
The LV end-diastolic dimensions (LVEDD/ mm), inter-ventricular septum thickness 
(IVS/ mm) posterior wall thickness (PW / mm) and LV ejection fraction (LVEF, %) 
were assessed using M-mode echocardiography as per the American Heart 
Association guidelines for reporting echocardiography 219. 
 
12.3 Invasive Haemodynamic Studies 
The pre-operative cardiac output was measured using a standard thermodilution 
technique at end-expiration with three successive injections of 10mls cold (6-10oC) 
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5% dextrose.  The recorded value was the mean of three individual measurements.  
Recorded values for pulmonary artery pressure, pulmonary artery wedge pressure 
(PAWP) and central venous pressure were obtained at end-expiration from graphic 
recordings. 
 
12.4 Myocardial Biopsies 
A single full thickness tru-cut biopsy was taken from the anterior wall of the left 
ventricle between the left anterior descending artery and its first diagonal branch 
immediately after instituition of cardiopulmonary bypass but prior to aortic cross-
clamping.  These were snap frozen and then stored at -80oC until the analysis. 
  
12.5 RT-PCr Analysis 
Total RNA from LV biopsies was isolated using TRI Reagent (Ambion, UK).  
Following nano-drop spectrophotometer analysis for purity, cDNA was reversed 
transcribed using Taqman MultiScribe (Applied Biosystems, UK).  Commercially 
available primers and probes were purchased (Applied Biosystems, UK) to amplify 
and quantify expression  levels of target genes (PGC1 ,ERRα , PPARα , CPT1M, 
PDK4, SLC2A4) and of housekeeping gene 18s using an ABI 7500 real time PCR 
machine (Applied Biosystems, UK).  PCR amplification was performed in duplicate 
and expression levels were normalised to 18s. Real time PCR data are presented as 
arbitrary units (AU) (calculated as AU=1000x2^(-∆Ct)). Expression levels of target 
genes were set as 1 in CABG patients (control) and compared to LVH using the 
Mann-Whitney-U test (statistical significance level was set as p<0.05). 
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12.6 Metabolomics  
Metabolites were extracted from cardiac tissue biopsies using a two-step 
methanol:water:chloroform protocol 218. The polar fraction from each biphasic mixture 
was removed, dried and then stored at -80°C until analysis.  The samples were then 
resuspended in 80:20 methanol: water, containing 0.25% formic acid or 20 mM 
ammonium acetate for positive and negative ion analysis respectively. Fourier 
transform ion cyclotron resonance (FT-ICR) mass spectrometry-based metabolomics 
was conducted using a hybrid 7-T LTQ FT (Thermo Scientific, Bremen, Germany) 
equipped with a chip-based direct infusion nanoelectrospray ion source (Triversa, 
Advion Biosciences, Ithaca, NY).  
 
Principal components analysis (PCA) was used to assess the metabolic differences 
between the sample groups confirmed using Student’s t-tests. Taylor strategy was 
then employed to determine empirical formulae and putative metabolite identities of 
key peaks in the mass spectra 220, was followed, and Student’s t-tests with 
appropriate correction for multiple hypothesis testing were conducted to assess the 
significance of these metabolic changes. 
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LVH 
 
Non-LVH 
 
p value 
    
Sample size n=10 n=10  
Age 69 ± 2.1 67 ± 2.4 0.67 
Gender M/F 5 / 2  5  / 2 0.45 
Height (cm) 167.0 ± 1.98 166.3 ± 1.78 0.8 
Weight (kg) 79.78 ± 2.95 82.1 ± 2.36 0.23 
BSA (m2) 1.89 ± 0.05 1.91 ± 0.05 0.1 
CCS  
     I 
     II 
     III 
     IV     
 
 
5 
5 
0 
0 
 
 
0 
9 
1 
0 
 
 
 
 
0.2 
NYHA  
     I 
     II 
     III 
     IV 
 
 
0 
4 
6 
0 
 
 
10 
0 
0 
0 
 
 
 
 
 
0.41 
Hypercholesterolaemia 1 7 0.08 
Hypertension 4 1 0.06 
CAD 0 10 0.001 
Pre-op Medication 
    β -Blocker 
     ACEi 
     Statin 
 
0 
6 
4 
 
10 
1 
9 
 
0.001 
0.5 
0.34 
BSA – Body Surface Area; CCS – Canadian Cardiovascular Society; NYHA – New York Heart Association; CAD – 
Number of Coronary Arteries with flow limiting lesions 
Table 4 Patient Demographics in the LVH and control groups  
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LVH 
 
Non-LVH 
 
p value 
 
IVSd (cm) 
 
1.64 ± 0.04 
 
1.06 ± 0.03 
 
<0.0001 
LVEDd (cm) 4.67 ± 0.13 4.97 ± 0.13 <0.0001 
PWd (cm) 1.51 ± 0.04 0.97 ± 0.02 <0.0001 
LVMI g/m2 151.73 ± 24.23 109.35 ± 21.16 0.001 
Peak Aortic velocity (ms-1) 4.78 ± 0.6 1.28 ± 0.2 <0.0001 
Mean AV Gradient (mmHg) 56 ± 6.11 6.1 ± 0.03 <0.0001 
Stroke Volume (mls) 46 ± 2.58 67 ± 3.46 <0.0001 
Ejection Fraction (%) 57 ± 6.16 64  ± 7.23 0.01 
IVSd – Interventricular septum in diastole; LVEDd – Left Ventricular End Diasolic dimension; PWd Posterior Wall in 
diastole; LVMI – Left Ventricular Mass Index 
Table 5.  Echocardiographic data from patient in the LVH and control groups 
 
13. Results 
13.1 Left Ventricular Hypertrophy and Diastolic Dysfunction in AS  
In comparison to control patients, patients with aortic stenosis had significant left 
ventricular hypertrophy characterised by significantly increased LV septal and free 
wall thickness and calculated left ventricular mass index (LVMI) as detailed in Table 
5.  Although these patients exhibited preserved systolic function (EF 57% ± 6.16 vs 
64% ± 7.23 in AS patients and controls respectively), the LVH patients had evidence 
of LV diastolic dysfunction manifested by an increase in PAWP (14 mmHg vs. 8 
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mmHg in LVH and non-LVH patients respectively, p=0.01) indicative of a raised left 
ventricular end diastolic pressure, and profoundly reduced stroke volumes (46 ml ± 
2.58 vs 67 ml ± 3.46 in LVH and non-LVH patients respectively, p=0.01) 
13.2 Down-regulation in the Cardiac Metabolic Transcriptome 
Compared to non-LVH controls, the patients with LVH exhibited profound down-
regulation of the mRNA transcript levels of the master transcriptional regulators 
PGC1α, PPARα, and ERRα. There was also a significant down-regulation of key 
metabolic enzymes involved with both free fatty acid metabolism and glucose 
transport (mCPT1 and GLUT4) (Fig 8). 
 
Figure 8. Cardiac Metabolic Gene Expression Studies From Cardiac Biopsies of Patients with 
LVH and Non-LVH undergoing Cardiac Surgery. Non-LVH controls have been normalised to 1 
*p<0.05, **p<0.01, ***p<0.001 
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13.3 Impaired Cardiac Energetics in LVH 
Results were obtained on 9 patients with LVH in both positive and negative mode 
ionisation and on 7 non-LVH in positive and 9 non-LVH in negative mode.  FT-ICR 
analysis of the cardiac extracts revealed 760 peaks in positive ion mode and 1464 
peaks in negative ion mode common to all the samples. PCA was used to visualise 
any metabolic differences between the FT-ICR metabolic profiles of non-LVH and 
LVH tissue extracts. The PCA score plots for positive and negative ion modes (Fig 9) 
were consistent, showing a clear separation between the two groups along the PC2 
axis. The p-values from t-tests conducted on the PC2 scores were 7.91 x 10-5 and 
0.0053 for positive and negative ion modes, respectively, confirming that the overall 
metabolic profile changes between non-LVH and LVH tissue extracts were 
significant. 
 
Peaks that contributed most to the separation of the metabolic profiles in multivariate 
space in both ionisation modes were identified, and the m/z values for these peaks 
were used to determine empirical formulae and putative metabolite identities. 
Alongside this approach, univariate statistical methods were applied to identify those 
metabolites that changed most significantly, and to assign statistical significance to 
the metabolites identified from the multivariate analysis; the significance of the p-
values was adjusted for a False Discovery Rate (FDR) of 5.  Table 6 lists selected 
metabolites associated with energy metabolism, as well as metabolites that were 
discovered to differentiate the two groups. Perturbations in energy-related 
metabolites included a 2-fold decrease in phosphocreatine and an almost 2-fold 
increase of both AMP and adenosine for LVH samples, with minimal change in ADP 
or ATP concentrations. Key metabolic changes from the positive ion data include 
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increases in glutamine, urocanate, phenylalanine, lysine and oxoproline in LVH, 
although only the latter two were significant after FDR correction. Changes linked to 
LVH in the negative ion data included increases in arginine, tyrosine, tryptophan and 
histidine, with a potential decrease in carnitine. 
se 
Figure 9 PCA scores plots from analysis of (A) positive and (B) negative ion direct-infusion FT-ICR mass 
spectra of non-LVH (○) and LVH (▲)  
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Observed 
peak (m/z) 
Potential 
empirical 
formula 
Putative 
metabolite 
identification 
Absolute 
mass error 
(ppm) 
Ion form 
Fold 
changea 
p-value 
Energy related metabolites 
382.0326 C10H14N5O7P AMP -0.289 [M + 35Cl]- 1.71 0.014 
302.0662 C10H13N5O4 adenosine -0.077 [M + 35Cl]- 1.84 0.065 
210.0286 C4H10N3O5P phosphocreatine -0.078 [M - H]- 0.52 0.128 
450.0189 C10H15N5O10P2 ADP -0.461 [M + Na]+ 0.87 0.279 
252.4907 C10H16N5O13P3 ATP 0.202 [2M - 2H]2- 0.96 0.922 
Key metabolites from positive ion analysisb 
152.0318 C5H7NO3 oxoproline -0.030 [M + Na]+ 1.48 <0.0001* 
147.1128 C6H14N2O2 lysine -0.106 [M + H]+ 1.55 <0.001* 
139.0502 C6H6N2O2 urocanate -0.112 [M + H]+ 2.92 0.002 
166.0863 C9H11NO2 phenylalanine 0.033 [M + H]+ 1.61 0.003 
147.0764 C5H10N2O3 glutamine -0.072 [M + H]+ 1.32 0.043 
Key metabolites from negative ion analysisb 
173.1044 C6H14N4O2 arginine 0.113 [M - H]- 1.39 <0.001 
180.0666 C9H11NO3 tyrosine 0.098 [M - H]- 1.52 <0.001 
203.0826 C11H12N2O2 tryptophan 0.008 [M - H]- 1.48 0.0015 
154.0622 C6H9N3O2 histidine 0.134 [M - H]- 1.24 0.0047 
196.0746 C7H15NO3 carnitine -0.073 [M + 35Cl]- 0.73 0.194 
Table 6. Summary of key metabolic changes associated with LVH a  
Fold change between the non-LVH and LVH samples, with positive value indicating an increase in LVH; b Metabolite 
selection based upon those with low p-values and high loadings, i.e., which defined the separation in the PCA scores 
plot; *p-value significant following FDR at <0.05 
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14. Discussion 
The transcriptome data clearly demonstrated a significant down regulation of the 
master regulators PGC1α, PPARα and ERRα and their downstream metabolic 
pathways including both fatty acid and glucose metabolisms.  Although the 
mechanisms underlying metabolic remodelling are poorly understood, there have 
been recent advances in defining the role of master transcriptional regulators such as 
PGC-1α, PPARα  and  ERRα in cardiac metabolism 221, 222. PGC-1α is recognised to 
contribute to mitochondrial biogenesis and intermediary metabolism; its absence 
predisposes to HF. However, the role of PGC-1α in acquired heart disease, in both 
well-validated animal models of LVH and and in human disease has been less well 
investigated 223, although one study, suggested that in HF resulting from human 
mitochondrial cardiomyopathies, that maladaptive mitochondrial biogenesis was 
driven in part by PGC-1α down regulation.  It has also been observed in both animal 
models and in patients with a more typical form of HF, that PGC-1α is progressively 
down regulated with worsening LV dysfunction 222. This observation has led to the 
hypothesis that PGC-1α down-regulation contributes to the metabolic remodelling 
and energy deficiency of heart failure 74, 222.  We would also speculate that in human 
LVH, the metabolic remodelling would also appear to be associated with the down 
regulation of the other master transcriptional regulators PPARα  and  ERRα. 
 
Additionally, we have demonstrated a significant down regulation of key steps of both 
the fatty acid and glycolytic pathways.  Down regulation of CPT 1 may result in a 
decrease in the transport of free fatty acids across the mitochondrial membrane 
leading to a reduction in β–oxidation.  This would correspond with the majority of the 
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animal data that suggest in LVH, there is a shift away from FFA utilisation 65.  It also 
corresponds with previous gene expression studies which have shown a shift 
towards a foetal pattern of myocardial gene expression with down regulation of 
genes involved in FFA metabolism 75. Considerable debate however remains as to 
whether this shift in substrate utilisation is an adaptive response (to reduced tissue 
oxygen) or a maladaptive response, predisposing to the development of HF 65.  In 
addition to this, if cellular fatty acid uptake remains constant then reduced uptake and 
utilisation by mitochondria will result in an increased cytosolic LCFA concentration 
which may itself drive further uncoupling protein expression further aggravating the 
energetic deficit 83. 
 
GLUT-4 transcription was also found to be significantly down regulated in LVH which 
corresponds with both the animal and human data in LVH that demonstrates cardiac 
insulin resistance.  These results are in accordance with recent studies in animal 
models of LVH have shown that while glucose uptake and glycolysis are maintained 
or even increased, glucose oxidation is reduced 84  
 
In summary, our transcriptome data correlates with recent animal studies of LVH that 
have suggested a down regulation of both FFA and carbohydrate metabolic 
pathways. This maladaptive down regulation would render the heart energetically 
vulnerable. Furthermore if down regulation of FA β-oxidation is greater than down 
regulation of FA uptake, accumulation of LCFA’s might increase uncoupling of the 
mitochondrial electron transport chain further aggravating energetic impairment 83. 
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The transition from compensated LVH to failure has previously been associated with, 
progressively compromised myocardial energetics 17, 58, 71, 74, 224.  Although there is 
consensus that this energetic compromise is attributable to maladaptive metabolic 
remodelling 65, 225, uncertainty remains regarding the precise changes that occur and 
their timing. For example, most studies suggest that in HF (including LVH+HF), 
inefficient FFA metabolism is diminished 65. However studies in rodent LVH induced 
by supra-renal aortic constriction exhibit a preserved expression of genes involved in 
FFA metabolism 226. Similarly, while a consensus exists about the adaptive up-
regulation of carbohydrate metabolism in HF 65, the adequacy and beneficial effect of 
this substrate switch have been questioned 170, 227.228, 229 It is likely that these 
discrepancies are attributable to the differing species, models/stages of LVH and the 
technologies with which metabolism has been studied 65. 
 
This novel human LVH metabolomic study yielded a clear and significant separation 
between the LVH and non-LVH group.  Whilst it is not possible at this stage to 
identify all the intermediates of carbohydrate and fatty acid metabolism within this 
analysis, we speculate that the complete separation we have demonstrated will 
reflect the highly abnormal concentrations of intermediate metabolites that will 
accumulate as a consequence of the transcriptional down regulation of significant 
metabolic pathways.  This metabolomic analysis also corroborates the impairment of 
the metabolic transcriptome by demonstrating a decreased cellular energy charge 
(PCr/ATP), and a trend to reduced PCr, and elevated AMP levels perhaps as a 
manifestation of reduced energy reserve. These findings precisely replicate previous 
studies of patients with advanced AS  assessed by 31P MRS 230.  In addition to a 
trend towards decreased myocardial energy levels, Table 6 also demonstrates a 
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clear increase in myocardial levels of the keto- and glucogenic proteins lysine, 
tyrosine, tryptophan and phenylalanine.  These changes are consistent with a 
derangement in glucose metabolism 231 and are consistent with existing small animal 
models of LVH and HF 232. 
 
Although others have previously identified consistent metabolomic changes in human 
atrial tissue that plausibly contribute to disease pathogenesis (i.e. atrial fibrillation), 
the present study is the first to provide insights into the metabolome of the human left 
ventricle in disease. While these data are preliminary, they highlight the potential for 
metabolomic analysis to yield insights into the pathophysiology of LVH.  
 
15. Conclusions 
The principal finding of this integrative systems biology study is that in LVH, there is a 
significant down regulation of both the master transcriptional regulators and the key 
stages of both carbohydrate and fatty acid metabolism which results in an abnormal 
metabolome which is characterised by an impaired cardiac energetic status.  This 
energy deficiency may contribute to the poor prognosis associated with untreated 
symptomatic AS.  The significance of this energy deficiency with regards to 
myocardial protection is however less clear.  A combination of inadequate delivery of 
cardioplegia through a less dense capillary bed, increased diffusion distance from 
oxygen and metabolites from capillary to myocyte and this impairment in myocardial 
energetics may contribute towards the findings that standard cardioplegic techniques 
may be inadequate in patients with LVH 165.  The resultant early post-ischaemic left 
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ventricular dysfunction may prejudice late reverse remodelling and reduce the 
prognostic benefits of surgery.  
16. Limitations 
The human non-LVH controls in this study were patients undergoing coronary artery 
bypass surgery and as such may not accurately reflect the metabolism of healthy 
hearts.  The difficulty in obtaining LV tissue from healthy controls will remain a 
challenge to such studies as there is an increasing recognition that even “normal” 
brain stem dead human transplant donor tissue is a suboptimal control. Although this 
study is novel with respect to the metabolomics of human LVH tissue, it is preliminary 
and further metabolomic analysis of larger numbers of LVH tissue samples is 
required. Existing studies are inevitably biased towards the most abundant cellular 
metabolites that are preserved during tissue retrieval and storage and by the 
constraints of existing technology.  
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Chapter 4. A study of the effects of GIK on clinical 
outcomes following aortic valve surgery for aortic 
stenosis associated with left ventricular hypertrophy  
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17.  Introduction 
Patients undergoing aortic valve replacement for aortic stenosis often have 
significant left ventricular hypertrophy as an adaptive response to the increased 
pressure load of aortic stenosis.  Whilst initially compensatory, this hypertrophy is 
associated with a significant down-regulation of metabolism that results in impaired 
cardiac energetics.  In combination with the morphological changes in hypertrophy 
described earlier this renders the hypertrophied ventricle more susceptible to 
ischaemia-reperfusion injury during aortic valve surgery. 
 
Approximately 30% of patients undergoing cardiac surgery develop significant 
ventricular dysfunction necessitating prolonged haemodynamic support.  Patients 
requiring inotropic support have a 10-fold increase in morbidity and mortality, and 
myocardial injury is implicated in the 1500 patients that die within 30 days of cardiac 
surgery in the U.K. each year.  Such patients consume 2.5 times more intensive care 
resources and in the long-term, early post-operative injury may prejudice late reverse 
remodelling and reduce the prognostic benefit of surgery.  
 
Glucose-Insulin-Potassium (GIK) has been postulated to improve myocardial 
protection and reduce ischaemia-reperfusion injury through a variety of mechanisms 
including metabolic shift by promoting more efficient glucose metabolism and a direct 
cardioprotective effect of insulin through Akt and GSK-3B cell signalling 134, 140.  
Previous trials GIK in patients undergoing coronary artery bypass grafting 
demonstrated a significant improvement in function with improved post-operative 
haemodynamics following surgery 198.  We hypothesised that the hypertrophied and 
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therefore energetically impaired ventricle of patients undergoing aortic valve 
replacement would benefit significantly from such metabolic support.  A clinical trial 
was therefore designed randomising patients admitted for aortic valve replacement 
with echocardiographic evidence of left ventricular hypertrophy to be randomised in a 
1:1 basis to either GIK or placebo in a double blind trial. 
 
18. Methods 
Following approval by the South Birmingham Research Ethics Committee, the 
HINGE Trial (Hypertrophy, Insulin, Glucose and Electrolytes) REC reference 
04/Q2707/23 commenced recruitment on 1/10/04.  This trial was registered with the 
International Standardised Randomised Controlled Trial Number Register (ISRCTN) 
Reference ISRCTN 05758301. For detailed materials and methods including intra 
and post operative management see Chapter 2: Core Methodology. 220 patients 
were randomised and trial recruitment was terminated on the 30.07.08.  An end-
points committee was appointed and the diagnosis of Low cardiac output episode 
(LCOE) was adjudicated.  Finally, the trial was then unblinded and the data analysed.  
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19.  Results 
548 patients listed for aortic valve surgery were assessed for eligibility.  258 patients 
did not meet the entry criteria.  39 patients declined participation and 31 patients 
could not be recruited for logistical reasons. This left a total of 220 patients suitable 
for recruitment.  217 of these were consented and randomised.  Patient recruitment 
and randomisation is detailed in the consort diagram (Fig 10). 
 
Figure 10 The HINGE Trial Consort Diagram 
 
Patients listed for AVR + CABG
Assessed for eligibility N=548
Did not meet criteria
- AR              n=102
- DM              n=96
- AF               n= 31
- No LVH        n=29
Refused          n=39
Logistical        n=31
Eligible for randomisation 
n = 220
Excluded n=3
- No PAFC
Randomised 1:1
n=217
GIK
n=110
Control
n=107
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The demographics of the study population randomised to each group is presented in 
Table 7. There were no major differences in demographics between patients 
randomised to GIK or to placebo.  The risk profile for the two groups was well 
matched.  The mean EuroSCORE (logistic) in the GIK arm was 5.6(5.7) and 5.7 (5.8) 
in the control arm.  
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 GIK n=110 Control n=107 
Age median, IQR 71.2 (63.4 to 76.5) 69.9 (65.0 to 74.4) 
Female gender 43 (39.1%) 30 (27.5%) 
CCS Class 
     I 
     II 
     III 
     IV 
 
46 (41.8%) 
50 (45.5%) 
13 (11.8%) 
1 (0.9%) 
 
42 (39.3%) 
53 (49.5%) 
12 (11.2%) 
0  
NYHA Class 
     I 
     II 
     III 
     IV 
 
38 (34.5%) 
16 (14.5%) 
51 (46.4%) 
5 (4.5%) 
 
37 (34.6%) 
15 (14%) 
51 (47.7%) 
4 (3.7%) 
Previous MI 5 (4.5%) 3 (2.8%) 
Priority 
     Elective 
     Urgent 
 
99 (90%) 
11 (10%) 
 
95 (88.8%) 
12 (11.2%)           
PVD 2 (1.8%) 2 (18.3%) 
TIA 2 (1.8%) 8 (7.3%) 
CVA 2 (1.8%) 2 (18.3%) 
Coronary artery disease 
     None 
     Single vessel 
     Double vessel 
     Triple vessel 
 
82 (74.5%) 
11 (10%) 
12 (10.9%) 
5 (4.5%) 
 
79 (73.8%) 
8 (7.5%) 
13 (12.1%) 
7 (6.5%) 
EuroSCORE median, IQR 6 (4 to 7) 6 (4 to 7) 
Logistic EuroSCORE median, IQR 4.4 (2.7 to 7.1) 4.5 (2.8 to 7.7) 
Table 7. Pre-operative demographics by patient group 
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191 patients had pure aortic stenosis and 26 had mixed aortic valve disease of which 
the predominant lesion was aortic stenosis.  All patients had a pre-operative trans-
thoracic echocardiogram to assess left ventricular hypertrophy.  Echocardiographic 
data is detailed in Table 8. 
 
Echocardiographic data GIK Control 
n= 
Peak Gradient (mmHg) 
110 
78±21 
107 
73±26 
Mean Gradient (mmHg) 43±16 42±12 
AVA cm2 0.73±0.21 0.75±0.23 
Aortic Regurgitation 
Mild or none      
Moderate / Severe      
 
98 (89.1%) 
12 (10.9%) 
 
97 (89.0%) 
12 (11.0%) 
EF (Simpsons) 58±11 60±4 
EF Category 
     Good (>50%) 
     Moderate (30-50%) 
     Poor (<30%) 
 
94 (85.5%) 
14 (12.7%) 
2 (1.8%) 
 
92 (86%) 
10 (9.3%) 
5 (4.7%) 
IVSd (mm) 16.1±3.4 16.4±3.9 
LVEDD (mm) 44.4±8.2 45.2±8.6 
PWDd (mm) 15.3±3.6 15.1±3.2 
Table 8. Echocardiographic data by randomisation group 
 
Pre-operative medications were given as per protocol.  Aspirin and clopidogrel were 
stopped at least 5 days prior to surgery; angiotensin converting enyzyme (ACE) 
inhibitors were withheld on the day of surgery. The pre-operative medications per trial 
group are detailed in Table 9. 
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 GIK Control 
n= 110 107 
Aspirin  61 (55.5%) 62 (57.9%) 
Clopidogrel 0 4 (3.7%) 
ACEi 15 (13.6%) 19 (17.8%) 
ACEii 12 (10.9%) 6 (5.6%) 
Beta blocker 36 (32.7%) 33 (30.8%) 
Ca2+ channel blocker 25 (23.7%) 22 (20.6%) 
Statin 60 (54.5%) 52 (48.5%) 
Diuretic 39 (35.5%) 36 (33.6%) 
NSAID 2 (1.8%) 7 (6.5%) 
ACE Angiotensin Converting Enzyme; NSAID Non-steroidal anti-inflammatory drug.  
Table 9  Pre-operative medication by randomisation group 
 
146 patients were listed for lone aortic valve replacement and 71 patients were listed 
for concomitant coronary artery bypass grafting.  Of the 71 patients listed for grafting 
2 did not have bypass grafts constructed because of surgeon choice.  On peri-
operative trans-oesophageal echocardiography, one patient was found to have 
severe functional mitral regurgitation in the context of impaired left ventricular 
function and a structurally normal mitral valve, and therefore underwent additional 
mitral valve repair with an annuloplasty ring only. One patient was found to have a 
structurally normal and non-calcified aortic valve and the outflow tract obstruction 
was instead due to a sub-aortic membrane which was resected.    
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5 patients underwent ascending aortic replacement due to post-stenotic dilatation.  In 
all cases this was performed using a Gelweave™ graft (Vascutec Terumo, Scotland).  
There were no aortic root or arch replacements and circulatory arrest was not 
required.  Surgical data is detailed in Tables 10 and 11. Mean bypass and cross 
clamp times were similar in both groups as were the number of bypass grafts 
required. Valve choice was at surgeon discretion and a wide variety of prosthesis 
were used.  
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 GIK Control p value 
n= 
Time GIK-AXC 
74 
48±19 
72 
N/A 
 
CPB  93±46 92± 36 0.78 
AXC 64±24 65±21 0.89 
No. CABG 0 0  
Asc Aortic Replacement 1 (1.4%) 1 (1.4%) 0.91 
Mitral Valve Repair 1 (1.4%) 0  
Resection sub-aortic 
membrane 
1 (1.4%) 0  
Table 10. Surgical Data AVR only 
 
 GIK Control p value 
n= 
Time GIK-AXC 
36 
53±48 
35 
n/a 
n/a 
CPB 128±45 135±40 0.67 
AXC 92±34 97±27 0.78 
No. Of Grafts 
            0 
            1 
            2 
            3 
            4 
      
1(2.8%) 
16 (44.4%) 
10 (27.8%) 
9 (25.0%) 
0 
 
1 (2.6%) 
15 (39.5%) 
9 (23.7%) 
9 (23.7%) 
4 (10.5%) 
 
1 
0.92 
0.89 
0.93 
 
Asc Aortic Replacement 0 1 (0.9%)  
Septal myectomy 1 (0.9%) 0  
Table 11. Surgical Data AVR + CABG 
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19.1 In-hospital Death 
There were 2 in-hospital deaths in the study group. In the patients randomised to 
control there was one death secondary to respiratory failure and in patients 
randomised to GIK there was one death secondary to cardiac failure. 
 
19.2 Low cardiac output episode 
For the purpose of this study Low cardiac output episode (LCOE) was defined as 
cardiac index (CI) ≤2.2Lmin-1m-2 in the presence of adequate filling pressure defined 
as CVP 8-12mmHg or PAWP 12-16 mmHg, and heart rate >75 bpm where systolic 
blood pressure <90mmHg and/or inotropic support and/or intra-aortic balloon 
pumping (IABP) for >60 minutes to maintain such a clinical picture.  This was the 
primary endpoint for the trial therefore all patients who required inotropic support or 
had a recorded post-operative cardiac index ≤2.2 at any stage were presented to a 
blinded end-points committee and the endpoint adjudicated. 
 
47 patients were diagnosed with a LCOE.  The incidence in the GIK arm was 11/110 
(10.0%) and in the Control arm was 36/107 (33%).  This was analysed by in a pre-
determined intention-to-treat non-linear mixed model accounting for surgeon and 
intention to perform CABG.  The use of GIK was associated with a highly significant 
reduction in the incidence of low cardiac output episode (OR 0.219 95% CI 0.103 to 
0.470, p=0.0001). 
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Study outcomes in Analyses Stratified According to CABG 
Outcome Control 
(n=107) 
GIK 
(n=110) 
Odds Ratio 
(95% CI) 
P Value 
Primary 
Outcome Low 
cardiac 
output 
episode 
36 (33.6%) 11 (10.0%) 0.219 0.103 to 
0.470) 
0.0001 
Table 12  Primary outcome stratified according to intention to perform CABG 
 
Further analysis was performed to assess the action of GIK in particular in patients 
with a higher (>6) logistic EuroSCORE, older patients (>70yrs) and in patients 
undergoing concomitant coronary artery bypass grafting.  These pre-specified 
subgroup analyses for the primary end point revealed no heterogeneity in the effect 
of GIK as shown in the Forest plot below (Figure 11)  
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Figure 11 Sub-group analysis of primary outcome 
  
0.01 0.1 0.2 0.5 1 2 
CABG Yes 0.35 (0.11, 1.10) 
CABG No 0.16 (0.05, 0.47) 
EuroSCORE <6 0.23 (0.06, 0.93) 
EuroSCORE ≥6 0.25 (0.10, 0.64) 
Age <70.4 yr 0.10 (0.02, 0.48) 
Age ≥70.4 yr 0.26 (0.10, 0.68) 
Overall 0.22 (0.10, 0.47) 
GIK better           Control Better 
Odds Ratio (95% CI) 
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19.3 Haemodynamic effects 
All patients studied had a pulmonary artery flotation catheter floated.  The rate, 
rhythm, mean arterial pressure (MAP), central venous pressure (CVP), pulmonary 
artery wedge pressure (PAWP) and cardiac output (CO) were recorded at baseline, 
immediately prior to administration of protamine, approximately 10 minutes post 
administration of protamine and then at 2, 4, 6, 9 and 12 hours post aortic cross 
clamp removal and a number of derived measures of cardiac performance were then 
calculated, the equations of which are listed in Appendix H. 
 
19.3.1 Preload and Heart Rate 
Throughout the study period (baseline to 12hrs) neither heart rate nor pre-load as 
measured by the pulmonary artery wedge pressure (PAWP) / mmHg differed 
significantly between groups.  The post-operative goals were to achieve a heart rate 
between 80 and 110 and this normally required epicardial pacing at 90 beats per 
minute (bpm).  The protocol also aimed for a post-operative filling pressure of a 
PAWP of 10-12mmHg and this is reflected in the PAWP in Figure 13.  
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Figure 12  Mean heart rate / beats per minute (BPM) between treatment groups during period of 
haemodynamic monitoring.  Error bars represent SEM. 
 
Figure 13.  Mean pulmonary artery wedge pressure (PAWP) mmHg between treatment groups 
during period of haemodynamic monitoring.  Error bars represent SEM, n=217 
0
20
40
60
80
100
H
e
a
rt
 R
a
te
Control
GIK
0
2
4
6
8
10
12
14
16
18
P
A
W
P
Control
GIK
Duration of GIK / Placebo Infusion 
Duration of GIK / Placebo Infusion 
  
Page 4-142 
 
19.3.2 Cardiac Index 
The baseline cardiac index (CI) was similar between GIK and control (2.12 vs. 2.27).  
Treatment with GIK was associated with a significant increase in CI throughout the 
treatment period (p=0.0001) as demonstrated in Figure 14. 
 
Figure 14.  Mean cardiac index (CI) / lm-2 between treatment groups during period of 
haemodynamic monitoring.  Error bars represent SEM, n=217 
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19.4.3.3 Systemic Vascular Resistance Index 
Baseline systemic vascular resistance index (SVRI) was similar between GIK and 
control at baseline (2450 vs. 2630 dynes s-1cm-5m-2).  Treatment with GIK was 
associated with a reduction in SVRI in the 0-6 hour period during which the treatment 
was running, which became similar to control during the 6-12 hour study period.  The 
mean SVRI between groups is shown in Figure 15. 
 
Figure 15.  Mean systemic vascular resistance index (SVRI) / dynes s-1cm-5m-2 between treatment 
groups during period of haemodynamic monitoring.  Error bars represent SEM, n=217 
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19.3.4 Left Ventricular Stroke Work Index 
 
The mean LVSWI was similar at baseline.  Throughout the infusion period the LVSWI 
was higher in the GIK group with the greatest difference seen at six hours.  Following 
cessation of therapy there was minimal difference between groups. 
 
Figure 16.  Mean left ventricular stroke work index (LVSWI)/ gmm-2beat-1 between treatment 
groups during period of haemodynamic monitoring.  Error bars represent SEM n=217. 
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19.3.5 Cardiac Power Index 
The mean cardiac power index was similar between groups at baseline.  Throughout 
the infusion period the cardiac power index was higher in the GIK group with the 
greatest difference seen at six hours.  Following cessation of therapy there was 
minimal difference between groups. 
 
Figure 17.  Mean cardiac power index/ Watts between treatment groups during period of 
haemodynamic monitoring.  Error bars represent 95% CI for the mean, n=217 
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19.4 Use of Inotropes 
In parallel with the reduction in the incidence of LCOE, the use of GIK was 
associated with a significant reduction in the prevalence of the use of inotropes in the 
study period baseline to 6 hours from 33% in the control group to 11.9% in the 
treatment group; OR 3.69 95%CI 1.77 to 7.69, p=0.0006.  This difference continued 
from 6 – 12 hours reducing the prevalence of inotrope use from 34.9% in the control 
group to 13.8% in the GIK group OR 3.37 95% CI 1.68 – 6.77, p=0.0007.  Estimates 
in differences between groups were adjusted for intention to perform CABG and 
Consultant.  
 
The dose administered was calculated per kg per set time period.  During the 0-
6hour period GIK use was associated with a significant reduction in Dopamine 
(p<0.0001) and Epinephrine (p=0.001) requirements.  Dose of Dopamine used per 
treatment group is shown in Figure18 and for Epinephrine in Figure 19. 
 
 
Figure 18  Total dose of Dopamine mg.kg-1 per pre-specified study period by treatment group, 
n=217 
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Figure 19  Total dose of Epinephrine mg.kg-1 per pre-specified study period by treatment group, 
n=217. 
 
19.5 Use of Vasoconstriction 
Bolus injections of Phenylephrine were titrated to blood pressure.  If these 
requirements were considerable then an infusion was started (10mg Phenylephrine 
50mls 5% dextrose).  In cases of severe vasoplegia vasopressin was also 
commenced.  Rarely (n=2), norepinephrine was used at medical staff request.   
 
The use of GIK was associated with an increase in the prevalence of vasoconstrictor 
use in the baseline – 6 hour period from 45.3% in the control group to 64.2% in the 
GIK group p=0.001.  The difference in prevalence of vasoconstrictor use was 
reduced in the 6 – 12 hour period but there was still a trend towards an increase in 
vasoconstrictor requirements from 40.6% in the control group to 56% in the GIK 
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group, p=0.04.  The dose administered was calculated per kg per set time period.  
During the 0-6 hour period GIK use was associated with a significant increase in  
phenylephrine use (p=0.001).  Dose of phenylephrine used per treatment group is 
shown in Figure 20. 
 
 
Figure 20.  Total dose of Phenylephrine mg.kg-1 per pre-specified study period by treatment 
group, n=217. 
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possible temporary pacing was halted to allow satisfactory ECG interpretation.   The 
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(5.5%) of patients in the GIK group met these diagnostic criteria, p=0.67.  Whole 
blood samples were obtained from all trial subjects for analysis of Troponin T (TnT) 
at baseline, 6, 12 and 24 hours following cross clamp removal. 
 
The primary endpoint for myocardial injury had been predetermined as the difference 
in means in the TnT levels at 6hrs when accounting for both consultant surgeon and 
intention to perform CABG using a continuous outcome.  When accounting for these 
two variables, there was no significant difference in TnT levels between treatment 
groups (Table 13). 
 
Continuous 
Outcome 
Control 
(n=106) 
GIK 
(n=107) 
Difference in Means 
(95% CI) 
P Value 
TnT  
Mean (SD) 
0.357  
(0.32) 
0.351  
(0.25) 
-0.00964  
(-0.0869-0.067) 
0.8059 
Table 13  Difference in mean TnT (µg.l-1) between groups at 6 hours 
No patient was found to have had a significant rise in Troponin at baseline (max 
baseline TnT 0.02), and the mean Troponin rise at each time point was similar 
between groups.   
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Label N Mean Lower 95% 
CL for Mean 
Upper 95% 
CL for Mean 
Minimum Maximum 
 
6 TnT 
12 TnT 
24 TnT 
 
106 
106 
101 
 
0.357 
0.512 
0.567 
 
0.296 
0.332 
0.426 
 
0.418 
0.692 
0.708 
 
0.030 
0.130 
0.040 
 
2.460 
9.600 
6.800 
Table 14 Mean TnT (µg.l-1) in the control group at each pre-specified time point 
GIK Group 
Label N Mean Lower 95% 
CL for Mean 
Upper 95% 
CL for Mean 
Minimum Maximum 
 
6 TnT 
12 TnT 
24 TnT 
 
107 
106 
105 
 
0.351 
0.497 
0.588 
 
0.304 
0.432 
0.507 
 
0.399 
0.563 
0.668 
 
0.110 
0.100 
0.110 
 
2.130 
2.130 
2.120 
Table 15 Mean TnT (µg.l-1) in the GIK group at each pre-specified time point 
In patients undergoing isolated AVR or combined AVR + CABG there was no 
significant difference in peri-operative infarction between patients randomised to GIK 
or control (Tables 14 and 15).  In patients undergoing isolated AVR treated with GIK, 
6.7% (5/74) had a significant TnT rise versus 14% (8/57) in the control group, p=0.42 
(Tables 16 and 17).  In patients undergoing combined AVR + CABG treated with 
GIK, 11% (3/28) had a significant TnT rise versus 11% (4/37) in the control group, 
p=0.57 (Tables 18 and 19).  When examining the incidence of a significant TnT rise 
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in patients diagnosed with a low cardiac output episode, again there was no 
correlation.  8.5% (4/47) patients diagnosed with LCOE had a significant plasma TnT 
rise versus 9.2% (16/146) in patients who required no inotropic support. When the 
group was split into those undergoing isolated aortic valve (Tables 20 and 21) and 
those undergoing combined AVR + CABG (Tables 22 and 23) again there was no 
difference in mean plasma TnT levels between patients randomised to placebo and 
those randomised to GIK. 
Isolated AVR 
Label N Mean Lower 95% 
CL for Mean 
Upper 95% 
CL for Mean 
Minimum Maximum 
 
6 TnT 
12 TnT 
24 TnT 
 
69 
69 
65 
 
0.312 
0.519 
0.585 
 
0.243 
0.470 
0.498 
 
0.384 
0.559 
0.672 
 
0.03 
0.13 
0.04 
 
 
2.46 
9.6 
6.8 
Table 16 Mean TnT (µg.l-1) in the control group undergoing AVR only at each pre-specified time 
point 
Label N Mean Lower 95% 
CL for Mean 
Upper 95% 
CL for Mean 
Minimum Maximum 
 
6 TnT 
12 TnT 
24 TnT 
 
73 
72 
71 
 
0.310 
0.420 
0.494 
 
0.103 
0.190 
0.195 
 
0.507 
0.650 
0.793 
 
0.11 
0.10 
0.11 
 
1.25 
1.36 
1.72 
Table 17  Mean TnT (µg.l-1) in the GIK group undergoing AVR only at each pre-specified time 
point 
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AVR + CABG 
Label N Mean Lower 95% 
CL for Mean 
Upper 95% 
CL for Mean 
Minimum Maximum 
 
6 TnT 
12 TnT 
24 TnT 
 
38 
38 
37 
 
0.432 
0.499 
0.532 
 
0.119 
0.251 
0.310 
 
0.745 
0.746 
0.754 
 
0.04 
0.21 
0.24 
 
1.5 
1.4 
1.24 
 
Table 18 Mean TnT (µg.l-1) in the control group undergoing AVR + CABG at each pre-specified 
time point 
 
Label N Mean Lower 95% 
CL for Mean 
Upper 95% 
CL for Mean 
Minimum Maximum 
 
6 TnT 
12 TnT 
24 TnT 
 
35 
35 
35 
 
 
0.441 
0.549 
0.669 
 
0.112 
0.094 
0.209 
 
0.770 
1.003 
1.214 
 
0.14 
0.13 
0.18 
 
2.13 
2.13 
2.12 
Table 19 Mean TnT (µg.l-1) in the GIK group undergoing AVR + CABG at each pre-specified time 
point,  
 
Examining the relationship between clinically-defined low cardiac output episode and 
rise in TnT, there was no significant difference in TnT levels between patients treated 
for LCOE and those who required no inotropic support in either patients undergoing 
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isolated aortic valve replacement (Tables 20 and 21) or in those undergoing 
concomitant coronary revascularisation (Tables 22 and 23).  The mean plasma TnT 
levels for each group are detailed below. 
 
Isolated AVR 
No Low cardiac output episode 
Label N Mean Lower 95% 
CL for Mean 
Upper 95% 
CL for Mean 
Minimum Maximum 
 
6 TnT 
12 TnT 
24 TnT 
 
115 
114 
110 
 
0.323 
0.501 
0.548 
 
 
0.05 
0.03 
0.04 
 
0.594 
1.42 
1.24 
 
0.12 
0.14 
0.04 
 
 
2.46 
9.6 
6.8 
 
Table 20 Mean TnT (µg.l-1 ) in patients who developed no LCOE undergoing AVR only at each 
time point 
Low cardiac output episode 
Label N Mean Lower 95% 
CL for Mean 
Upper 95% 
CL for Mean 
Minimum Maximum 
 
6 TnT 
12 TnT 
24 TnT 
 
27 
27 
26 
 
 
0.252 
0.333 
0.495 
 
0.110 
0.269 
0.163 
 
0.399 
0.497 
0.894 
 
 
0.03 
0.10 
0.92 
 
 
0.72 
0.92 
1.91 
Table 21 Mean TnT(µg.l-1)  in patients who developed LCOE undergoing AVR only at each time 
point 
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AVR + CABG 
No Low cardiac output episode 
Label N Mean Lower 95% 
CL for Mean 
Upper 95% 
CL for Mean 
Minimum Maximum 
 
6 TnT 
12 TnT 
24 TnT 
 
53 
53 
53 
 
 
0.427 
0.543 
0.598 
 
0.071 
0.187 
0.254 
 
0.783 
0.899 
0.942 
 
0.14 
0.13 
0.18 
 
2.13 
1.82 
1.72 
Table 22 Mean TnT (µg.l-1) in patients who developed no LCOE undergoing AVR + CABG at each 
time point 
 
Low cardiac output episode 
Label N Mean Lower 95% 
CL for Mean 
Upper 95% 
CL for Mean 
Minimum Maximum 
 
6 TnT 
12 TnT 
24 TnT 
 
20 
20 
20 
 
0.460 
0.642 
0.779 
 
0.264 
0.188 
0.203 
 
0.656 
1.096 
1.366 
 
0.04 
0.21 
0.26 
 
0.79 
2.13 
2.12 
Table 23 Mean TnT (µg.l-1) in patients who developed no LCOE undergoing AVR + CABG  at each 
time point 
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TnT release was also analysed by degree of LV hypertrophy as defined by the LVMI 
calculated from pre-operative echocardiographic measurements and indexed to body 
surface area.  Extreme hypertrophy (LVMI >200 g.m-2) was found to be associated 
with increased plasma TnT levels, p=0.01 (Fig 21). 
 
 
Figure 21 TnT (µg.l-1) vs. LVMI (g.m-2) n=217 
 
19.7 Glucose, Insulin and Free fatty acids 
GIK administration was associated with a rise in plasma glucose which was 
maintained throughout the infusion period (Figure 22).  This was accompanied by 
similar rise in insulin levels to over four times baseline which normalised following 
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discontinuation of GIK therapy (Figure 23).  The high level of insulin associated with 
GIK also lead to suppression of plasma free fatty acid levels throughout ischaemia 
and the six hour reperfusion during which the GIK was administered (Fig 24). 
 
 
Figure 22. Mean blood glucose (mmol.l-1) at each pre-specified time point by treatment group.  
Error bars represent SEM. n=150 
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Figure 23 Mean blood insulin levels (µU.ml-1) at each pre-specified time point by treatment group.  
Error bars represent SEM.n=150 
 
 
Figure 24 Mean blood free fatty acid levels (µmol.l-1) at each pre-specified time point by treatment 
group.  Error bars represent SEM. n=150 
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19.8 Insulin Requirements 
 
Following commencement of the trial infusion, arterial blood gases were taken every 
20 minutes to allow accurate titration of blood glucose levels.  Additional insulin 
requirements were significantly higher in the GIK group versus the control group 
(91% vs 18%, p=0.01).  The prevalence of insulin use fell to that of the control group 
following termination of GIK infusion, 45% GIK versus 39% control, p=0.89. 
 
In parallel with the increase in incidence of additional insulin requirements, the total 
dose of insulin required was significantly higher in the GIK group both in the 0-6 hour 
study period (p<0.0001) and in the 6-12 hour period (p=0.001).  The dose per kg is 
shown in Figure 25. 
 
 
Figure 25.  Total dose of Insulin( IU kg-1) per pre-specified study period by treatment group. 
n=217 
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19.9 Use of Volume Expansion 
Gelofusine was used as the first choice volume expander. 4.5% Human Albumin 
solution was used as second line volume expander when more than 2l of Gelofusine 
(1.5l if patient <70Kg) had been given.  Volume expansion was indicated in patients 
with a MAP <60mm Hg or a CI <2.2 in the presence of a CVP or PAWP <15mmHg.  
There was no significant difference in the amount of Gelofusine or HAS transfused 
during any of the pre-specified time points (Figures 26 and 27). 
 
 
Figure 26.  Mean volume of Gelofusine (mls) transfused by treatment group per pre-specified 
time period. Error bars represent the SEM. n=217 
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Figure 27.  Mean volume of 4.5% HAS (mls) transfused by treatment group per pre-specified time 
period. Error bars represent the SEM. n=217 
 
19.10 Use of blood and blood products 
The indication for transfusion of blood and/ or blood products is detailed in the trial 
methodology.  50 (47%) patients in the control group and 57 (53%) patients in the 
GIK group required blood transfusion, p=0.07. 29 (27%) patients in the control arm 
and 29 patients (27%) required transfusion of blood products, p=0.97.  The mean 
number of units of packed red cells per pre-specified time period is shown in Figure 
28. 
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Figure 28.  Mean number of units of packed red cells transfused per pre-specified time period.  
Error bars represent the SEM. n=217 
 
19.11 New Arrhythmias and Need for Permanent Pacing 
Data on post-operative atrial and ventricular arrhythmias were collected.  Atrial 
fibrillation is one of the most common post-operative complications.  Atrial fibrillation 
or flutter occurred post-operatively in 49 (45%) patients in the control arm and in 30 
(27%) patients in the GIK arm, p=0.01.  Ventricular fibrillation following cross clamp 
removal requiring DC cardioversion occurred in nine (8%) in the control group and in 
10 (9%) patients in the GIK arm, p=0.85. 
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Three (2.7%) patients in the control group and two (1.8%) patients in the GIK group, 
p=0.87 required a permanent VVI pacemaker for sustained complete heart block 
post-operatively.  No other type of pacemaker was implanted. 
 
19.12 Length of Stay  
The time from admission to the intensive care unit to warming to 36oC, extubation, 
step down from Level three (Intensive Care) to Level two (High Dependency) and 
then to Level one (Ward level care) to discharge was recorded. Mean times per 
group.  The median length of time for each of these pre-specified time periods is 
detailed in Table 24 
 
 Control Group GIK Group p value 
Hours to 36oC 9.4 ± 2.4 8.7 ± 2.1 0.56 
Hours to Extubation 15.3 ± 4.3 16.2 ± 4.9 0.78 
Step-down to L2 / days 1 ± 0.5 1 ± 0.5 1 
Step-down  to L1 / days 2 ± 2.2 2 ± 2.8  
L1 to Discharge 3 ± 4.2 3 ± 3.6  
Table 24  Median length of stay at each level of care by treatment group n=217 
19.13 Safety Outcomes 
The incidence of standard post-operative complications including re-operations for 
bleeding/ tamponade or deep wound infections, pulmonary complications including 
tracheostomy, new stroke and need for new dialysis and early post-operative 
endocarditis were recorded.  The criteria for meeting the above diagnoses is detailed 
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in Chapter 2.   In addition, other pre-determined safety outcome measures included 
episodes of hypoglycaemia requiring treatment with 50% glucose, the bleeding rate 
at 12 hours following cross clamp removal and the total chest drainage at 12 hours. 
 
5 (4.5%) patients in the control group and 6 (5.4%) patients required return to theatre 
for bleeding or suspected tamponade (p=0.9) and the mean drain loss at 12 hours 
following cross clamp removal was similar between groups, (876 ± 196 mls in the 
control group versus 986 ± 213 mls in the GIK group, p=0.76). 
 
10 (9%) patients in the control group and 4 (3.6%) patients in the GIK group 
developed significant pulmonary complications, p=0.1, of which 3 (2.7%) patients in 
the control arm and 2 (1.7%) patients in the GIK arm required tracheostomy for 
ventilatory weaning, p=0.85. 
 
2 (1.8%) in the control arm and 1(0.9%) required temporary haemofiltration (p=0.93).  
No patients required long term dialysis following surgery.  There was 1 (0.9%) stroke 
in the control group and no new strokes in the GIK arm.  No patients developed early 
infective endocarditis and at the time of writing no patient has been diagnosed with 
late endocarditis.  No cases of significant mesenteric ischaemia or significant hepatic 
impairment were identified.  
 
2 (1.8%) patients in the GIK group and no patients in the control group (p=0.12) 
required management of hypoglycaemia with 50% dextrose; both these events were 
without further complication. 
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20. Discussion 
The key finding of this study is that infusion of GIK, initiated prior to aortic cross 
clamping and terminated 6 hours following reperfusion, results in a significant 
improvement in post-operative haemodynamic variables.  There was a significant 
reduction in the incidence of post-operative low cardiac output episode and 
consequently a significant reduction in inotrope requirements. 
 
The objective of every cardiac surgical operation is to produce a technically perfect 
result without producing myocardial damage.  The consequences of inadequate 
myocardial protection range from subtle degrees of damage causing delayed 
myocardial fibrosis, to low cardiac output episode leading to multi-organ failure, 
increased mortality and prolonged hospital stay.  
 
Myocardial stunning and cardiomyocyte necrosis associated with ischaemia-
reperfusion injury results from the attenuation or cessation of coronary blood flow, 
such that oxygen delivery to the myocardium is insufficient to meet basal metabolic 
requirements to preserve cellular membrane integrity and viability.  Recovery 
involves the resumption of normal oxidative metabolism and the restoration of 
myocardial energetics, the reversal of ischaemia-induced swelling, the loss of 
membrane ion gradients, and the repair of damaged cell organelles, such as the 
mitochondria and cytoplasmic reticulum. 
 
After the aortic cross-clamp is removed, the cardiomyocyte may function normally, be 
stunned, or become dysfunctional from either necrosis or apoptosis.  There is a 
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wealth of evidence that all patients undergoing cardiac surgery experience varying 
degrees of myocardial stunning.  This is defined as a form of post-ischaemic 
dysfunction where there is normal myocardial perfusion, preserved contractile 
reserve and delayed but full recovery of function.  This may require inotropic support, 
and resolves after hours or days leaving behind no objective evidence of myocardial 
infarction 233.  In this study LCOE, as a surrogate marker of myocardial stunning,  as 
diagnosed by a blinded end-points committee, was reduced from 30% in the 
treatment arm to 10% in the GIK arm and there was consequently a similar reduction 
in the need for inotrope support. 
 
The disadvantages of inotrope use in the early post-operative period is that 
increasing doses of catecholamines may cause cardiomyocyte necrosis as the 
myocardial oxygen consumption will exceed the hearts ability to increase coronary 
blood flow.  There is recent evidence that therapeutic levels of inotropic support in 
the post-ischaemic heart increases intra-cellular calcium and subsequent apoptosis 
results in cell death 234.  We therefore hypothesise that a significant reduction in the 
incidence of myocardial stunning reflects improved myocardial protection and will 
result in less late fibrosis, improved reverse remodelling leading to improved exercise 
capacity, quality of life and ultimately increased late survival post surgery. 
 
The incidence of low cardiac output episode in the control arm is reflective of the 
overall incidence of low cardiac output episode as defined by the need for inotropic 
support in the department Patient Analysis and Tracking Service (PATS) database of 
approximately 35%.  The reduction in the incidence of low cardiac output episode 
associated with GIK therapy in this trial however was significantly greater than that 
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demonstrated in the MESSAGE trials 196, 198.  The trials were run with similar 
protocols for the diagnosis of low cardiac output episode and the institution of 
inotropic therapy. 
 
Plasma Troponin levels are frequently elevated following cardiac surgery but multiple 
previous studies have demonstrated that low plasma levels should be considered 
innocuous caused simply by cardiac manipulation and surgical trauma to cardiac 
tissue and therefore of no prognostic significance.  In this study, the mean plasma 
Troponin levels at baseline, 6, 12 and 24 hrs were similar between patients 
randomised to GIK and control.  When accounting for intention to perform CABG and 
consultant surgeon, there was no significant difference between groups.   
 
Increased levels of Troponin have however been shown to correlate with an increase 
incidence of adverse events.  A prospective study of 1918 patients undergoing 
cardiac surgery in Canada demonstrated that significantly raised TnT levels were 
associated with a step-wise increase in MACCE, a composite end-point of all cause 
in-hospital death, LCOE (as defined by inotropic or IABP support to achieve a CI>2.0 
l.min-1.m-2) and peri-operative MI (defined as new Q waves >0.04mm or R-wave 
reduction by >25% in at least 2 contiguous leads).  The area under the receiver 
operating curve (AUROC) was used to determine significant TnT values by 
procedure type.  A TnT value of 0.8 µg.l-1 was discriminatory for patients undergoing 
isolated CABG or valve surgery, and a TNT value of 1.3 µg.l-1 for patients undergoing 
combined procedures 235. 
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In this study, the values of 0.8 µg.l-1 and 1.3 µg.l-1   for AVR only and AVR + CABG 
corresponded to the top decile of plasma TnT levels.  There was no significant 
difference between the incidence of a significant rise in TnT between treatment 
groups.  Examining the relationship between a clinical diagnosis of low cardiac output 
episode requiring inotropic support and plasma TnT levels demonstrated no 
differences in mean levels at the pre-specified 6, 12 and 24 hr time period, and again 
when accounting for intention to perform CABG and consultant surgeon, there was 
no significant difference between groups.  There was no significant difference in the 
incidence of a TnT ≥0.8 µg.l-1 or 1.3 µg.l-1   between patients diagnosed with low 
cardiac output episode and those requiring no inotropic support. The mean peak TnT 
in patients diagnosed with LCOE was 0.49 µg.l-1 and only 8.5% (4/47) patients 
diagnosed with LCOE had a significant plasma TnT rise. 
 
The clinical interpretation of plasma TnT levels following cardiac surgery remains 
controversial, and whilst there is no doubt that significant myocardial necrosis 
resulting in high plasma TnT levels is associated with poor outcome, the absolute 
levels used to define a significant TnT release remain somewhat arbitrary.  The study 
by Nesher et al defining the predictive power of a peak TnT rise as ≥0.8 µgl-1 or 1.3 
µgl-1  is highly dependent on the diagnosis of LCOE as this was the overwhelming 
component of MACCE 235.  However in this study there was no protocol directing the 
use of inotropes and the patients’ volume status, right heart catheterisation results 
and amount of inotropic support is unknown 235. 
 
This trial used strict criteria for inotrope support dependent upon cardiac output 
studies and only after pre-specified measures to address inadequate output and the 
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diagnosis of LCOE was only made following detailed discussion by a blinded end-
points committee.  In addition, the mean peak TnT following isolated AVR was 0.6 
µg.l-1 and it is therefore unsurprising that a peak TnT of ≥0.8 µg.l-1 was not associated 
with significantly worse MACCE outcomes.  
 
Ischaemia-reperfusion results in a vast number of cellular and metabolic changes.  
Initially these are only minor and reversible.  Ongoing injury will lead to loss of 
contractile function as ATP and creatine phosphate stores are depleted and there is 
an increase in cytoplasmic ionised calcium but at this stage cellular ultra-structural 
changes appear only minor with mitochondrial swelling and contracture formation.  
Only continued injury will lead to irreversible cellular changes with activation of 
lipoprotein lipases, increasing cellular oedema, loss of mitochondrial respiratory 
control, major ultra-structural changes in mitochondria and myofibrils and finally cell 
death and tissue necrosis resulting in cellular autolysis and leakage of 
macromolecules such as Troponin into the interstitial space.   
 
This pattern of ischaemia injury justifies both the rationale for metabolic therapy in 
improving myocardial function and reducing post ischaemic stunning following 
cardiac surgery and explains the failure to identify a reduction in TnT release with this 
therapy.  Initial reduction of oxidative metabolism reduces myocardial contractility 
and therefore therapies to improve ATP and phosphocreatine during early 
reperfusion should improve myocardial contractility and therefore reduce the 
incidence of low cardiac output episode.   
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There are a number of potential reasons to explain the increased effectiveness of the 
use of GIK in patients with left ventricular hypertrophy.  It has been shown that in 
patients with significant left ventricular hypertrophy undergoing aortic valve 
replacement standard myocardial protection strategies are not always adequate 165.  
Patients with LVH have a global down-regulation in the metabolism and indeed have 
a significantly different metabolome characterised by a reduced ATP: PCr ratio 58.  
This impairment in energetics may increase the vulnerability of the myocardium to 
ischaemia-reperfusion, and therefore metabolic manipulation with GIK suppressing 
free fatty acids and stimulating more efficient carbohydrate metabolism may lead to 
significant metabolic improvement.  In addition, compared to the non hypertrophied 
heart, LVH secondary to AS has been shown to demonstrate insulin resistance with a 
significant decrease in the GLU4-GLUT1 ratio.  GIK infusion during critical 
reperfusion with high circulating levels of both insulin and glucose may therefore be 
beneficial in overcoming this resistance 86. 
 
In conjunction with a sustained increase in cardiac index patients treated with GIK 
had significantly higher requirements for vasoconstriction with Phenylephrine as 
demonstrated by the higher incidence of the use of Phenylephrine in this group and 
also by the increase in total dose administered.  This well recognised vasodilatation 
associated with high dose insulin infusion with the associated need for 
vasoconstriction has meant that the overall intensive care length of stay and length of 
stay overall is similar between groups.  It has also lead to controversy over whether 
or not the increase in cardiac output we have demonstrated is the result primarily of 
improved myocardial protection and increased cardiac function following ischaemia-
reperfusion or a manifestation of the low systemic vascular resistance.  It was 
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attempted to address this issue within the trial methodology with all patients 
managed with vasoactive drugs to achieve a target SVR of 800 – 1400. However, 
analysis of SVRI demonstrated a reduction in patients treated with GIK during the 
infusion period and therefore the vasoactive properties of insulin cannot simply be 
discounted.  
 
To attempt to account for the impact of the differing load conditions, cardiac power 
and LVSWI were also calculated and compared between patient groups.  CP and 
LVSWI both attempt to account for both the flow generated, and the perfusion 
pressure maintained.  The two measurements do however differ.  LVSWI is energy 
output per stroke whereas cardiac power is energy per unit time.  For this reason 
recent analysis of the SHOCK registry has noted that cardiac power is the strongest 
predictor of mortality with cardiogenic shock  236.  In this trial however, the results of 
these two calculations were clearly similar as patients were all paced to achieve a 
target HR of 90-110 bpm. 
 
This study has demonstrated that GIK is a safe agent to use with a satisfactory side-
effect profile.  Only 2 patients in the treatment group required treatment with 50% 
dextrose for hypo-glycaemic episodes and there were no gross neurological 
sequelae in either patient.  Hyperglycaemia (as defined as blood glucose >10mmol/l) 
has been associated with poor outcomes in patients in intensive care but this is 
clearly not in the context of infusing high levels of glucose and insulin and we 
demonstrated no increased incidence of either superficial or deep wound infections.  
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Data from previous studies had suggested a trend to increased blood and blood 
product usage, although no increased rate of re-operation for bleeding was identified.  
In this study, we demonstrated no increased requirements for transfusion, or 
coagulopathy as defined by the need for transfusion of blood products.  The re-
exploration rate in both the treatment and control group was similar suggesting no 
increased risk of bleeding with GIK therapy, although during the time period of this 
study Aprotinin was used in all patients as part of a blood conservation strategy. 
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21. Conclusion 
The use of GIK in patients with LVH secondary to aortic stenosis undergoing AVR 
was associated with a significant reduction in the incidence of LCOE, a reduction in 
the requirements for inotropic support and a significant reduction in the incidence of 
post-operative AF, but GIK was also associated with a significant increase in the 
need for vasoconstriction.  The reduction in LCOE in this trial however was not 
associated with either a reduction in TnT release or a reduction in the length of stay 
on intensive care. 
 
GIK is a safe adjunct with no significant increase in the incidence of bleeding, as 
defined by a return to theatre for bleeding or the need for transfusions of blood or 
blood products, and no increase the rate of infections or stroke despite higher levels 
of blood glucose. 
 
22. Study Limitations 
The main limitation of the haemodynamic data from this trial is that a load dependent 
measure (cardiac index) was used.  Whilst every attempt was through strict 
adherence to trial protocols to try and obtain consistent loading conditions and heart 
rates, it is not feasible to ensure that this occurred on an individual patient basis, 
although comparison of the two treatment arms reveals similar loading conditions, 
heart rates and volume expansion.  Although we have attempted to perform 
calculations to assess left ventricular work these data need to be interpreted with 
caution as they remain load dependent.   
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The main assessment of cardiac performance during this trial was of systolic 
function.  This was assessed by haemodynamic measurement with a PAFC, the 
results of which are dependent upon loading parameters.  As well as improving 
myocardial systolic function, GIK has also been hypothesised to improve diastolic 
function, which is now well recognised to be an active, energy dependent process.  
There are a number of ways to assess diastolic function using Doppler 
echocardiography.  This can be used to measure the peak early filling (E Wave 
caused by differences in atrium-ventricle pressure) and atrial filling (A wave caused 
by atrial contraction).  During the design phase of this trial, early post operative 
assessment of diastolic function utilising this methodology was suggested.  However, 
all these patients had severe LV hypertrophy and therefore by definition, some 
degree of diastolic dysfunction.  This in combination with cold blood cardioplegic 
arrest, topical hypothermia and subsequent requirements for sequential pacing at 90 
– 110 bpm because of AV conduction delay, meant that all patients manifested 
severe diastolic dysfunction, with almost no recordable A wave. This unfortunately 
meant that tissue Doppler echocardiography could not be employed to compare 
diastolic function in the immediate post-operative phase. 
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Chapter 5. A study of the cardioprotective 
mechanism of GIK during aortic valve surgery. 
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23. Introduction 
Although the cardioprotective properties of glucose-insulin-potassium (GIK) remain 
controversial, in part due to the different contexts, doses, timing and protocol of GIK 
employed in different studies, there is a growing consensus supporting GIK’s utility in 
cardiac surgery 190, 196.  Multiple complimentary mechanisms may contribute to GIK 
related myocardial protection: (i) suppression of lipolysis resulting in a reduction of 
circulating levels of free fatty acids available for cardiac metabolism 93, 104, 107, 175 ; (ii) 
increasing insulin-related glucose flux and increasing myocardial oxygen efficiency, 
increasing cardiac energy provision (i.e. glycolytic ATP) 174 which may augment 
myocardial glycogen levels 40, 173, 176 and mitigate the consequences of low 
myocardial pH 99; (iii) beneficial augmentation of TCA intermediates (anaplerosis) 178; 
and (iv) through insulin’s pleotropic signalling properties including its anti-apoptotic 
properties acting via phosphatidylinositol 3-kinase (PI-3-K) which may directly reduce 
myocardial injury 180. Activation of a cascade of what have been termed “Reperfusion 
Injury Salvage Kinases” such as PI-3K/protein kinase B (Akt) and AMP-activated 
protein kinase, which have an established role in insulin signalling237, may have a 
role in cardioprotection238.  In addition to these established post-translational 
modifications (e.g. phosphorylation), insulin may promote modification of serine and 
threonine residues in proteins by O-linked beta-N-acetylglucosamine (O-GlcNAc)157.  
However the pertinence and contribution of these mechanisms in clinical context, 
especially in human LVH, remains speculative and unclear. 
 
In Chapter 4, it was demonstrated that this regimen of GIK is highly efficient in 
suppressing FFA levels and gives rise to sustained increased levels of insulin and 
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glucose which will facilitate increasing cardiac energy provision via glycolytic ATP 
production  174 mitigating the consequences of low myocardial pH 99 and also 
augmenting TCA intermediates (anaplerosis).  We now proposed to examine the 
potential beneficial effect of Reperfusion Injury Salvage Kinases” such as PI-
3K/protein kinase B (Akt) and AMP-activated protein kinase, which have an 
established role in insulin signalling237, may have a role in cardioprotection238, and 
also to attempt a novel exmaination of the effect of insulin on O-linked beta-N-
acetylglucosamination of myocardial proteins. 
 
Cardiomyocyte survival after reperfusion has been negatively correlated to the 
fraction of cellular mitochondria that undergo mPTP induction 122.  Activation of a 
number of complex sets of cell signalling pathways which increase the mPTP-ROS 
threshold can provide the cardiomyocyte with increased protection. These signalling 
pathways include the Akt signalling pathway and it was therefore elected to study iys 
phosphorylation during reperfusion.   
 
Activation at a variety of points along the various signalling pathways will result in 
comparable levels of protection of cardiomyocytes from reperfusion injury and it has 
therefore been hypothesised that there exists a common final mechanism to integrate 
these diverse signals to the end effecter, the mPTP 122.  It has been proposed that 
GSK-3β is the most likely candidate for this point of convergence 122.  Unlike most 
kinases, GSK-3 is highly active in the basal state and exerts a tonic-negative 
inhibitory effect on down-stream pathways.  Phosphorylation results in enzyme 
inactivation and therefore relief of its tonic inhibition and activation of downstream 
targets 131 
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Extensive evidence has now accumulated that GSK-3β is critical to the role of 
cardioprotection 133-136, it has been proposed that cardioprotective signalling 
deactivates GSK-3β by phosphorylation and leads either directly or indirectly by 
involving de-phosphorylation of VDAC and the release of VDAC from the GSK-3β-
bound pool of ANT, to a shift in balance within the Bcl-2 family of proteins.  The 
resultant de-phosphorylation of VDAC may then increase the ROS threshold for 
mPTP induction 141 thus improving myocardial protection 
 
AMPK activation itself has also been shown to induce preconditioning in isolated 
cardiomyocytes and to prevent hypoxic injury 116, although the degree to which 
AMPK activation is either required or sufficient to induce preconditioning is uncertain.  
The molecular mechanism behind which AMPK activation might induce 
preconditioning are complex but may include activation of ATP-sensitive potassium 
channels 116.  Activation stimulates the movement of these channels from storage 
membranes to cell surface membranes where they are physiologically active and can 
shorten the action potential and therefore potentially reduce calcium overload during 
reperfusion 116.  In addition to this preconditioning effect, AMPK also plays a number 
of key metabolic roles.  It increases cardiac glucose utilisation by a number of 
different mechanisms including   promoting glucose uptake 112, phosphorylates and 
therefore activates (PFK-2) a potent promoter of glycolysis, and therefore its 
activation during ischaemia may be beneficial to the heart in terms of increasing 
glucose utilisation and subsequent anaerobic ATP production.  A second major 
metabolic consequence of AMPK activation during ischaemia and reperfusion, is a 
stimulation of fatty acid oxidation 61 via phosphorylated and therefore inhibition of  
  
Page 5-178 
 
Acetyl-CoA Carboxylase (ACC), the enzyme that converts acetyl CoA to malonyl-
CoA, an inhibitor of CPT-1 62.  Inactivation therefore of ACC results in increase in 
fatty acid transport into the mitochondria and subsequent oxidation.  The question 
therefore of whether or not AMPK activation is beneficial during reperfusion remains 
to be fully elucidated.  113  
 
Increased O-GlcNAc levels have been proposed to increase tolerance to ischaemic 
stress via a number of different mechanisms 146.  Increasing O-GlcNAc levels have 
been associated with increased transcription of heat shock proteins (HSP), especially 
HSP70 147,150.  Activation of O-GlcNAc formation has also been shown to attenuate 
mPTP opening, a critical step in oxygen free radical-induced apoptosis and necrosis 
151, 152
.  One of the O-GlcNAc modified proteins identified as a potential O-GlcNAc 
target is VDAC, and it has been hypothesised that VDAC may preserve mitochondrial 
integrity by interfering with mPTP formation 151.  Increased O-GlcNAc levels with 
glucosamine attenuated the ischaemia-induced p38 MAPK phosphorylation, 
decreased ischaemic contracture and reduced the incidence of reperfusion 
arrhythmias 146, 148.  Increased levels of O-GlcNAc have also been reported to inhibit 
protein degradation 147 most likely due to inhibition of the proteasome 147 and this 
could also contribute to improved cell survival.  In addition there is also some 
experimental evidence that increasing O-GlcNAc levels inhibit Ca 2+ overload during 
reperfusion 155. 
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24. Methods 
24.1 Myocardial biopsies 
Ventricular biopsies were taken from age- and sex-matched patients enrolled in the 
HINGE trial undergoing isolated AVR with no significant coronary artery disease and 
no previous percutaneous coronary artery intervention.  These biopsies were taken 
from the left ventricular wall between the left anterior descending artery and its first 
diagonal branch and were immediately snap frozen in liquid nitrogen at -80oc until the 
analysis.  Pre-operative demographics are detailed in Table 25.  Biopsies were taken 
at baseline; after institution of bypass but before aortic cross clamping, and then at 
reperfusion, 10 minutes after release of the aortic cross clamp. 
24.2 Protein extraction 
Biopsies were initially homogenised using Ultraturax homogenizer at 10,000 rpm for 
30-60 seconds in the presence of 1ml Tri Reagent©.  The samples were allowed to 
stand at room temperature for 5 minutes. 0.2ml chloroform per ml of TRI Reagent© 
was added and thoroughly mixed.  This was then allowed to stand for a further 10 
minutes at room temperature. 
 
Samples were centrifuged at 12000g for 15 minutes at 4 oC separating into an upper 
colourless aqueous phase containing RNA, a middle layer of protein and a lower 
layer of DNA.  Following removal of the aqueous phase containing RNA, the DNA 
was precipitated with 0.3ml of 100% ethanol per 1ml TRI Reagent© used for the 
initial homogenisation.  The samples were thoroughly mixed and incubated at room 
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temperature for 2-3 minutes.  The sample was centrifuged at 2000g for 5 minutes at 
4 oC to sediment the DNA. 
 
300 µl of the supernatant (phenol/ethanol phase) was transferred to a clean 
eppendorf and the DNA destroyed.  Proteins were then precipitated by adding three 
volumes of acetone.  The sample was thoroughly mixed for 10-15 seconds to obtain 
a homogenous solution and stored at room temperature for 10 minutes at room 
temperature before being centrifuged at 2000g for 10 minutes at 4 oC to sediment the 
protein. 
 
The supernatant was discarded and the protein pellet re-suspended in 0.5mk of 0.3M 
guanidine HCl in 95% ethanol 2.5% glycerol (1:1).  Following dispersion a further 
0.5ml of guanidine HCL in 95% ethanol 2.5% glycerol (1:1) wash solution was added 
and the sample incubated at room temperature for a further 10 minutes.  The protein 
was sedimented by centrifugation at 8000g for 5 minutes at room temperature.   
 
The wash solution was decanted and two further washes with incubations and spins 
in 1 ml of guanidine HCL in 95% ethanol 2.5%glycerol (1:1) were made.  After each 
wash the sample was vortexed to disperse the pellet and remove residual phenol. 
 
The final wash was made in 1ml ethanol containing 2.5% glycerol (v:v) and the 
sample was incubated for 10 minutes at room temperature. The proteins were 
sedimented by centrifuging at 8000g for 5 minutes at room temperature.  The alcohol 
was decanted and the samples air dried for 30 minutes at room temperature.  The 
proteins were then solubilised by adding 200µl 1% SDS and gently dispersed and 
  
Page 5-181 
 
supplemented with 0.025% Tween 80.  The proteins were stored at -80oC until 
required.  
 
22.3 Western blotting  
A stacking gel of 5% acylamide, 0.2M Tris-HCl pH 6.87, 7mM SDS, 0.2% v/v TEMED 
and 8.8mM APS was then prepared and layered on top of the resolving gel.  Protein 
samples were loaded alongside Bio-rad Precision Plus Protein Prestained Dual 
Colour standards.  Gels were run using the Mini-Protean III electrophoresis cell (Bio-
Rad) and electrophoresed at 200 V through the resolving gel in SDS running buffer 
(25mM Trizma base, 192 mM glycine, 3.5 mM SDS) for 50 minutes. 
 
Two pieces of 3mm filter paper (Whatmann, Kent, UK), a 10 cm x 8 cm sheet of 
PVDF membrane (Hybond-P, Amersham Biosciences, Amersham, UK pre-soaked in 
100% methanol), and two fibre pads were equilibrated in transfer buffer (25mM 
Trizma base, 192mM glycine, 20% methanol), and the electrophoresed SDS-PAGE 
gel was sandwiched in a transfer cassette of the Mini Protean III transfer apparatus 
(Bio-Rad, Hemel Hempstead, UK).   
 
Protein was transferred onto the PVDF membrane at 250 mAmp for ninety minutes.  
Following transfer, the membrane was blocked with 5% (w/v) Marvel dried skimmed 
milk in TBS-T (Tris-buffered saline containing 20mM Tris-HCl pH 7.6, 140mM NaCl 
and supplemental with 0.025% Tween 80) for at least one hour on a rocker bed at 
room temperature.  Membranes were probed overnight with the primary antibodies 
diluted in 5% (w/v) milk-TBS-T at 4 oC on a rocker bed.  Primary antibodies are 
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detailed in Appendix F.  Membranes were then washed four times in TBS-T with 
fifteen minute incubations on a rocker bed between each wash. 
 
The membrane was incubated with the appropriate secondary antibody diluted in 5% 
milk TBS-T for one hour on a rocker bed.  The membranes were further washed for 
one hour with TBS-T at room temperature changing the wash solution every ten 
minutes. Excess wash buffer was then discarded and the membranes incubated with 
ECL (Enhanced Chemiluminesence) Plus (Amersham Biosciences) at 5 minutes at 
room temperature.  The excess detection reagent was then drained off and the blots 
covered and then placed protein side up in an X-Ray film cassette.  A sheet of 
autoradiography film (Hyperfilm© ECL, Amersham Biosciences) was then placed on 
top of the membrane.  The cassette was then closed and exposed for 10 seconds 
and the developed.  On the basis of the appearance of this film, the exposure time for 
further films was adjusted to give optimal results. 
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25. Results 
Baseline biopsies demonstrated no evidence of AMPK or Akt phosphorylation, and 
insignificant levels of protein O-GlcNAcylation (data not shown).  The reperfusion 
biopsies however demonstrated significant post-translational change. 
Phosphorylation and GlyNAcylation was compared between GIK and control. 
 
Akt, GSK-3β and AMPK signalling was studied in 16 patients (8 control and 8 GIK) 
undergoing isolated AVR. There were no significant differences in the pre-operative 
demographics or in the echocardiographic markers of function between groups 
(Tables 25 and 26).  Immunoblotting demonstrated a ~2.5 fold increase in the 
phosphor-Akt:pan-Akt ratio (p=0.03) (Fig. 29 ), a ~2.2 fold increase in the phosphor-
GSK-3β: pan- GSK-3β ratio (p=0.001) (Fig. 30 ), and a ~1.7 fold increase in the 
phospho-AMPK:AMPK ratio (p=0.0004) (Fig 31) 
 
Protein O-GlcNAcylation was studied in a further 16 (8 GIK 8 control) undergoing 
isolated AVR.  Again there were no significant differences in the pre-operative 
demographics or in the echocardiographic markers of function between groups 
(Tables 31 and 32).  O-GlcNAcylation as assessed by visual inspection suggested 
that the GIK group were more prominently O-GlcNAcylated. Accordingly, individual 
band analysis suggested that a band of approximately ~60 kDa in the GIK group was 
46% more O-GlcNAcylated when than controls, p=0.01 (Fig.33). Protein loading was 
assessed by GADPH and β-tubulin.  Formal band densitometry was performed using 
the Quantity One software package. 
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25.1 The effect of GIK on Akt, GSK-3β and AMPK signalling 
 GIK Control p value 
Sample size n=8 n=8  
Age 67 ± 2.2 68 ± 2.3 0.63 
Gender M/F 3 / 0  3  / 0 0.45 
CCS  
     I 
     II 
     III 
     IV     
 
 
0 
3 
0 
0 
 
 
0 
3 
0 
0 
 
 
 
 
1.0 
NYHA  
     I 
     II 
     III 
     IV 
 
 
0 
3 
0 
0 
 
 
0 
3 
0 
0 
 
 
 
 
 
0.41 
Hypercholesterolaemia 0 0  
Hypertension 2 2  
CAD 0 0  
Pre-op Medication 
    β -Blocker 
     ACEi 
     Statin 
 
0 
7 
7 
 
0 
7 
7 
 
CCS – Canadian Cardiovascular Society; NYHA – New York Heart Association; CAD – Number of Coronary Arteries 
with flow limiting lesions; ACEi – Angiotensin Converting Enzyme Inhibitor 
Table 25 Demographics of patients undergoing analysis of Akt and AMPK signalling pathways.  
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GIK 
 
Control 
 
p value 
Sample size n=8 n=8  
IVSd (cm) 1.47 ± 0.14 1.41 ± 0.13 0.78 
LVEDd (cm) 4.67 ± 0.15 4.47 ± 0.21 0.81 
PWd (cm) 1.45 ± 0.09 1.37 ± 0.12 0.83 
LVMI g.m-2 147.81 ± 27.23 143.35 ± 31.61 0.67 
Peak Aortic velocity (m.s-1) 4.698 ± 0.5 4.65 ± 0.4 0.8 
Mean AV Gradient (mmHg) 52 ± 7.23 53 ± 8.12 0.85 
Stroke Volume (mls) 49 ± 3.83 47 ± 4.46 0.77 
Ejection Fraction (%) 55 ± 7.6 54  ± 6.11 0.9 
IVSd – Interventricular septum in diastole; LVEDd – Left Ventricular End Diastolic dimension; PWd Posterior Wall in 
diastole; LVMI – Left Ventricular Mass Index 
Table 26  Echocardiographic data of patients undergoing analysis of Akt, GSK-3β and AMPK 
signalling pathways 
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GIK Ctr
p-Akt:Akt ratio 
p-AKT –  
AKT  - 
GAPDH – 
 
 
 
 
 
 
 
 
 
Figure 29 Western blotting for phospho-Akt and pan-Akt in patients randomised to GIK and 
control (.n=8).   
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GIK Ctr
p-GSK3β – 
 GSK3β  – 
GAPDH – 
p-GSK 3β:GSK 3β ratio 
 
 
 
 
 
 
 
 
 
 
Figure 30 Western blotting for phospho-GSK-3β and pan- GSK-3β in patients randomised to GIK 
and control (n=8) 
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p-AMPK:AMPK ratio 
GIK Ctr
GAPDH – 
p-AMPK – 
AMPK –  
 
 
 
 
 
 
 
 
 
 
Figure 31 Western blotting for phospho-AMPK and pan- AMPK in patients randomised to GIK 
and control (n=16) 
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25.2 The effect of GIK on Protein O-GlcNAcylation  
 
 
GIK 
 
Control 
 
p value 
Sample size n=8 n=8  
Age 69 ± 1.8 68 ± 2.1 0.63 
Gender M/F 7 / 1  6  / 2 0.45 
CCS  
     I 
     II 
     III 
     IV     
 
 
1 
4 
3 
0 
 
 
2 
3 
3 
0 
 
 
 
 
1.0 
NYHA  
     I 
     II 
     III 
     IV 
 
 
0 
5 
3 
0 
 
 
0 
5 
3 
0 
 
 
 
 
 
0.41 
Hypercholesterolaemia 0 0  
Hypertension 4 3  
CAD 0 0  
Pre-op Medication 
    β -Blocker 
     ACEi 
     Statin 
 
0 
7 
6 
 
1 
6 
6 
 
CCS – Canadian Cardiovascular Society; NYHA – New York Heart Association; CAD – Number of Coronary Arteries 
with flow limiting lesions; ACEi – Angiotensin Converting Enzyme Inhibitor 
Table 27 Demographics of patients undergoing analysis of Protein O-GlcNAcylation   
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GIK 
 
Control 
 
p value 
 
IVSd (cm) 
 
1.48 ± 0.24 
 
1.43 ± 0.19 
 
0.82 
LVEDd (cm) 4.58 ± 0.19 4.41 ± 0.20 0.81 
PWd (cm) 1.41 ± 0.09 1.42 ± 0.12 0.73 
LVMI g.m-2 145.81 ± 25.3 142.41 ± 29.82 0.72 
Peak Aortic velocity (m.s-1) 4.72 ± 0.4 4.68 ± 0.5 0.80 
Mean AV Gradient (mmHg) 53 ± 6.89 54 ± 7.99 0.85 
Stroke Volume (mls) 48 ± 2.9 49 ± 546 0.80 
Ejection Fraction (%) 57 ± 8.6 55  ± 6.5 0.92 
IVSd – Interventricular septum in diastole; LVEDd – Left Ventricular End Diastolic dimension; PWd Posterior Wall in 
diastole; LVMI – Left Ventricular Mass Index 
Table 28.  Echocardiographic data of patients undergoing analysis of Protein O-GlcNAcylation 
Western blot analysis of global O-GlcNAc of total human left ventricular protein. 
Immunoblotting was performed using the CTD 110.6 antibody, and normalised 
against loading control, β-tubulin, in control and GIK samples, n=8 respectively. 
Arrows indicate the molecular weight of bands analysed for O-GlcNAc (dashed: ~80 
kDa; solid: ~60 kDa; dotted ~40 kDa) (Fig 32). 
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Control 
GIK 
β-tubulin 
80 Kda 
60 Kda 
40 Kda 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 32 Western blot Analysis of O-GlcNAcylation of human left ventricular biopsy derived 
protein in control and GIK treated samples (n=16) 
 
Whole lane analysis showed a tendency towards an increase in the levels of O-
GlcNAcylation in the GIK group (control 1.00±0.09 SEM, n=8; GIK 1.09±0.13 SEM, 
n=8). A significant increase in O-GlcNAcylation was seen in a band of approximately 
60kDa (control 1.00±0.13 SEM, n=8; GIK 1.46±0.10 SEM, n=8). In contrast, no 
significant changes were evident for the 40 kDa bands (control 1.00±0.11 SEM, n=8; 
GIK 1.02±0.18 SEM, n=8) or the ~80kDa bands (control 1.00±0.53 SEM, n=8; GIK 
1.30±0.38 SEM, n=8) (Fig 33). 
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Figure 33 Bar charts describing results of normalised optical densitometry analysis. (n=16)  
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26. Discussion 
The clinical trial presented in Chapter 4 demonstrated that GIK therapy was 
associated with a significant improvement in haemodynamics and a reduction in low 
cardiac output episode suggestive of improved myocardial contractility following 
aortic valve replacement.  Recovery from peri-operative myocardial stunning involves 
normalisation of intermediary and oxidative metabolism resulting in restitution of 
myocardial energy reserves, reversal of cell swelling, and gradual accumulation of 
the total adenine nucleotide pool. The more established role for insulin in 
cardioprotection is through amelioration of myocardial metabolism including a switch 
from deleterious free fatty acid metabolism to more efficient glucose metabolism.  
Such a role for GIK has been extensively established in experimental studies 178, 
however, in addition to the metabolic benefits conferred by GIK, recent studies have 
adduced a role for pH homeostasis 239, and insulin mediated anti-apoptotic and 
cardioprotective signalling pathway activation180. Thus while it is likely that the main 
cardioprotective action of GIK is through a shift to more efficient glucose metabolism, 
we investigated whether myocardial signalling events contributed towards GIK-
related myocardial protection. 
 
26.1  The role of insulin on Akt/ GSK 3β signalling with GIK therapy 
Insulin, acting through the insulin receptor’s tyrosine kinase activity, phosphorylates 
and activates insulin receptor substrate–1/2, which in turn activate PI3K. PI3K 
activation generates phosphoinositide-3,4,5 triphosphate, which mediates the 
phosphorylation and activation of Akt.  In cardiomyocytes, Akt has been shown to 
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protect against apoptosis after ischemia/reperfusion injury 180, and as a corollary, 
pharmacological inhibition of Akt has been shown to abolish the cardioprotective 
effect of insulin 180. To the best of our knowledge, the present study is one of the first 
to confirm, in accordance with the extensive animal model literature associating Akt 
/GSK 3β phosphorylation with insulin treatment, that GIK activates this pathway.  
This in part is likely to confer some of the myocardial protection suggested in Chapter 
4. 
 
26.2  AMPK Activation by GIK during reperfusion 
In this study we have demonstrated a significant increase in AMPK phosphorylation. 
AMPK.  AMPK activation is known to play a crucial role in the regulation of cardiac 
energy metabolism, and is thought to be an adaptive mechanism in cardiac ischemia 
240
.  The question however of whether or not AMPK activation is beneficial during 
reperfusion remains to be completely elucidated, and the finding that AMPK 
phosphorylation is enhanced in the context of GIK, may be considered paradoxical 
241
 This apparent “paradox” is predicated on the observation that insulin, via 
activation of Akt, inhibits AMPK by phosphorylation of Ser 485/491 of α-AMPK242, 243.  
Reconciling these observations, it appears that while high insulin concentrations, 
especially in the absence of lipid do indeed inhibit AMPK activity, the inhibitory effect 
of insulin on AMPK activity is relieved when insulin and lipid concentrations are more 
physiological (palmitate 0.2 - 1.2 mmol/L) 244.  Accordingly, we propose that GIK in 
this study was able to activate Akt with its attendant benefits, but suppressed 
systemic lipid levels to such a permissive level that the beneficial effects of AMPK 
activation were manifest during ischemia-reperfusion 245. 
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Recently it has been shown that activation of the survival pathways associated with 
ischaemic preconditioning is also associated with significant activation of AMPK 114.  
This activation is associated with up-regulation of GLUT-4 expression, which occurs 
in a protein kinase C-dependent manner 115.  The activation of H11 kinase that 
occurs in preconditioned hearts is also associated with activation of AMPK, therefore 
resulting in an increase in the transcription of metabolic enzymes such as GLUT-4.  
Although the activation of AMPK and increases in glucose uptake has the potential to 
benefit the heart, it has yet to be directly determined whether this activation of AMPK 
is associated with cardioprotection in the setting of ischaemic preconditioning. 
 
AMPK activation itself has also been shown to induce preconditioning in isolated 
cardiomyocytes and to protect against hypoxic injury 116, although the degree to 
which AMPK activation is either required or sufficient to induce conditioning is 
uncertain.  The molecular mechanism behind which AMPK activation might induce 
preconditioning are complex but may include activation of ATP-sensitive potassium 
channels 116.  Activation stimulates the movement of these channels from storage 
membranes to cell surface membranes where they are physiologically active and can 
shorten the action potential thereby preventing calcium overload during reperfusion. 
 
26.3 Increased Protein O-GlyNAcylation with GIK 
 
We also observed a selective increase in protein O-GlcNAcylation.  This is the first 
evidence of O-GlcNAcylation in humans and its potential interaction with insulin.  
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Protein O-GlcNAcylation refers to the post-translational modification of serine and 
threonine residues of nuclear and cytoplasmic proteins by the O-linked attachment of 
the monosaccharide β-N-acetylglucosamine (O-GlcNAc). This modification is 
emerging as a key regulator of a number of critical biological processes including 
nuclear transport, translation and transcription, signal transduction and apoptosis and 
in the settings, activation appears to be an endogenous stress response designed to 
enhance cell survival 146. In the isolated perfused heart, ischemia has been shown to 
increase overall O-GlcNAc levels 148 suggesting that this endogenous stress-
activated pathway is active in the heart, and that increased O-GlcNAc levels, 
improved contractile function and decreased tissue injury after reperfusion 149, 155.   
 
Several mechanisms have been suggested to explain the increased tolerance to 
stress associated with increased O-GlcNAc levels.  Increasing O-GlcNAc levels have 
been associated with increased transcription of heat shock proteins including HSP40 
and HSP70 147 HSP70 in particular has been identified as a target for GlcNAcylation 
150
, and activation of O-GlcNAc formation has also been shown to attenuate mPTP 
opening.  There is also some experimental evidence that increasing O-GlcNAc levels 
inhibit Ca 2+ overload during reperfusion 155, and that increase in ROS production 
leads to an increase in O-GlcNAc synthesis 156 via the Hexosamine biosynthesis 
pathway (HBP), which in turn leads to increase in O-GlcNAcylation of mitochondrial 
proteins and increased tolerance of mitochondria to stress 151.  Furthermore, there is 
some experimental data that suggests that inhibition of GADPH by mitochondrial 
superoxide is an important factor leading to increased O-GlcNAcylation 156 and taken 
together these studies suggest that ROS and mitochondria may contribute towards 
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the regulation of O-GlcNAc synthesis which could in turn modulate the response to 
oxidative stress. 
 
A number of components of the insulin signalling pathway including IR-β, IRS-1/2, 
PI3K, Akt and GSK-3β have all been reported to be O-GlcNAcylated resulting in 
reduced activity148.  Insulin signalling is also regulated by nitric oxide (NO), the 
production of which could also be regulated by direct O-GlcNAcylation of NO 
synthetase (NOS).  Increasing flux through the HPB pathway is therefore envisaged 
to decrease NO production not only by direct modification of NOS but also by 
reducing NOS phosphorylation via O-GlcNAcylation of the IR complex.  We therefore 
speculate that insulin increases GlcNACation by increasing intracellular glucose flux 
through the HPB pathway thus improving myocardial protection. We speculate that 
insulin increases O-GlcNAcylation by increasing intracellular glucose flux and hence 
delivers cardioprotection. Which proteins are modified and the specificity of this 
process remains the subject of investigation. 
 
27. Conclusion 
While we present novel human data supporting the role of metabolic modulation, 
insulin signalling pathway activation (e.g. via traditional pathways such Akt and 
AMPK activation), and protein O-GlcNAcylation in insulin mediated cardioprotection, 
this data is preliminary and necessarily only hypothesis generating.  Further evidence 
will be required to ascertain whether this protective pathway is responsible for 
improved myocardial protection in the context of GIK therapy.  It is likely that the 
main beneficial effect of GIK during ischaemia-reperfusion is to drive more efficient 
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carbohydrate metabolism.  Insulin may exert an additional cardioprotective effect on 
the cardiomyocyte and the evidence that we present is that this is most likely through 
increased protein O-GlcNAcylation. 
28. Study Limitations 
The data on myocardial protein phosphorylation is based upon small (<30mg) 
biopsies.  Although the biopsies are all taken from full thickness of the left ventricular 
anterior wall, concerns exist that differences in perfusion, particularly in the sub-
endocardium could affect the results.  
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29. Study Conclusions 
Over the last decade, the department of cardiac surgery at University Hospital 
Birmingham has conducted 3 trials of the cardioprotective effect of GIK in patients 
undergoing cardiac surgery.  The first 2 trials were conducted in patients undergoing 
CABG.  These studies demonstrated a significant improvement in haemodynamics 
as assessed by PAFC thermodilution studies but although there was a trend towards 
a reduction in the incidence of LCOE, these studies were underpowered to 
demonstrate this end-point.  This HINGE trial was the first trial to demonstrate a 
significant reduction in the incidence of LCOE.  This was not due to LCOE being 
more frequently diagnosed, indeed the incidence of 30-35% LCOE would appear to 
be consistent throughout the range of elective adult cardiac surgical procedures in 
our department, and instead the use of GIK in this group of patients was associated 
with a significant reduction in this endpoint (10%). 
 
Although patients undergoing both CABG and AVR are subject to almost identical 
ischemia-reperfusion injury, the two disease processes result in very different 
pathological states.  It has been clearly demonstrated that the hypertrophied ventricle 
is energetically impaired as demonstrated by a significant reduction in the ATP: PCr 
ratio.  In Chapter 3, we have demonstrated that this energetic abnormality however is 
the result of significant changes in both the master transcriptional regulators of 
energy pathway control which results in a degree of change of metabolism that 
principal component analysis results in complete chemotatic separation of 
hypertrophied and non-hypertrophied hearts. 
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There are a number of speculative reasons to account for the improved 
cardioprotection afforded by GIK in patients with LVH.  The mechanisms through 
which GIK has been hypothesised to work  are many and varied including as 
discussed before, the suppression of lipolysis resulting in a reduction of circulating 
levels of free fatty acids available for cardiac metabolism, increasing insulin-related 
glucose flux and increasing myocardial oxygen efficiency, increasing cardiac energy 
provision through the generation of  glycolytic ATP, mitigating the consequences of 
low myocardial pH,  augmenting TCA intermediates (anaplerosis) as well as through 
insulin’s pleotropic signalling properties including its anti-apoptotic properties acting 
via phosphatidylinositol 3-kinase (PI-3-K) which may directly reduce myocardial 
injury.   
 
When we examine these potential beneficial actions of GIK in association with the 
metabolic changes demonstrated in Chapter 3, it becomes apparent that GIK may 
potentially offer more cardioprotective benefits in the energetically impaired 
hypertrophied heart than in the heart without limitations in resting coronary flow 
undergoing CABG.  Hypertrophied hearts have been shown in vivo to demonstrate 
insulin resistance, and in Chapter 3 we demonstrate a significant reduction in GLUT-
4 the key glucose transport transcription mechanism.  GIK may therefore play a 
substantial role in increasing glucose flux resulting in increased glycolytic ATP 
production via both a direct action of insulin and an indirect action on lipolysis.  The 
abnormal metabolome we have shown may also derive greater benefit from 
increased anapleurosis which may well reduce the impairment in energy production 
during the key period of reperfusion. 
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The role of insulin’s pleotropic signalling and anti-apoptotic properties acting via 
phosphatidylinositol 3-kinase (PI-3-K) have also been hypothesised to reduce 
myocardial injury.  We have demonstrated a significant increase in AMPK and Akt / 
GSK-3β signalling.  Presumably the activation of this cardio-protective signalling 
pathway is equally prevalent in both hypertrophied and non-hypertrophied hearts.  It 
may therefore be speculated that whilst GIK has a direct and beneficial 
cardioprotective effect on hearts undergoing ischemia-reperfusion, energetically 
impaired hearts may derive additional metabolic benefit.  This may explain the 
difference in magnitude of results obtained in our series of GIK trials. 
 
This speculation raises a number of further questions which future work will attempt 
to address.  If GIK has a significant effect on glucose flux, glycolytic ATP production 
and anaplerosis then these changes may be measured by further metabolomic 
analysis.  Even small insignificant changes in metabolite concentration, if present 
throughout the numerous metabolic pathways, may result in a significant change in 
metabolome on principal component analysis. 
 
If the metabolome of the hypertrophied cell can be acutely manipulated by GIK, it 
may be possible to chronically improve metabolism over a number of weeks or 
months prior to surgery.  This would have several potential advantages.  Chronic 
improvements in metabolism over such a time period could potentially near-
normalise cardiac energetics prior to surgery, rather than simply attempting to acutely 
improve metabolism during the time of ischemia-reperfusion.   Employing GIK as part 
of a standard cardioprotective strategy is labour intensive.  It is associated with 
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vasodilatation, increased vasoconstrictor requirements and hyperglycaemia.  
Although in our trials these were not associated with adverse outcomes they were 
intensively managed by research fellows aware of these potential complications.  The 
use of such a metabolic agent rather than a metabolic cocktail that contains agents 
such as insulin which itself has been demonstrated to have a cardioprotective effect 
is also useful from a scientific point of view.  It may allow comparison of the effect of 
one particular mode of action; metabolic manipulation, rather than attempting to 
speculate upon which action or combination of actions has produced the desired 
effect.  It may also demonstrate that a cardio-protective from metabolic manipulation 
is minimal, and that the other direct actions of insulin are of greater importance. 
 
There are a number of pharmacological agents, including Perhexiline and 
Trimetazidine, which may exert a similar glucose sparing metabolic effect, without 
these other manifestations.  Perhexiline has a license from use in the UK and is 
currently being trialled in the context of heart failure in this department and it was 
therefore elected to examine its use in a further trial.  
 
30. Limitations of the GIK studies  
The main problem we have encountered in running these studies is the validity of 
using a diagnosis of LCOE as a marker for myocardial stunning. The exact 
mechanism behind myocardial stunning remains unclear as is the reason why some 
patients with very similar pathologies and very similar ischaemia-reperfusion injuries 
manifest such different requirements for inotropic support following surgery.  It has 
been hypothesised that fundamental genetic traits determine our own individual 
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response to such stresses but pilot work by our group and others have failed to take 
this concept forward.   
 
The diagnosis of LCOE and all the haemodynamic data are derived from 
thermodilution measurements of cardiac output with a pulmonary artery catheter.  
Although this is a well validated technique, it remains both dependent on preload and 
afterload.  Whilst in our trials, every effort was made to try and achieve similar filling 
pressures and resistance with targeted and protocol driven filling and 
vasoconstriction, in all our trials we see a reduction in the SVRI, and a mode of 
action dependent on vasodilatation cannot therefore be excluded.   
 
Ultimately, to demonstrate a beneficial effect of GIK as an adjunct to myocardial 
protection a reduction in mortality will have to be demonstrated, either peri-operative 
mortality with large multi-centre trials or improved late outcome by following this 
cohort of patients up.  Whilst the logistical difficulties associated with GIK mean a 
multi-centre trial may not be feasible, late follow up of this cohort may further our 
understanding of its potential benefits. 
 
31. Metabolome changes in ischaemia-reperfusion 
Just as LV hypertrophy results in an abnormal metabolome we hypothesise that 
ischaemia-reperfusion will result in similar changes in intermediate metabolites and 
high energy phosphates.  The use of FT-ICR may therefore allow us to quantify these 
changes and to evaluate the effects of GIK on myocardial protection in patients 
undergoing cardiac surgery. 
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Before this study can take place a number of steps are required to optimise the 
methodology.  These were designed as: 
 
Phase 2A - dilution optimisation 
Phase 2B - confirmation that mass spectrometric analysis can be conducted across 
multiple measurement days 
Phase 2C – study of cardiac samples 
 
We have subsequently carried out Phase 2A but not without difficulty.  Although in 
principle this was an easy experiment to conduct, it was dependent upon there being 
a clear metabolic difference between the biopsies at the set time-points, and more 
importantly that this difference was statistically significantly when using a small 
number of cardiac samples. Unfortunately the study we planned and conducted 
comprised too few biological replicates per dilution.  Although this gave us a little 
insight into optimal dilution, it was not successful at answering the question with 
sufficient rigour.  Consequently, phase 2A was redesigned to include more biological 
replicates for each of only two dilutions. This experiment proved successful, and we 
have concluded that a 1:5 dilution of the samples would yield high quality mass 
spectra, with considerable number of peaks/metabolites detected, but with low 
technical variation. This phase is now complete. 
 
The planned analysis of multiple cardiac biopsies will analyse more samples than 
has ever been analysed in a single metabolomics study. That number of samples 
cannot be measured in one "run", so Phase 2B has been designed to evaluated how 
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best to collect the data such that it can be properly combined and then subject to 
statistical analysis.  Although we are in principle ready to proceed with phase 2B, we 
have secured support from the University to upgrade the FT-ICR mass spectrometer 
FT-ICR Ultra. This new spectrometer has higher sensitivity, mass accuray and 
resolution but this upgrade will delay the start of this phase of the experiment until the 
end of 2010 with analysis of cardiac biopsies following completion of this work. 
 
32. Defining myocardial metabolome in patients with LVH 
FT-ICR spectroscopy with the ability to measure thousands of individual metabolites 
based upon the charge to mass ratio was used in this research to identify the 
abnormal metabolome in patients with left ventricular hypertrophy, consisting of 
changes in both high energy phosphates and metabolite pathway intermediates.  
Having demonstrated the ability of metabolomics to discover such perturbed 
molecular pathways, one of the next steps is to construct a more extensive library of 
metabolic pathways.  Mining that more comprehensive dataset could then provide a 
definitive series of metabolic pathways.  Rapid targeted analyses using multiplexed 
LC-MS approaches could then be used to screen thousands of chemical for 
disruption of these multiple pre-specified pathways. 
 
33. Improving the myocardial metabolome in patients with LVH 
It has been hypothesised that the energetic impairment associated with LV 
hypertrophy and failure predisposes the myocardium to injury during cardiac surgery.  
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Work presented in this thesis correlates severe hypertrophy with raised plasma 
Troponin levels following surgery and impaired contractility.  Chronic metabolic 
therapy in the weeks before surgery may therefore improve the metabolome of 
patients with LV hypertrophy and decrease the vulnerability of the myocardium to 
injury.   
 
There are a number of metabolic agents that have been shown in small series to 
improve myocardial metabolism in patients with hypertrophy and failure.  Perhexiline 
maleate is an anti-anginal drug that inhibits the enzymes carnitine-palmitoyl-
transferase-1 and -2 (CPT 1 and 2), shifting substrate utilisation from FFA towards 
glucose. Perhexiline has no direct negative inotropic effects and does not alter 
systemic vascular resistance at plasma levels within the therapeutic range. 
Randomised controlled trials have demonstrated that perhexiline exerts marked and 
incremental anti-anginal effects in patients receiving β−blockers or “triple” anti-
anginal therapy. A recently completed study in patients with severe chronic heart 
failure, demonstrated that the addition of perhexiline to standard medical treatment 
was associated with substantial improvements in VO2 max, quality of life and LV 
function, particularly in patients with both ischaemic and non-ischaemic heart failure.  
 
The potential side effects of long term perhexiline therapy (neuropathy and 
hepatotoxicity) occurring in slow metabolisers can be prevented by monitoring and 
maintaining the plasma levels within the therapeutic range (0.15 - 0.60 mg.L-1) and 
the safety of the drug has been demonstrated in a randomised, double blind 
crossover study. 
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We therefore hypothesise that pre-operative treatment of patients with LV 
hypertrophy secondary to aortic stenosis undergoing planned AVR with Perhexiline 
maleate would improve myocardial energetics as defined by the metabolome 
assessed by FT-ICR spectroscopy toward that of the non-hypertrophied ventricle and 
improve myocardial protection. 
 
Authorisation to conduct this trial was obtained by the Medicines and Healthcare 
Regulatory authority and from the Central Office for NHS Research Ethics, UK.  An 
application made to the British Heart Foundation for a 3 year project grant to conduct 
this trial was successful.  A research fellow has been appointed and trial recruitment 
began in January 2010. 
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34. Appendix A - The AHA Indications for Aortic Valve Replacement  
 
Class I 
AVR is indicated for symptomatic patients with severe AS (Level of Evidence B) 
AVR is indicated for patients with severe AS undergoing coronary artery bypass graft 
surgery (CABG).  (Level of Evidence C). 
AVR is indicated for patients with severe AS undergoing surgery on the aorta or 
orther heart valves. (Level of Evidence C). 
AVR is recommended for patients with severe AS and LV systolic dysfunction (EF 
<0.50) (Level of Evidence C). 
 
Class IIa 
AVR is reasonable for patients with moderate AS undergoing CABG or surgery on 
the aorta or other heart valves. (Level of Evidence B) 
 
Class IIb 
AVR may be considered for asymptomatic patients with severe AS and abnormal 
response to exercise. (Level of Evidence C) 
AVR may be considered for adults with severe asymptomatic AS if there is a high 
likelihood of rapid progression (age, calcification, and CAD) or if surgery might be 
delayed at the time of symptom onset. (Level of Evidence C) 
AVR may be considered in patients undergoing CABG who have mild AS when there 
is evidence such as moderate to severe calcification that progression may be rapid. 
(Level of Evidence C). 
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AVR may be considered for asymptomatic patients with extremely severe AS (aortic 
valve area less than 0.6cm2, mean gradient >60mmHg and jet velocity >5.0ms-1) 
when the operative mortality is 1% or less. (Level of Evidence C) 
 
Class III  
AVR is not useful for the prevention of sudden death in asymptomatic patients with 
AS who have none of the findings listed under the class IIa/IIb recommendations. 
(Level of Evidence B) 
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35. Appendix B Patient Information 
 
PATIENT INFORMATION SHEET 
Metabolic and Substrate Support in Left Ventricular Hypertrophy – The HINGE Trial 
 
An invitation to participate in research. 
 
The heart surgery team at the Queen Elizabeth Medical Centre is inviting patients to 
participate in research aimed at making aortic valve surgery safer. We would like to 
recruit patients undergoing this kind of surgery into a clinical trial where potentially 
advantageous methods of altering the way we treat patients are used to see what 
differences they actually make to the patient’s progress. We include a simple and 
non-technical summary of the reasons for the trial and what it involves for patients 
over and above their routine treatment if they take part. If you are being approached 
in the pre-admission clinic we would like you to take these information sheets 
provided home with you to read and consider participating in this trial between now 
and your admission date at which time a heart surgical research doctor will be 
available to discuss the trial further and answer any questions. You can only be 
included in this clinical trial if you give your express permission in the form of signed 
consent.  If you are already an inpatient on the ward then a member of the heart 
surgical team will be happy to discuss the trial with you once you have had at least 
24 hours to read through these information sheets.  
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PATIENT INFORMATION SHEET 
Metabolic and Substrate Support in Left Ventricular Hypertrophy – The HINGE Trial 
 
What is the study about? 
This study is about trying to improve the treatment of patients undergoing surgery on 
their aortic valve. A heart operation to replace the aortic valve requires the help of a 
heart-lung machine. This supports your body’s circulation whilst the surgeon replaces 
the defective aortic valve. During your surgery the heart has to be protected so that it 
is not injured by the strain of the operation. Despite using standard techniques to 
protect the heart some temporary injury still occurs from which the heart gradually 
recovers during the first few hours and days following operation.  The aim of this 
study is to see whether by the use of a special sugar drip we can improve the 
protection of the heart during the valve surgery. 
 
How has this clinical trial been designed? 
This study is what is called a double-blind randomized placebo-controlled trial. This 
means that if you agree to take part you would be allocated by chance to receive 
either a sugar solution containing glucose, insulin and potassium (GIK) or a placebo 
– a standard weak sugary drip. The code is broken once all the patients in the trial 
have been completed.  
 
How will we measure the effects of this treatment? 
To detect changes in heart function we need to take measurements of performance 
before, during and after surgery to show that the treatments that are used have made 
a difference. To do this we will make use of small monitoring catheters (plastic tubes) 
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inserted in blood vessels that are routinely used in many heart surgical procedures. 
These catheters are placed in position in blood vessels whilst you are under 
anaesthetic and are usually removed on the first or second post operative day. We 
will record measurements from these catheters throughout this period at specific time 
points. We will insert an additional sampling catheter during your operation to monitor 
blood in the veins of your heart. This will be removed at the end of the use of the 
heart lung machine. Again such catheters or plastic tubes are in routine use in many 
heart operations. In your case we will insert these catheters to measure heart 
function and take samples from them to provide the research team with additional 
information on how your heart is working.  
 
Measuring the possible beneficial effects on the heart’s metabolism  
The sampling of additional blood tests: the blood tests performed on these samples 
can tell us how well the heart is tolerating the surgery. These blood samples are 
removed through the same pressure measuring lines already mentioned. The total 
amount of additional blood taken for this study is about a cupful. 
 
Imaging the heart using a transthoracic echocardiogram: An Echocardiogram is a 
scan that uses ultrasound (sound waves) to produce pictures of the heart.  The test is 
painless and without side effects.  An ultrasound probe and a small amount of gel are 
gently placed on your chest and will be moved to different positions.  The scan will 
take approximately 20 –40 minutes to complete and will be performed once before 
surgery and once after.   
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The removal of tiny samples of the heart muscle known as biopsies: This will help tell 
us how the treatment improves the way the heart works. We would aim to obtain 3 
heart muscle biopsies all whilst you are asleep under the anaesthesia, one at the 
beginning, middle and end of the bypass. They will be performed by the operating 
surgeon and are very small, about so long and thin (==). A suture is placed in the tiny 
defect left behind and their removal incurs no increased risk during the surgery nor 
has any effect on the strength of the heartbeat. We have performed on more than 
1500 biopsies in patients at the time of writing of this information leaflet with no 
complications.  
 
What will I have to do? 
If you decide to participate then there are a number of stages to the study. You will 
be guided through these stages by us (the research doctors looking after you).  
 
You will by now have received the written relevant information and asked to read this 
at your leisure at home or on the ward if you are already an inpatient. On the day 
prior to your surgery a member of the research team will visit you so you can ask any 
questions. If you give signed consent to participate then we will take the opportunity 
to perform a transthoracic echocardiogram (20 minutes) on the day before surgery. 
 
In the anaesthetic room of the operating theatre the anaesthetist will give you a 
general anaesthetic. Once you are asleep the anaesthetists will insert the pressure 
measuring catheters normally inserted at this stage. The operation will be conducted 
in a normal way under the care of the consultant cardiac surgeon, who is in charge of 
your case. The blood samples and biopsies will be performed while you are asleep 
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and you will be unaware of them. The sampling of blood from the veins of the heart 
will be performed whilst you are asleep during the use of the heart-lung machine 
only.  
 
When you awake you will be on the intensive care unit as routine. Only some further 
blood tests and monitoring tests will remain. The last blood test will be performed 48 
hours after the operation. 
 
In summary we will be taking measurements from pressure measuring catheters that 
are routinely used in heart surgery. The entire sampling of blood for the research will 
total 160 ml and will not affect your recovery and, because we can use intravenous 
pressure measuring lines, there will be no additional need for needles. The biopsies 
that we take are removed painlessly during the operation and have no effect on the 
heartbeat.  
 
What are the benefits? 
We do not know whether the treatment will benefit you as an individual. This study is 
investigating that very question. It is hoped that this study will provide information that 
will benefit future populations of patients undergoing cardiac surgical procedures. In 
particular it will help us design more suitable treatments for patients who have a very 
weak heartbeat before surgery and are at considerable risk of complications after 
surgery. In the future and after more research the use of this tablet could make all the 
difference in their recovery.  
 
What are the risks? 
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All heart operations carry some risk and these will have already been discussed with 
you. For this study we insert routinely used monitoring lines to measure heart 
function. The risks of this are minimal and the possibility of a severe complication is 
in the region of 1 in 15000. The only additional invasive procedure performed on you 
is the biopsy.  
 
What are the alternatives? 
If you do not wish to take part in the study, your surgery will be undertaken in the 
standard manner without any additional measurements, treatments or tests.  Your 
surgeon and anaesthetist may still use the monitoring lines that we have described if 
they feel that their use is in your best interest. 
 
What happens to the information? 
The information from the study will be analysed. The information will be presented at 
scientific meetings and published in scientific journals to inform other doctors and 
health professionals of our findings. All data is confidential and stored by code on 
computer. This ensures that your identity will not be revealed at any time. 
 
Who else is taking part? 
We will recruit 220 patients to this study.  
 
What if something goes wrong? 
The standard care of patients undergoing heart surgery involves intensive 
monitoring. This monitoring allows us to detect any problems early in their 
development. We do not expect the study itself to cause any problems, however as 
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for all heart surgery we are in an ideal position to deal with any untoward events 
during your operation and these will be treated in the normal manner, regardless of 
the research study. At the time of all the measurements you will be in the theatre or 
I.T.U. where trained staff is at hand at all times.  Your safety during and after surgery 
is paramount, and takes precedence over any research. 
 
What happens at the end of the study? 
At the end of the study all test infusion will stop and treatment will continue as would 
that of a patient who had not been involved with the study.  
 
What if I have more questions or do not understand something? 
Please feel free to ask one of the investigators about any questions or worries that 
you may have so that any points can be clarified. You should feel free to ask 
questions at any time you like.  Contact number 0121 472 1311 ask QE switch board 
to page Mr Neil Howell or if on the ward ask the nurses to contact either Mr Howell 
for you. 
 
What happens now if I decide to take part? 
We will take some details and ask you to sign a consent form that documents your 
willingness to participate. You will be listed for surgery as normal. You are free to 
withdraw from this study after initially consenting without prejudice to your continuing 
care. 
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36. Appendix C Consent Form 
Metabolic and Substrate Support in Left Ventricular Hypertrophy 
- The HINGE Trial 
 
This is a consent form that documents your agreement to participate in this particular 
research.  Before signing this form please tick the boxes below. 
 
I have read the invitation form  
I have read the information sheet 
I have understood the nature of the research 
I have had time to consider my response/reply 
I have been able to ask any questions and am satisfied with the answers 
I understand that I can withdraw at any time without giving explanation 
The participation or lack of it in this research will not affect my clinical care in any way 
 
Please remember that there is no obligation to participate in this study and that even 
if you do you can withdraw at any time. If you do not consent to this study your 
operation and care will proceed as planned. There are no rewards or penalties for 
participating in research although we are grateful for your efforts and inconvenience.  
If after reading this consent form and the patient information sheet you agree to 
participate please sign the form below and return to Mr Neil Howell. If you have any 
further questions about any aspect of the research feel free to ask Mr Neil Howell.  
 
The study has been explained by: 
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Print Name: 
 
Signature:    Date: 
 
Please sign below if you agree to participate in this study 
  
I have read and understand the above, and I am happy to take part in the above 
study. 
 
 
Signed   Name (Print)    Date 
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37. Appendix D Management of Glucose 
Target glucose range of 4.0-10.0mmol.l-1  
Insulin Sliding scale:  50IU of insulin actrapid in 50ml normal saline 
Sliding scale for use in operating theatre, prior to removal of the AXC 
Blood glucose    Units/hr 
0-10.0     0 
10.1-15.0    5 (plus additional 4 unit bolus if required) 
≥ 15.1     10 plus additional 8 unit bolus if required) 
 
Sliding scale for use in operating theatre and on ICU in the first six hours 
following removal of the AXC 
Blood glucose    Units/hr  
0-10.0      0 
10.1-15.0     5 
≥ 15.1      10 
 
Sliding scale for use in the six to 12 hour period following removal of the AXC 
Blood glucose    Units/hr 
0-10.0      0 
10.1-14.0     2-4 
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14.1-18.0     6 
18.1–22.0     8 
22.1–26.0     12 
≥ 26.1      14 
 
Management of hypoglycaemia 
Hypoglycaemia for the purposes of this study was defined as a blood glucose level 
less than 4.0mmol.l-1. This requires a bolus of 25mls of 50 % dextrose. Blood glucose 
measurement should be repeated after 30 minutes. 
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38. Appendix E - Guidelines for extubation and discharge criteria 
 
Guidelines for Weaning from the Ventilator 
Adequate spontaneous respiratory rate of 8-18 breaths per minute 
Core temperature > 35.5°C (nasopharyngeal probe) 
PaO2> 10kPa on an FiO2 of ≤ 0.5 
PaCO2 < 7kPa 
pH> 7.30 
Haemodynamic parameters met as set by patient’s clinical team 
Acceptable safe limits of chest tube drainage < 100ml.h-1 blood for two hours. 
Stable rhythm 
 
Criteria for Extubation 
Co-operative 
Adequate spontaneous respiratory rate of 8-18 breaths per minute 
Core temperature > 35.5°C (nasopharyngeal probe) 
PaO2 > 10kPa on an FiO2 of ≤ 0.5 
PaCO2 < 7kPa 
pH > 7.3 
Haemodynamic parameters met as set by patient’s clinical team 
Acceptable safe limits of chest tube drainage < 100ml.h-1 blood for two hours. 
Stable rhythm 
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Criteria for discharge from ITU 
Good pain control at least 60 minutes after extubation 
Acceptable safe limits of chest tube drainage < 100ml.h-1 blood for two hours. 
Cardiac index ≥ 2.2l.min-1.m-2 on ≤ 10µg.kg-1.min-1 dopamine 
Adequate ventilation 
Adequate urinary output > 0.5ml.kg.h-1 
Criteria for discharge from the ward 
Alert 
Orientated 
Temperature < 37.5 °C for 24 hours 
Walk for 30 m and up one flight of stairs 
Wounds manageable at home 
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40. Appendix F - Stacking Gel Mixes & Buffers 
 6% 7.5% 9% 10.5% 12% 15% 
30% Acrylamide 
0.8% Bisacylamide 
1.0 1.25 1.5 1.75 2.0 2.5 
2x TRIS HCl/SDS 
pH 8.8 
2.5 2.5 2.5 2.5 2.5 2.5 
Water 1.5 1.25 1.0 0.75 0.5 0 
Then add 10 µl TEMED + 30 µL Ammonium Persulphate (APS) 
SDS-PAGE Separating Gel Buffer 
45.5g Tris-Base in 350ml dH20 adjusted to pH 8.8  
Made up to 490 ml with dH20.  Filtered. Add 10ml 20% SDS. 
 
SDS-PAGE Stacking Gel Buffer 
19.75g Tris-HCl in 200 ml dH20 adjusted to pH 6.8  
Made up to 500 ml with dH20.  Filtered. Add 10ml 10% SDS. 
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41. Appendix G - Primary Antibodies 
 
Antibodies Source  Dilution Supplier Cat. No. 
 
O-GlcNAc  
CTD 110.6  Mouse  1:2000  Covance MMS-
248R 
Anti-mouse IgM  Goat  1:5000  Sigma  A8786 
β-tubulin Rabbit  1:2000  Abcam  ab6046 
Anti-rabbit IgG  Donkey  1:2000  GE Healthcare
 NA934 
 
Kinases  
AKT Rabbit  1:1000  Abcam  ab8805 
Phospho-AKT (Ser473) Rabbit  1:1000  Abcam  ab28821 
AMPKα1/2 Rabbit  1:1000  Santa-Cruz sc-25792 
Phospho-AMPKα (Thr172) Rabbit  1:1000  Santa-Cruz sc-33524 
GSK-3β Mouse  1:1000  Sanat-Cruz sc-56911 
Phospho- GSK-3β Mouse  1:1000  Sanat-Cruz sc-81494 
GAPDH Rabbit  1:1000  Abcam  ab9485 
Anti-rabbit IgG Goat  1:4000  Abcam  ab6721 
Anti-mouse IgG Goat  1:4000  Abcam  ab20043 
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42. Appendix H - Equations for calculation of derived variables 
 
Systemic vascular resistance indexed 
SVRI = (MAP-CVP) *80 
          CI  
Left ventricular stroke work indexed 
LVSWI = (MAP-PAWP)*CI *0.0136*1000 
             HR  
Cardiac power output 
CPO = CO*MAP*0.00222 
Systemic oxygen delivery indexed 
O2 delivery = 0.134*CI*Hb*SaO2 
Systemic oxygen consumption indexed 
O2 consumption = 0.134*CI((Hb*SaO2)-(Hb*MvO2)) 
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Abstract 
 
Background 
Patients undergoing aortic valve replacement (AVR) for critical aortic stenosis (AS) often have 
significant left ventricular hypertrophy (LVH). LVH has been identified as an independent predictor for 
poor outcome following AVR, due to a combination of maladaptive myocardial changes and inadequate 
myocardial protection at the time of surgery. Glucose-insulin-potassium (GIK) is a potentially useful 
adjunct to myocardial protection, this study was designed to evaluate the effects of GIK infusion in 
patients undergoing AVR surgery. 
Methods and Results 
Patients undergoing AVR for AS with evidence of LVH were randomly assigned to GIK or placebo. The 
trial was double blind and conducted at a single centre. The primary outcome was the incidence of low 
cardiac output syndrome. Left ventricular biopsies were analysed to assess changes in 5' adenosine 
monophosphate-activated protein kinase (AMPK) and Akt phosphorylation; and protein O-linked beta N-
acetylglucosamination (O-GlcNAcylation).  217 patients were randomised over a four year period (107 
control; 110 GIK). GIK treatment was associated with a significant reduction in the incidence of low 
cardiac output state (OR 0.22 95% CI 0.10 to 0.47, p= 0.0001), and a significant reduction in inotrope 
use 6 to 12 hours postoperatively, (OR 0.30 95% CI 0.15 to 0.60) p=0.0007. These changes were 
associated with a substantial increase in AMPK and Akt phosphorylation and a significant increase in 
the O-GlcNAcylation of selected protein bands. 
Conclusions 
Peri-operative treatment with GIK was associated with a significant reduction in the incidence of low 
cardiac output state and the need for inotropic support. This benefit was associated with increased 
signalling protein phosphorylation and O-GlcNAcylation.  Multi-centre studies and late follow up will 
determine if routine use of GIK improves patient prognosis. 
 
Clinical Trial Registration Information 
This trial was registered with the International Standardised Randomised Controlled Trial Number 
Register (ISRCTN) Reference ISRCTN 05758301. 
http://www.controlled-trials.com/ISRCTN05758301/05758301 
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Introduction 
 
The natural history of aortic stenosis (AS) is characterized by a protracted latent period accompanied by 
the development of left ventricular hypertrophy LVH as a compensatory mechanism to reduce wall 
stress. Although the operative mortality for AVR in the UK has remained approximately 3% despite an 
increasing elderly population with a greater risk profile 208,  the presence of LVH is associated with an 
increased risk and severity of post-ischemic myocardial injury and contractile dysfunction post AVR 246, 
of post-surgical complications including respiratory failure, renal failure, heart failure and arrhythmias 247, 
and has been identified as an independent predictor of in-hospital mortality following AVR 248.  The 
increased risk associated with LVH is, at least in part, attributable to inadequate myocardial protection 
due to a combination of inadequate delivery of cardioplegia through a less dense capillary bed 249, 
increased diffusion distance for oxygen / metabolites from capillary to myocytes 250 impaired myocardial 
metabolism characterised by a shift away from free fatty acid utilisation 65, uncoupling of glycolysis and 
glucose oxidation 84 and an increase in expression of mitochondrial uncoupling proteins 251 resulting in a 
reduction in the PCr:ATP ratio 58.  The resultant early post-ischemic left ventricular dysfunction may not 
only prejudice late reverse remodelling of LVH following AVR and reduce the prognostic benefits of 
surgery, but also predicts the potentially important role of metabolic interventions. 
 
Although the cardioprotective properties of glucose-insulin-potassium (GIK) remain controversial, in part 
due to the different contexts, doses, timing and protocol of GIK employed in different studies, there is a 
growing consensus supporting GIK’s utility in cardiac surgery 190, 196.  Multiple complimentary 
mechanisms may contribute to GIK related myocardial protection: (i) suppression of lipolysis resulting in 
a reduction of circulating levels of free fatty acids available for cardiac metabolism 93, 104, 107, 175 ; (ii) 
increasing insulin-related glucose flux and increasing myocardial oxygen efficiency, increasing cardiac 
energy provision (i.e. glycolytic ATP) 174 which may augment myocardial glycogen levels 40, 173, 176 and 
mitigate the consequences of low myocardial pH 99; (iii) beneficial augmentation of TCA intermediates 
(anaplerosis) 178; and (iv) through insulin’s pleotropic signalling properties including its anti-apoptotic 
properties acting via phosphatidylinositol 3-kinase (PI-3-K) which may directly reduce myocardial injury 
180
. Activation of a cascade of what have been termed “Reperfusion Injury Salvage Kinases” such as PI-
3K/protein kinase B (Akt) and AMP-activated protein kinase, which have an established role in insulin 
signalling237, may have a role in cardioprotection238.  In addition to these established post-translational 
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modifications (e.g. phosphorylation), insulin may promote modification of serine and threonine residues 
in proteins by O-linked beta-N-acetylglucosamine (O-GlcNAc)157.  However the pertinence and 
contribution of these mechanisms in clinical context, especially in human LVH, remains speculative and 
unclear. 
 
Although the results of AVR continue to improve, some patients exhibit a low cardiac output episode 
(LCOE) characterised by a period of left ventricular dysfunction requiring inotropic support.  In some 
patients, this dysfunction will be severe and prolonged, and the morbidity and mortality associated with 
LCOE continues to be substantial 252. In patients undergoing AVR with LVH, LCOE has been identified 
as the most common cause of death 248.  In addition to increasing resource allocation, in the long-term, 
myocardial injury sustained during surgery may result in heart failure. The need to improve myocardial 
protection in patients with LVH is well recognised and may reduce mortality, morbidity and the resource 
implications of heart surgery. We report herein, a single-centre prospective double-blind randomised 
controlled trial to investigate the effect of GIK on the incidence of LCOE in patients with aortic stenosis 
and LVH undergoing aortic valve replacement (AVR), either in isolation or in combination with coronary 
artery bypass grafting (CABG). To test the hypothesis that any cardioprotection delivered by GIK is 
contributed to by rapid and diverse post-translational modifications, we assessed any changes in 
established insulin-related signalling molecules Akt and AMPK, and any increase in protein O-
GlcNAcylation in left ventricular biopsies from GIK treated patients in relation to controls. 
 
Methods 
Study Design 
We performed a prospective, single centre, double blind, randomised placebo controlled trial of GIK in 
patients undergoing isolated AVR ± CABG with echocardiographic evidence of LVH as defined by a left 
ventricular mass index greater than 134 g.m-2 for men, or 100 g.m-2 for women205, 206.  The study was 
approved by the South Birmingham Research Ethics Committee (REC reference 04/Q2707/23), and the 
Hospital Trust Board of Research.  The trial was registered with the International Standardised 
Randomised Controlled Trial Number Register (ISRCTN) Reference ISRCTN 05758301. Patients were 
enrolled between October 2004 and June 2008. All research was performed in accordance with the 
Declaration of Helsinki within a Research Governance framework. 
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Surgery, Anaesthesia, Cardiopulmonary Bypass and Myocardial Protection 
Anaesthesia, cardiopulmonary bypass (CPB) and myocardial protection utilizing intermittent antegrade 
cardioplegia using St Thomas’ solution buffered in cold blood, were all standardised as previously 
described 196, except that Aprotinin (Bayer) was used in all patients as per departmental blood 
conservation strategy during this time, Phenylepherine was used as the first line vasoconstrictor, and 
patients were cooled to 32oC on bypass.  Surgical technique was also standardised. In patients 
undergoing concomitant revascularisation, the distal anastomoses of all free grafts were first performed.  
Proximal graft anastomoses were performed during a period of partial aortic clamping.  If the ascending 
aorta was dilated then it was replaced with a Gelweave™ interposition graft (Vascutec Terumo, 
Scotland). 
 
End-points 
The primary outcome was the incidence of low cardiac output state (LCOE).  This was defined a priori 
as CI of less than 2.2l.min-1.m-2 refractory to appropriate intra-vascular volume expansion following 
correction or attempted correction of any dysrhythmias 253. In the case of inotropic support being 
instituted due to a LCOE, a blinded end-points committee assessed all data.  In order to qualify as a 
LCOE episode a unanimous verdict was sought but in the event of disagreement, contentious cases 
were discussed and a consensus opinion agreed.  Secondary end-points included comparison of 
cardiac index (CI) and the use of inotropes and vasoconstrictors.  Peri-operative myocardial infarction 
(PMI), assessed by an independent blinded cardiologist, was defined by the presence of new Q-waves 
≥2mm in ≥2 contiguous leads by postoperative day 4. 
 
Statistical Analysis 
All pre-specified analyses were conducted according to the intention-to-treat principle.  The study had a 
statistical power of 80% to identify a relative risk of 0.50 statistically significant given an incidence of 
LCOE in the control group of 0.37 and a conventional one-sided α value of 0.025. Analyses were 
conducted with the use of SAS software (version 9.1, SAS Institute). P values other than for the primary 
end point are nominal. Dichotomous outcomes were analysed with the use of nonlinear mixed models, 
which included CABG as a patient-level covariate and surgeons as random effects. Continuous data 
were analysed with the use of mixed models, which included CABG as a patient-level covariate and 
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surgeons as random effects.  215 The authors had full access to the data and take responsibility for their 
integrity.  All authors have read and agree the manuscript as written. 
 
Results 
Study population 
A total of 220 patients were eligible for randomisation, however, in three patients, a pulmonary artery 
flotation catheter could not be placed, so they were excluded from the study.  In total 107 patients were 
randomised and received the control infusion and 110 were randomised and received the GIK infusion 
(Figure 1).  Baseline pre-operative characteristics were similar between groups (Table 1). There were no 
differences in demographics and risk profile between the groups with a median EuroSCORE in the GIK 
arm of 4.4 (interquartile range 2.7 to 7.1) and 4.5 (IQR 2.9 to 7.7) in the control arm.  191 patients had 
lone AS and 29 had mixed aortic valve disease of which the predominant lesion was AS.  All patients 
had pre-operative transthoracic echocardiography (Table 1). 146 patients were scheduled for isolated 
AVR and 75 patients were scheduled for concomitant CABG.  Of the 75 patients listed for additional 
CABG, 2 did not receive this additional procedure due to small coronary artery size.  Seven patients 
underwent additional procedures.  One underwent mitral valve annuloplasty. One patient was found to 
have a structurally normal and non-calcified aortic valve and the outflow tract obstruction was due to an 
undiagnosed sub-aortic membrane, which was resected.  Five patients underwent ascending aortic 
replacement due to post-stenotic dilatation. Median bypass and cross clamp times were similar in both 
groups as were the number of bypass grafts required. Valve choice was at surgeon discretion and a 
wide variety of prostheses were used. 
 
GIK administration is associated with hyperglycaemia, therefore in this trial all patients were closely 
monitored with hourly blood glucose measurements throughout the study period.  Patients with 
hyperglycaemia were treated aggressively with supplemental insulin aiming for a blood glucose 
<10mml.l-1. Despite this approach patients randomised to GIK demonstrated a rise in blood glucose 
which was maintained throughout the infusion period (mean reperfusion glucose 11.8 mmol.l-1 GIK vs. 
7.3 mmol.l-1 control, p=0.01). Once the period of GIK infusion had terminated blood glucose levels were 
similar between groups (mean glucose 7.3 mmol l-1 GIK vs. 7.7 mmol.l-1 control, p=0.78). (Figure 2).  
GIK infusion was accompanied by a similar rise in insulin levels to over four times baseline (mean 
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reperfusion 478 µU.ml-1 GIK vs. 66 µU.ml-1, p=0.0001) which returned to baseline following 
discontinuation of GIK therapy.  The high level of insulin associated with GIK also lead to suppression of 
plasma free fatty acids throughout ischemia and the six hour period of reperfusion during which GIK was 
infused (mean reperfusion 483 µU.ml-1 GIK vs. 892 . µU.ml-1 control, p=0.0001). 
 
Primary Outcome 
A Low Cardiac Output Episode was diagnosed in 47 patients.  The incidence in the GIK group was 
11/110 (10.0%) and in the Control group was 36/107 (33.6%).  The use of GIK was associated with a 
significant reduction in the incidence of low cardiac output state (OR 0.22 95% CI 0.10 to 0.47, p= 
0.0001) (Table 1). Pre-specified subgroup analyses revealed no heterogeneity in the effect of GIK on 
LCOE (Figure 3). 
 
Secondary endpoints 
Haemodynamic Data 
Cardiac index was higher in the GIK group from starting the treatment until 12 hours after removal of 
cross clamp (p=0.0001) (Figure 2).  Throughout the study heart rate, central venous pressure and 
pulmonary artery wedge pressure were similar between groups. 
 
Inotrope and Vasoconstrictor Use 
The use of GIK was associated with a significant reduction in the use of inotropes during the infusion 
period (n=35 patients (33.0%) in the control group vs. 13 patients (11.9%) in the treatment group; OR 
0.27 (95% CI 0.13 to 0.57; p=0.0006).  This difference continued from 6 to 12 hours (Table 2).  The use 
of a GIK infusion was also associated with an increase in the prevalence of vasoconstrictor use in the 
period between baseline to 6 hour after removal of aortic cross clamp (48 patients (45.3%) in the control 
group vs. 70 patients (64.2%) in the GIK group p=0.005).  The difference in vasoconstrictor use was 
reduced in the 6 to 12 hour period but evidence of increased vasoconstrictor requirements remained 
(Table 2; p=0.02). 
 
Myocardial Injury 
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ECG evidence of myocardial injury occurred in 9 (8%) patients in the control group and 6 (5.5%) 
patients in the GIK group (p=0.67).  When accounting for both surgeon and intention to perform CABG 
using a continuous outcome, there was no significant difference in plasma Troponin levels between 
treatment groups, at 6hrs the difference in means was -0.01 (95% CI -0.09 to 0.07, p=0.81). 
 
Akt and AMPK signalling and Protein O-GlcNAcylation  
Akt and AMPK signalling was studied in 16 patients (8 control and 8 GIK) and protein O-GlcNAcylation 
was studied in 16 (8 GIK 8 control) undergoing isolated AVR.  There were no significant differences in 
the pre-operative demographics or in the echocardiographic markers of function between groups.  
Immunoblotting demonstrated  a ~2.5 fold increase in the phosphor-Akt:pan-Akt ratio (p=0.03) and a 
~1.7 fold increase in the phospho-AMPK:AMPK ratio (p=0.0004) (Fig. 4a and b respectively).  Visual 
inspection suggested that there was more prominent O-GlcNAcylation in the GIK group .Individual band 
analysis suggested that in the GIK group a band of approximately ~60 kDa manifested ~1.85 fold more 
O-GlcNAcylation  than controls, p=0.004. Protein loading was assessed by GADPH and β-tubulin. Band 
densitometry was performed using the Quantity One package.  
 
 
Discussion 
In this trial of GIK in addition to standard myocardial protection during AVR and combined AVR and 
CABG, GIK treatment resulted in a significant reduction in LCOE. There was an associated significant 
reduction in the use of inotropic support but an increase in the need for vasoconstrictor therapy. The 
addition of GIK however had no effect on the incidence of postoperative MI on ECG criteria or on serial 
plasma troponin release. We also report that GIK therapy was associated with an increase in dynamic 
post translational protein modification including AMPK and Akt phosphorylation and selective protein O-
GlcNAcylation that may have contributed to GIK’s beneficial cardioprotective effect 
 
The results of this trial are likely to correspond to real-world clinical practice, the median logistic 
EuroSCORE of the patients not recruited during the study period was 5.1 (IQR range 2.3 to 8.2), 
compared to 4.5 (IQR 2.8 to 7.1) for patients enrolled, suggesting a non-likelihood of bias. Additionally, 
the incidence of inotrope usage in patients randomised to control is similar to that of patient’s not 
enrolled (data not shown). 
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We previously studied the use of GIK in patients undergoing isolated CABG and demonstrated a similar 
improvement in cardiac haemodynamic performance and a reduction in the need for inotropic support 
196
, however, the magnitude of effect seen in relation to GIK therapy in this study was significantly 
greater than that which we have previously reported.  All the patients randomised in this trial manifested 
significant LV hypertrophy secondary to aortic stenosis.  LVH has been shown to be associated with an 
impairment in cardiac energetics manifested by a reduction in PCr:ATP ratio on MRS and a down 
regulation in metabolism 58, 76. This energetically impaired myocardium may be more vulnerable to 
ischemia-reperfusion injury and may thus derive greater benefit from improved metabolism. 
 
In both these studies, although hemodynamic indices were improved, no significant effect on plasma 
TnT levels was demonstrated.  The discrepancy between improved haemodynamic performance and 
TnT release has led to speculation that rather than improving myocardial protection, GIK increases 
cardiac output simply by vasodilatation 254. Consistent with this hypothesis, we have detected an 
increase in the need for vasoconstriction in patients treated with GIK. While there is evidence to suggest 
that TnT release has modest prognostic value in cardiac surgery235, myocardial protection in cardiac 
surgery is highly efficacious and the majority of patients undergoing surgery have only modest TnT rise 
of insignificant value.  Myocardial necrosis with TnT release is the end stage of a series of reversible 
and finally irreversible steps the myocytes undergoes during ischemia-reperfusion, and significant TnT 
release only occurs in a minority of patients undergoing cardiac surgery. Myocardial stunning however is 
more common following cardiac surgery, is likely to significantly contribute to LCOE, is not necessarily 
associated with TnT release 255 and may be responsive to GIK therapy.  The dissociation of the 
influence of GIK on LCOE and TnT release may thus be explained by the impact of GIK on myocardial 
stunning rather than necrosis per se. 
 
Recovery from peri-operative myocardial stunning involves normalisation of intermediary and oxidative 
metabolism resulting in restitution of myocardial energy reserves, reversal of cell swelling, and gradual 
accumulation of the total adenine nucleotide pool. The more established role for insulin in 
cardioprotection is through amelioration of myocardial metabolism including a switch from deleterious 
free fatty acid metabolism to more efficient glucose metabolism.  Such a role for GIK has been 
extensively established in experimental studies 178, however, in addition to the metabolic benefits 
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conferred by GIK, recent studies have adduced a role for pH homeostasis 239, and insulin mediated anti-
apoptotic and cardioprotective signalling pathway activation180. Thus while it is likely that the main 
cardioprotective action of GIK is through a shift to more efficient metabolism, we investigated whether 
myocardial signalling events contributed towards GIK-related myocardial protection. 
 
Insulin, acting through the insulin receptor’s tyrosine kinase activity, phosphorylates and activates insulin 
receptor substrate–1/2, which in turn activate PI3K. PI3K activation generates phosphoinositide-3,4,5 
triphosphate, which mediates the phosphorylation and activation of Akt.  In cardiomyocytes, Akt has 
been shown to protect against apoptosis after ischemia/reperfusion injury 180, and as a corollary, 
pharmacological inhibition of Akt has been shown to abolish the cardioprotective effect of insulin 180. To 
the best of our knowledge, the present study is one of the first to confirm, in accordance with the 
extensive animal model literature associating Akt phosphorylation with insulin treatment, that GIK 
activates Akt, which is likely to contribute to the benefits noted herein. We also demonstrate a significant 
increase in AMPK phosphorylation. AMPK activation is known to play a crucial role in the regulation of 
cardiac energy metabolism, and is thought to be an adaptive mechanism in cardiac ischemia 240. 
However the finding that AMPK phosphorylation is enhanced in the context of GIK, may be considered 
paradoxical 241.  This apparent “paradox” is predicated on the observation that insulin, via activation of 
Akt, inhibits AMPK by phosphorylation of Ser 485/491 of -AMPK242, 243.  Reconciling these 
observations, it appears that while high insulin concentrations, especially in the absence of lipid do 
indeed inhibit AMPK activity, the inhibitory effect of insulin on AMPK activity is relieved when insulin and 
lipid concentrations are more physiological (palmitate 0.2 - 1.2 mmol/L) 244.  Accordingly, we speculate 
that GIK in this study was able to activate Akt with its attendant benefits, but suppressed systemic lipid 
levels to such a permissive level that the beneficial effects of AMPK activation were manifest during 
ischemia-reperfusion 245. The magnitude of kinase activation in this study may however have been 
mitigated by hyperglycemia secondary to glucose infusion. There is a compelling association between 
hyperglycemia and increased mortality from myocardial ischemia, whether in the context of myocardial 
infarction 256, 257 or coronary surgery 258.  This effect of hyperglycemia is, at least in part, due to the 
hyperglycemia-induced decrease of myocardial Akt activation and may have been relevant to the 
present GIK study 259  
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We also observed a selective increase in protein O-GlcNAcylation.  This is the first evidence of O-
GlcNAcylation in humans and its potential interaction with insulin.  Protein O-GlcNAcylation refers to the 
post-translational modification of serine and threonine residues of nuclear and cytoplasmic proteins by 
the O-linked attachment of the monosaccharide β-N-acetylglucosamine (O-GlcNAc). This modification is 
emerging as a key regulator of a number of critical biological processes including nuclear transport, 
translation and transcription, signal transduction and apoptosis and in the settings, activation appears to 
be an endogenous stress response designed to enhance cell survival 146. In the isolated perfused heart, 
ischemia has been shown to increase overall O-GlcNAc levels 148 suggesting that this endogenous 
stress-activated pathway is active in the heart, and that increased O-GlcNAc levels, improved contractile 
function and decreased tissue injury after reperfusion 149, 155.  We speculate that insulin increases O-
GlcNAcylation by increasing intracellular glucose flux and hence delivers cardioprotection. Which 
proteins are modified and the specificity of this process remains the subject of intensive investigation. 
. 
Conclusion 
In patients with significant left ventricular hypertrophy, the addition of peri-operative GIK therapy to 
standard myocardial protective techniques resulted in a significant reduction in LCOE.  We observed a 
significant reduction in inotrope usage but a corresponding rise in vasoconstrictor usage, secondary to 
the known vasodilatation associated with insulin, consequently resulted in no reduction in post-operative 
resource utilisation. Although the mortality in this trial was significantly lower than predicted, this study 
was not powered to detect a difference in mortality. While we present novel human data supporting the 
role of metabolic modulation, insulin signalling pathway activation (e.g. via traditional pathways such Akt 
and AMPK activation), and protein O-GlcNAcylation in insulin mediated cardioprotection, this data is 
preliminary and necessarily only hypothesis generating.  Further evidence will be required to ascertain 
whether this protective pathway is responsible for improved myocardial protection in the context of GIK 
therapy. 
 
Study Group 
Anaesthesiologists: Muzzafar Faroqui FRCA; Tariq Hoth FRCA; John Lilley FRCA; Tessa Oleofose 
FRCA; David Riddington, FRCA; Hari Singh FRCA;  Peter Townsend FRCA; Laura Tasker FRCA;  
Deborah Turfery FRCA;  Tony Whitehouse FRCA, Mark Wilkes FRCA.  
 
  
Page 7-242 
 
Funding Sources 
This project was supported by the British Heart Foundation.  Dr Howell and Dr Drury were supported by 
the British Heart Foundation. Dr Ashrafian is supported by a British Heart Foundation Clinical Research 
Excellence Award. Dr Ranasinghe is supported by a National Institute for Health Research UK (NIHR) 
Clinical Lectureship award. Professor Frenneaux is supported by a British Heart Foundation Programme 
Grant. 
 
Acknowledgments 
We would like to thank Dr Natasha Zachara who generously provided ag-purified CTD 110.6. 
 
Conflict of Interest Disclosures 
None. 
References 
1. Bridgewater B, Keogh BE, Kinsman R, Walton P. Sixth national adult cardiac 
surgical database report; 2008. 
2. Attarian DE, Jones RN, Currie WD, Hill RC, Sink JD, Chitwood WR, Wechsler 
AS. Characteristics of chronic left ventricular hypertrophy induced by 
subcoronary vavular aortic stenosis. II. Response to ischemia. J Thorac 
Cardiovasc Surg. 1981;81:389-395. 
3. Orsinelli DA, Aurigemma GP, Batista S, Kendel S, Gaasch WH. Left 
ventricular hypertrophy and mortality after aortic valve replacement for aortic 
stenosis: a high risk subgroup identified by preoperative wall thickness. J Am 
Coll Cardiol. 1993;5:811-826. 
4. Mehta RH, Ruckman D, Das S, Tsai T, Russman P, Karavite D, Monaghan H, 
Sonnad S, Shea MJ, Eagle KA, Deeb GM. Implications of increased left 
ventricular mass index on in-hospital outcomes in patients undergoing aortic 
valve surgery. J Thorac Cardiovasc Surg. 2001;122:919-928. 
5. Tomanek RJ, Palmer PJ, Peiffer GL, Schreiber KL, Eastham CL, Marcus ML. 
Morphometry of canine coronary arteries, arterioles, and capillaries during 
hypertension and left ventricular hypertrophy. Circ Res. 1986;58:38-46. 
6. Bache RJ, Vrobel TR, Ring WS, Emery RW, Anderson RW. Regional 
myocardial blood flow during exercise in dogs with chronic left ventricular 
hypertrophy. Circ Res. 1981;48:76-87. 
7. Stanley WC, Recchia FA, Lopaschuk GD. Myocardial substrate metabolism in 
the normal and failing heart. Physiol Rev. 2005;85:1093-1129. 
8. Lydell CP, Chan A, Wambolt RB, Sambanadam N, Parsons H, Bondy GP, 
Rodrigues B, Popov KM, Harris RA, Brownsley RW, Allard MF. Pyruvate 
  
Page 7-243 
 
dehydrogenase and the regulation of glucose oxidation in hypertrophied rat 
hearts. Cardiovasc Res. 2002;53:841-851. 
9. Murray AJ, Anderson RE, Watson GC, Radda GK, Clarke K. Uncoupling 
proteins in human heart. Lancet. 2004;364:1786-1788. 
10. Neubauer S. The failing heart: an engine out of fuel. NEJM. 2007;356:1140-
1151. 
11. Quinn DW, Pagano D, Bonser, Rooney SJ, Graham TR, Wilson IC, Keogh 
BE, Townend JN, Lewis ME, Nightingale P. Improved myocardial protection 
during coronary artery surgery with glucose-insulin-potassium:  A randomized 
controlled trial. J Thorac Cardiovasc Surg. 2006;131  34-42. 
12. Bothe W OM, Beyersdorf F, Doenst T. Glucose-insulin-potassium in cardiac 
surgery: A meta-analysis. Ann Thorac Surg. 2004;78:1650-1657. 
13. Lerch R, Tamm C, Papageogiou I, Benzi RH, . Myocardial fatty acid oxidation 
during ischemia and reperfusion. Mol Cell Biochem. 1992;116:103-109. 
14. Liedtke AJ, DeMaison L, Eggleston AM, Cohen LM, Nellis SH. Changes in 
substrate metabolism and effects of excess fatty acids in reperfused 
myocardium. Circ Res. 1988;62:535-542. 
15. Stanley WC, Lopaschuk GD, Hall JL, McCormack JG. Regulation of 
myocardial carbohydrate metabolism under normal and ischemic conditions: 
Potential for pharmacological interventions. Cardiovasc Res. 1997;33:243-
257. 
16. Kantor PF, Dyck JR, Lopaschuk GD. Fatty acid oxidation in the reperfused 
ischemic heart. Am J Med Sci. 1999;318:3-14. 
17. Neely JR, Morgan HE. Relationship between carbohydrate and lipid 
metabolism and the energy balance of heart muscle. Annu Rev Physiol. 
1974;36:413-459. 
18. Iyengar SRK, Charette JP, Iyengar CKS, Wasan S. Myocardial glycogen in 
prevention of perioperative ischemia injury of the heart. Can J Surg. 
1976;19:246-251. 
19. Lolley DM, Ray JF, Myers WO, Tewsbury DA. Importance of preoperative 
myocardial glycogen levels in human cardiac preservation. J Thorac 
Cardiovasc Surg. 1978;78:678-687. 
20. Das I. Effects of heart work and insulin on glycogen metabolism in the 
perfused rat heart. Am J Physiol. 1973;224:7-12. 
21. Dennis SC, Gevers W, Opie LH. Protons in ischemia: Where do they come 
from; where do they go to? J Mol Cell Cardiol. 1991;23:1077-1086. 
22. Apstein CS, Taegtmeyer H. Glucose-insulin-potassium in acute myocardial 
infarction: the time has come for a large prospective trial. Circulation. 
1997;96:1152-1156. 
23. Jonassen AK, Sack MN, Mjos O, Yellon D. Myocardial protection by insulin at 
reperfusion requires early administration and is mediated via Akt and p70s6 
kinase cell-survival signalling. Circ Res. 2001;89:1191-1198. 
  
Page 7-244 
 
24. Bertrand L, Horman S, Beauloye, Vanoverschelde JL. Insulin signalling in the 
heart. Cardiovasc Res. 2008;79:238-248. 
25. Hausenloy DJ, Yellon DM. Reperfusion injury salvage kinase signalling: 
taking a RISK for cardioprotection. Heart Failure Reviews. 2007;12(3-4):1382-
4147. 
26. Fulop N, Marchase RB, Chatham JC. Role of protein O-linked N-acetyl-
glucosamine in mediating cell function and survival in the cardiovascular 
system. Cardiovasc Res. 2007;73:288-297. 
27. Maganti M, Rao V, Borger MA, Ivanov J, David TE. Predictors of low cardiac 
ouput syndrome after isolated aortic valve surgery. Circulation. 
2005;112:I448-I452. 
28. Devereaux RB, Reichek N. Echocardiographic determination of LV mass in 
man: anatomic validation of the method. Circulation. 1977;55:613-619. 
29. Devereaux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I. 
Echocardiographic assessment of left ventricular hypertrophy: comparison to 
necropsy findings. Am J Cardiol. 1986;57:450-458. 
30. Cohen G, Feder-Elituv R, Iazetta J, Bunting P, Mallidi H, Bozinovski J, 
Deemar C, Christakis GT, Cohen EA, Wong BI, McLean RD, Myers M, 
Morgan CD, Mazer CD, Smith TS, Goldman BS, Naylor CD, Fremes SE. 
Phase 2 studies of adenosine cardioplegia. Circulation. 1998;98:I225-233. 
31. McCulloch CE, Searle SR, ed. Generalized linear and mixed models. New 
York; 2001. 
32. Razeghi P, Young ME, Alcorn JL, Moravec CS, Frazier OH, Taegtmeyer H. 
Metabolic gene expression in fetal and failing human heart. Circulation. 
2001;104:2923-2931. 
33. Gradinac S, Coleman GM, Taegtmeyer H, Sweeny MS, Frazier OH. Improved 
cardiac function with GIK after aorto-coronary bypass grafting. Ann Thorac 
Surg. 1989;48:284-289. 
34. Nesher N, Alghamdi AA, Singh SK, Sever JY, Christakis GT, Goldman BS, 
Cohen GN, Moussa F, Fremes SE. Troponin after cardiac surgery: a predictor 
or phenomenon? Ann Thorac Surg. 2008;85:1348-1354. 
35. Feng J, Schaus BJ, Fallavollita JA, Lee TC, Canty J. Preload induces 
Troponin I degradation independently of myocardial ischemia. Circulation. 
2001;103:2035-2037. 
36. Oates A, Nubani R, Kistler L, Hughey S, Theiss P, Perez-TamayoRA, 
Eiferman D, Lonychyna V, Higgins RS. Myocardial protection of insulin and 
potassium in porcine ischemia-reperfusion model. Surgery. 2009;146:23-30. 
37. Wang Y, Gao E, Tao L,  Lau WB, Yuan Y, Goldstein BJ, Lopez BL, 
Christopher TA, Tian R, Koch W, Ma XL AMP-activated protein kinase 
deficiency enhances myocardial ischaemia/reperfusion injury but has minimal 
effect on the antioxidant/antinitrative protection of adiponectin. Circulation. 
2009;119:835-844. 
  
Page 7-245 
 
38. Beauloye C, Marsin AS, Bertrand L, Krause U, Hardie DG, Vanoverschelde 
JL, Hue L. Insulin antagonizes AMP-activated protein kinase activation by 
ischemia or anoxia in rat hearts, without affecting total adenine nucleotides. 
FEBS Lett. 2001;505:348-352. 
39. Kovacic S, Soltys CL, Barr AJ, Shiojima I, Walsh K,  Dyck JR. Akt activity 
negatively regulates phosphorylation of AMP-activated protein kinase in the 
heart. J Biol Chem. 2003;278:39422-39427. 
40. Horman S VD, Heath R, Neuman D,  Mouton V, Woods A, Schlattner U, 
Walliman T, Carling D, Hue L, Rider MH. Insulin antagonizes ischemia-
induced Thr172 phosphorylation of Ser485/491. J Biol Chem. 2006;281:5335-
5340. 
41. Folmes CD, Clanachan AS, Lopaschuk GD. Fatty acids attenuate insulin 
regulation of 5'-AMP-activated protein kinase and insulin cardioprotection 
after ischemia. Circ Res. 2006;99:61-68. 
42. Tian R, Balschi JA. Interaction of insulin and AMPK in the ischemic heart: 
another chapter in the book of metabolic therapy? Circ Res. 2006;99:3-5. 
43. Ishihara M, Inoue I, Kawagoe T, Shimatani Y, Kurisu S, Nishioka K, Umemura 
T, Nakamura S, Yoshida M. Impact of acute hyperglycaemia on left 
ventricular function after reperfusion therapy in patients with a first anterior 
wall acute myocardial infarction. AHJ. 2003;146:674-678. 
44. Ishihara M, Kojima S, Sakamoto T, Asada Y, Tei C, Kimura K, Miyazaki S, 
Sonoda M, Tsuchihashi K, Yamagishi M, Ikeda Y, Shirai M, Hiraoka H, Inoue 
T, Saito F, Ogawa H. Acute hyperglycaemia is associated with adverse 
outcomes after acute myocardial infarction in the coronary intervention era. 
AHJ. 2005;150:814-820. 
45. Doenst T, Wijeysundera D, Karkouti K, Zechner C, Maganti M, Rao V, Borger 
MA. Hyperglycaemia during cardiopulmonary bypass is an independent risk 
factor for mortality in patients undergoing cardiac surgery. J Thorac 
Cardiovasc Surg. 2005;130:1144.e1141-e1148. 
46. Su H, Sun X, Zhang HF, Yu QJ, Huang C, Wang XM, Luan RH, Wang HC, 
Gao F. Acute hyperglycaemia exacerbates myocardial ischemia/ reperfusion 
injury and blunts cardioprotective effect of GIK. Am J Phsyiol Endocrinol 
Metab. 2007;293:E629-635. 
47. Laczy B, Hill BG, Wang K, Paterson AJ, White CR, Xing D, Chen YF, Darley-
Usmar V, Oparil S, Chatham JC. Protein O-GlcNAcylation: a new signalling 
paradigm for the cardiovascular system. Am J Physiol Heart Circ Physiol. 
2009;296:13-28. 
48. Fulop N, Zhang Z, Marchase RB, Chatham JC. Glucosamine cardioprotection 
in perfused rat hearts associated with increased O-linked N-acetyl-
glucosamine protein modification and altered p38 activity. Am J Physiol Heart 
Circ Physiol. 2007;292:H2227-2236. 
49. Liu J, Marchase RB, Chatham JC. Glutamine induced protection of isolated 
rat heart from ischemia/reperfusion injury is mediated via the hexosamine 
  
Page 7-246 
 
biosynthesis pathway and increased protein O-GlcNAc levels. J Mol Cell 
Cardiol. 2007;42:177-185. 
50. Liu J, Marchase RB, Chatham JC. Increased O-GlcNAc levels during 
reperfusion leads to improved functional recovery and reduced calpain 
proteolysis. Am J Physiol Heart Circ Physiol. 2007;293:H1391-1399. 
 
  
  
Page 8-247 
 
 
Chapter 8. References 
1. Donner R, Carabello BA, Black I, Spann JF. Left ventricular wall stress in 
compensated aortic stenosis. Am J Cardiol. 1983;51:946-951. 
2. Spann JF, Bove AA, Natarajan G, Kreulens T. Ventricular performance, pump 
function and compensatory mechanisms in patients with aortic stenosis. 
Circulation. 1989;62:576-583. 
3. Krayenbaul HP, Hess OM, Ritter M. Left ventricular function in aortic stenosis. 
Eur Heart J. 1988;9:19-22. 
4. Gunther S, Grossman W. Determinants of ventricular function in pressure 
overload hypertrophy in man. Circulation. 1979;56:679-684. 
5. Ross J. Afterload mismatch and preload reserve: A conceptual framework for 
the analysis of ventricular function. Prog Cardiovasc Dis. 1976;18(255-9). 
6. Fifer MA, Gunther S, Grossman W. Myocardial contractile function in aortic 
stenosis as determined from the rate of stress development during isovolumic 
systole. Am J Cardiol. 1979;44(1318-22). 
7. Villari B, Vasalli G, Monrad ES. Normalisation of diastolic dysfunction in aortic 
stenosis late after valve replacement Circulation. 1995;91(2353-9). 
8. Hess OL, Villari B, Krayenbuehl H. Diastolic dysfunction in aortic stenosis. 
Circulation. 1993;87(IV):73-77. 
9. Dineen A, Brent BN. Aortic valve stenosis: Comparison of patients to those 
without congestive heart failure. Am J Cardiol. 1986;57:419-414. 
10. Fifer MA, Borrow KM, Colan SD, Lorelli BH. Early diastolic left ventricular 
function in aortic stenosis. J Am Coll Cardiol. 1985;5:14147-14151. 
11. Stott DK, Marpole DG, Bristow JD, Kloster FE, Griswold HE. The role of left 
atrial transport in aortic and mitral stenosis. Circulation. 1970;1970:1031-
1041. 
12. Schwartz F, Flameng W, Schaper J. Myocardial structure and function in 
patients with aortic valve disease and their relationship to post-operative 
results. Am J Cardiol. 1978;41:661-669. 
  
Page 8-248 
 
13. Bertand ME, LaBlance JM, Tilmant PY. Coronary sinus blood flow at rest and 
during isometric exercise in patients with aortic valve disease.  Mechanisms 
of angina pectoris in the presence of normal coronary arteries. Am J Cardiol. 
1981;47:199-208. 
14. Smucker ML, Tedesco CL, Manning SB. Demonstration of an imbalance 
between coronary perfusion and excessive load as a mechanism of ischemia 
during stress in patients with aortic stenosis. Circulation. 1988;78:573-578. 
15. Vinten-Johansen J, Weiss HR. Oxygen consumption in subepicardial and 
subendocardial regions of the canine left ventricle - The effect of experimental 
acute valvular aortic stenosis. Circ Res. 1980;46:139-125. 
16. Rajappan K, Rimoldi OE, Dutka DP, Ariff B, Penell DJ, Sheridan DJ, Camici 
PG. Mechanisms of coronary microcirculatory dyfunction in patients with 
aortic stenosis and normal coronary arteries. Circulation. 2002;105:470-476. 
17. Peyton RB, Jones RN, Attarian D et al. Depressed high-energy phosphate 
content in hypertrophied ventricles of animal and man: the biologic basis for 
increased sensitivity to ischemic injury. Ann Surg. 1982;196:278-284. 
18. Aurigemma G, Battista S, Orsinelli D, Sweeney A, Pape L at al. Abnormal 
ventricular intracavity flow acceleration in patients undergoing aortic valve 
replacment for aortic stenosis: a marker for high postoperative morbidity and 
mortality. Circulation. 1992;86:926-936. 
19. Aurigemma G, Silver KH, McLaughlin M, Mauser J, Gaasch WH. Impact of 
chamber geometry and gender on left ventricular function in patients with 
aortic stenosis. Am J Cardiol. 1994;74:794-798. 
20. Bonow RO, Carabello BA, Kanu C et al. ACC/AHA 2006 Guidelines for the 
management of patients with valvular heart disease: A report of the American 
College of Cardiology/ American Heart Association Task Force on Practice 
Guidelines: developed in collaboration with the Society of Cardiovascular 
Anaethsiologists: endorsed by the Society for Cardiovascular Angiography 
and the Society of Thoracic Surgeons. Circulation. 2006;114:e84-231. 
21. Connolly HM, Oh JK, Orszulak TA at al. Aortic valve replacement for aortic 
stenosis with severe left ventricular dysfunction: prognostic indicators. 
Circulation. 1997;95:2395-2400. 
  
Page 8-249 
 
22. Bell GI, Buse JB, Burant CF, Takeda J, Lin D, Fukomoto H, Seino S. 
Molecular Biology of mammalian glucose transporters. Diabetes Care. 
1990;13:198-208. 
23. James DE, Strube M, Mueckler M. Molecular cloning and characterisation of 
an insulin regulatable glucose transporter. Nature. 1989;338:83-87. 
24. Ren-fu Y, Hu X, Russel R, Young L. Translocation of glucose transporter 
isoforms in vivo: effects of hyper-insulinemia and low flow ischemia in the 
canine heart. Circulation. 1995;1995(92):I760-769. 
25. Sun D, Nguyen N, Degrado TJ, Schwaiger M, Brosius FC. Ischemia induces 
translocation of the insulin responsive glucose transporter GLUT4 to the 
plasma membrane of cardiac myocytes Circulation 1994;89(793-8). 
26. Slot JW, Geuze HJ, Gigengack S, James DE, Lienhard GE. Translocation of 
the glucose transporter GLUT4 in cardiac myocytes of the rat. Proc Natl Acad 
Sci USA. 1991;88:71815-71819. 
27. Stryer L, ed. Biochemistry. 3rd ed. New York: W.H. Freeman; 1988. 
28. Manchester J, Kong X, Nerbonne J, Lowry OH, Lawrence JC. Glcuose 
transport and phosphorylation in single cardiac myocytes: rate limiting step in 
glucose metabolism. Am J Physiol. 1994;266:E326-333. 
29. Kashiway Y, Sato K, Tsuchiya N, Thomas S, Fell DA, Veech RL, Passonneau 
JV. Control of glucose utilization in working perfused rat hearts. J Biol Chem. 
1994;269:25502-25514. 
30. Depre C, Rider MH, Veitch K, Hue L. Role of fructose 2,6,-bisphosphate in 
the control of heart glycolysis. J Biol Chem. 1993;269:13274-13279. 
31. Hue L, Depre C, Lefebvre V, Rider MH, Veitch K. Regulation of glucose 
metabolism in cardiac muscle Biochem Soc Trans. 1995;23:311-314. 
32. Kobayashai K, Lamberton WF, Neely JR. Control of maximum rates of 
glycolysis in rat cardiac muscle. Circ Res. 1979;44:166-175. 
33. Rovetto MJ, Lamerton WF, Neely JR. Mechanism of glycolytic inhibition in 
ischemic rat hearts. Circ Res. 1975;37:742-751. 
34. Jeremy RW, Koretsune Y, Marban E, Becker LC. Relationship between 
glycolysis and and calcium homeostasis in post ischemic myocardium. Circ 
Res. 1992;70:1180-1190. 
  
Page 8-250 
 
35. Kusoka H, Marban E. Mechanism of diastolic dysfunction induced by 
glycolytic inhibition J Clin Invest. 1994;93:1216-1223. 
36. Weiss J, Hilderbrand B. Functional compartmentation of glycolytic versus 
oxidative metabolism in isolated rabbit heart. J Clin Invest. 1985;75:436-447. 
37. Weiss J, Lamp ST. Cardiac ATP-sensitive K+ channels.  Evidence for 
preferential regulation by glycolysis. J Gen Physiol. 1989;94(911-935). 
38. Goudemant JF, Brodure G, Mottet I, Demure R, Melin JA et al. ATPase 
abolishes the protection afforded by glycolysis against myocardial ischemic 
injury. Circulation. 1995;92:631-635. 
39. Alonso MD, Lomako J, Lomako W, Whelan WM, Whelan WJ. A new look at 
the biogenesis of glycogen. FASEB. 1995;9:1126-1137. 
40. Das I. Effects of heart work and insulin on glycogen metabolism in the 
perfused rat heart. Am J Physiol. 1973;224:7-12. 
41. Goodwin GW, Arteaga JR, Taegtmeyer H Glycogen turnover in the isolated 
working rat heart. J Biol Chem. 1995;270:9234-9240. 
42. Henning SL, Wambolt RB, Schonekess R, Lopaschuk GD, Allard MF. 
Contribution of glycogen to aerobic myocardial glucose utilisation. Circulation. 
1996;93(1549-1555). 
43. Vane der Vusse GJ, Renemans RS. Glycogen and lipds (endogenous 
substrates). New York: Wiley; 1983. 
44. Wisneski JA, Gertz EW, Neesa RA, Gruenke LD, Morris DL, Craig JC. 
Metabolic fate of extracted glucose in normal human myocardium. J Clin 
Invest. 1985;76:1819-1827. 
45. Gertz EW, Wisneski JA, Stanley WC, Neese RA. Myocardial substrate 
utilization during exercise in humans: dual carbon-labelled carbohydrate 
isotope experiments. J Clin Invest. 1988;82:2017-2025. 
46. Stanley WC. Myocardial lactate metabolism during exercise. Med Sci Sport 
Exerc. 1991;23:920-924. 
47. Randle PJ. Fuel selection in animals. Biochem Soc Trans. 1986;14:799-806. 
48. Kerbey AL, Randle PJ, Cooper RH, Whitehouse S, Pask HT, Denton RM. 
Regulation of pyruvate dehydrogenase. Biochem J. 1976;154:327-348. 
  
Page 8-251 
 
49. Randle PJ, Hales CN, Garland PB, Newsholme EA. The glucose fatty-acid 
cycle.  Its role in insulin sensitivity and the metabolic disturbance of diabetes 
mellitus. Lancet. 1963;iii:785-789. 
50. Randle PJ, Garland PB, Newsholme EA. Regulation of glucose uptake by 
muscle.  Effects of fatty acids, ketone bodies and pyruvate, and of alloxan 
diabetes and starvation, on the uptake and metabolic fate of glucose in rat 
heart and diaphragm muscles. Biochem J. 1964;93:652-665. 
51. Hansford RG, Cohen L. Relative importance of pyruvate dehydrogenase 
interconversion on the feedback inhibition in the effect of fatty acids on 
pyruvate oxidation by rat heart mitochondria. Arch Biochem Biophys. 
1978;143:593-601. 
52. Higgins AJ, Morville M, Burges RA, Gardiner DG, Page MG, Blackburn KJ. 
Oxfenicine diverts rat muscle metabolism from fatty acid to carbohydrate 
oxidation and protects the ischemic rat heart. Life Sci. 1980;27:963-970. 
53. Korge P, Honda H, Weiss JN. Effects of fatty acids in isolated mitochondria: 
implications for ischemic injury. Am J Physiol Heart Physiol J. 2003;285:259-
269. 
54. Bittl JA, Westfeldt ML, Jacobus WE. Creatine kinase of heart mitochondria.  
The progressive loss of enzyme activity during in vivo ischemia and its 
correlation to depressed myocardial function. J Biol Chem. 1985;260:208-
214. 
55. Rong T, Ingwal JS. The molecular energetics of the failing heart from animal 
studies. Heart Failure Reviews. 2004;4:245-253. 
56. Nakae I, Mitsunami K, Omura T, Yabe T, Tsutamuto T, Matsuo S et al. Proton 
magnetic resonance spectroscopy can detect creatine depletion associated 
with the progression of heart failure. J Am Coll Cardiol. 2003;42:1587-1593. 
57. Conway MA, Allis J, Ouwerkerk R, Niioka T, Rajagopalan B, Radda GJ. 
Detection of low phosphocreatinine to ATP ratio in failing hypertrophied 
human myocardium by 31P magnetic resonance spectroscopy. Lancet. 
1991;338:973-976. 
58. Neubauer S. The failing heart: an engine out of fuel. NEJM. 2007;356:1140-
1151. 
  
Page 8-252 
 
59. Hardie DG, Carling D. The AMP-activated protein kinase - fuel gage of the 
mammalian cell? Eur J Biochem. 1997;246:259-273. 
60. Young LH, Li J, Baron SJ, Russel RR. AMP-activated protein kinase: a key 
stress signalling pathway in the heart. Trends Cardiovasc Med. 2005;15:110-
118. 
61. Kudo N, Barr AJ, Barr RL, Desai S, Lopaschuk GD. High rates of fatty acid 
oxidation during reperfusion of ischemic hearts are associated with decrease 
in malonyl CoA levels due to an increase in 5'-AMP activated protein kinase 
inhibition of acetyl-CoA carboxylase. J Biol Chem. 1995;270:17513-17520. 
62. Kudo N, Gillespie JG, Kung L, Witters LA, Lopashuk GD. Characterisation of 
5'-AMP-activated protein kinase activity in the heart and its role in inhibiting 
acetyl-CoA carboxylase during reperfusion following ischemia. Biochem 
Biophys Acta. 1996;1301:67-75. 
63. Marsin AS, Bertrand L, Rider MH, Deprez J, Beauloye C, Vincent MF, Van 
der Berghe G, Carling D, Hue L. Phosphorylation and activation of heart PFK-
2 by AMPK has a role in the stimulation of glycolysis during ischemia. Curr 
Biol. 2000;10:1247-1255. 
64. Carling D, Clarke P, Zammit V, Hardie D. Purification and characterisation of 
the AMP-activated protein kinase Eur J Biochem. 1989;186:129-139. 
65. Stanley WC, Recchia FA, Lopaschuk GD. Myocardial substrate metabolism in 
the normal and failing heart. Physiol Rev. 2005;85:1093-1129. 
66. Hein S, Arnon E, Kostin S et al Progression from compensated hypertrophy to 
failure in the pressure overload human heart; structural deterioration and 
compensatory mechanisms. Circulation. 2003;107(984-91). 
67. Sabbah HN, Sharov VG, Lesch M, Goldstein S. Progression of heart failure: A 
role for interstitial fibrosis. Mol Cell Biochem. 2005;147:29-34. 
68. Kupari M, Turto H, LommiJ. Left ventricular hypertrophy in aortic valve 
stenosis: preventative or promotive of systolic dysfunction and heart failure. 
Eur Heart J. 2005;26:1790-1796. 
69. Wallus TR, Taylor M, DeGrado TR, Russel DC, STanko P et al. Myocardial 
free fatty acid and glucose use after Carvedilol treatment in patients with 
congestive heart failure. Circulation. 2001;103:2441-2446. 
  
Page 8-253 
 
70. Liedtke AJ. Alterations of carbohydrate and lipid metabolism in the acuteli 
ischemic heart. Prog Cardiovasc Dis. 1981;23:321-336. 
71. Beer M, Seyfarth T, Sandstede J, Landschutz W, Lipke C, Kostler H et al. 
Absolute concentrations of high energy phosphate metabolites in normal 
hypertrophied and failing human myocardium measured non-invasively with 
(31) SLOOP magnetic resonance spectrscopy. J Am Coll Cardiol. 
2002;40:1267-1274. 
72. Ingwall JS, Kramer MF, Fifer MA,Lorell BH, Shemin W, Grossman W, Allen 
PD. The creatine kinase system in normal and diseased human myocardium. 
N Engl J Med. 1985;313:1050-1054. 
73. Shen W, Asai K, Uechi M, Mathier M, Shannon R, Vatner SF, Ingwall JS. 
Progressive loss of myocardial ATP due to loss of total purines during the 
development of heart failure. Circulation. 1999;100:2113-2118. 
74. Ingwall JS, Weiss RG. Is the failing heart energy starved? On chemical 
energy to support cardiac function. Circ Res. 2004;95(2):135-145. 
75. Sack MN, Rader TA, Park S, Bastin J, McCune SA, Kelly DP. Fatty acid 
oxidation enzyme gene expression is donwnregulated in the failing heart. 
Circulation. 1996;94:2837-2842. 
76. Razeghi P, Young ME, Alcorn JL, Moravec CS, Frazier OH, Taegtmeyer H. 
Metabolic gene expression in fetal and failing human heart. Circulation. 
2001;104:2923-2931. 
77. Opie LH, Thandroyen FT, Muller C, Bricknell OL. Adrenaline induced oxygen 
wastage and enzyme release from working rat heart.  Effects of calcium 
antagonism, beta-blockade, nicotinic acid and coronary ligation. J Mol Cell 
Cardiol. 1979;11(10):1073-1094. 
78. Mjos OD, Bugge Asperheim B, Kiil F. Factors determining myocardial oxygen 
consumption during elevation of aortic blood pressure. Relationship with free 
fatty acids. Cardiovasc Res. 1972;6(1):23-27. 
79. How OJ, Aasum E, Severson DL, Chan WYA. Increased myocardial oxygen 
consumtion reduces cardiac efficiency in diabetic mice. Diabetes. 
2006;55(2):466-473. 
  
Page 8-254 
 
80. Korvald C, Elvenes OP, Myrmel T. Myocardial substrate metabolism 
influences left ventricular energetics in vivo. Am J Physiol Heart Physiol J. 
2000;278(4):1345-1351. 
81. Boudina S, Abel ED. Mitochondrial uncoupling: a key contributor to reduced 
cardiac efficiency in diabetes. Physiology 2006;21:250-258. 
82. Brand MD, Esteves TC. Physiological functions of the mitochondrial 
uncoupling proteins UCP2 and UCP3. Cell metabolism. 2005;5(2):85-93. 
83. Murray AJ, Anderson RE, Watson GC, Radda GK, Clarke K. Uncoupling 
proteins in the human heart. Lancet. 2005;364(9447):1786-1788. 
84. Lydell CP, Chan A, Wambolt RB, Sambanadam N, Parsons H, Bondy GP, 
Rodrigues B, Popov KM, Harris RA, Brownsley RW, Allard MF. Pyruvate 
dehydrogenase and the regulation of glucose oxidation in hypertrophied rat 
hearts. Cardiovasc Res. 2002;53:841-851. 
85. Seymour AM, Chatham JC. The effects of hypertrophy and diabetes on 
cardiac pyruvate dehydrogenase activity. J Mol Cell Cardiol. 1997;29:2771-
2778. 
86. Paternostro G, Pagano D, Gnecchi-Ruscone T, Bonser RS, Camici PG. 
Insulin resistance in patients with cardiac hypertrophy. Cardiovasc Res. 
1999;42(1):246-253. 
87. Friddle CJ, Koga T, Rubin EM, Bristow J. Expression profiling reveals a 
distinct set of genes altered during induction and regression of cardiac 
hypertrophy. Proc Natl Acad Sci USA. 2000;97:6745-6750. 
88. Razeghi P, Young ME, Alcorn JL, Moravec CS, Frazier OH, Taegtmeyer H. 
Metabolic gene expression in fetal and failing human heart. CIrculation. 
2001;11:2922-2931. 
89. Wagner A, Tabibiazar R, Powers J, Bernstein D,, Quertermous T Genome 
wide expression profiling of a cardiac pressure overload model identifies 
major metabolic signaling pathway responses. J Mol Cell Cardiol. 
2004;37:1159-1170. 
90. Guth BD, Wisneski JA, Neese RA, White FC, Heusch G, Mazer CD. 
Myocardial lactate release during ischemia in swine.  Relation to regional 
blood flow. Circulation. 1990;1990(81). 
  
Page 8-255 
 
91. Marshall RC, Nash WW, Shine KI, Phelps ME, Ricchiuti N. Glucose 
metabolism during ischemia due to excessive oxygen demand or altered 
coronary flow in the isolated arterially perfused rabbit septum. Circ Res. 
1981;49:640-648. 
92. Pantely GA, Malone SA, Rhen WS, Anselone CG et al. Regeneration of 
myocardial phosphocreatine in pigs despite continued moderate ischemia. 
Circ Res. 1990;67:1481-1493. 
93. Stanley WC, Lopaschuk GD, Hall JL, McCormack JG. Regulation of 
myocardial carbohydrate metabolism under normal and ischemic conditions: 
Potential for pharmacological interventions. Cardiovasc Res. 1997;33:243-
257. 
94. Stanley WC, Hernandez LA, Spires DA, Bringas J, Wallace S, McCormack 
JG. Pyruvate dehydrogenase activity and malonyl CoA levels in normal and 
ischemic swine myocardium: Effect of dichloroacetate. J Mol Cell Cardiol. 
1996;28:905-914. 
95. Hoffman JIE. Transmural myocardial perfusion Prog Cardiovasc Dis. 
1987;29:429-464. 
96. Dieterle F, Ross A, Schlotterbeck G, Senn H. Probabilistic quotient 
normalization as robust method to account for dilution of complex biological 
mixtures. Application in 1H NMR metabonomics. Anal Chem. 
2006;78(13):4281-4290. 
97. Van der Vusse GJ, Arts T, Glatz JFC, Reneman RS. Transmural differences 
in energy metabolism of the left ventricular myocardium: fact or fiction? J Mol 
Cell Cardiol. 1990;22:23-37. 
98. Stanley WC, Hall JL, Stone CK, Hacker TA. Acute myocardial ischemia 
causes a transmural gradient in glucose extraction but not glucose uptake. 
Am J Physiol. 1992;262:91-96. 
99. Dennis SC, Gevers W, Opie LH. Protons in ischemia: Where do they come 
from; where do they go to? J Mol Cell Cardiol. 1991;23:1077-1086. 
100. Lazdunski M, Frelin C, Vigne P. The sodium/hydrogen exchange system in 
cardiac cells: Its biochemical and pharmacological properties and its role in 
regulating internal concentrations of sodium and internal pH. J Mol Cell 
Cardiol. 1985;17:1029-1042. 
  
Page 8-256 
 
101. Cross HR, Lu L, Steenbergen C, Philipson KD, Murphy E. Overexpression of 
the cardiac Na+/Ca2+ exchanger increases susceptibility to 
ischemia/reperfusion injury. Circ Res. 1998;83:1215-1223. 
102. Lopaschuk GD, Wambolt RB, Barr RL. An imbalance bewteen glycolysis and 
glucose oxidation is a possible explanation for the detrimental effects of high 
levels of fatty acids during aerobic perfusion of ischemic hearts. J Pharmacol 
Exp Ther. 1993;264:135-144. 
103. Liu B, Talibi ZA,Clanachan AS, Schultz R, Lopaschuk GD. Uncoupling of 
contractile function from mitochondria TCA cycle activity and oxygen 
consumption during reperfusion of ischemic rat hearts. Am J Physiol. 
1996;270:72-80. 
104. Lerch R, Tamm C, Papageogiou I, Benzi RH, . Myocardial fatty acid oxidation 
during ischemia and reperfusion. Mol Cell Biochem. 1992;116:103-109. 
105. Lewandowski ED, White LT. Pyruvate dehydrogenase influences 
postischemic heart function. Circulation. 1995;91:2071-2079. 
106. Lopaschuk GD, Spafford M, Davies NJ, Wall SR. Glucose and palmitate 
oxidation in isolated working rat hearts perfused after a period of global 
transient ischemia. Circ Res. 1990;66:546-553. 
107. Liedtke AJ, DeMaison L, Eggleston AM, Cohen LM, Nellis SH. Changes in 
substrate metabolism and effects of excess fatty acids in reperfused 
myocardium. Circ Res. 1988;62:535-542. 
108. Saddik M, Lopaschuk GD. Myocardial triglyceride turnover during reperfusion 
of isolated rate hearts subjected toa transient period of global ischemia. J Biol 
Chem. 1992;267:3825-3831. 
109. Schwaiger M, Lopaschuk GD. Sustained nonoxidative glucose utilisation and 
depletion of glycogen in reperfused canine myocardium. J Am Coll Cardiol. 
1989;13:745-754. 
110. Allard MF, Schonekess BO, Henning SL, English DR, Lopaschuk GD. 
Contribution to oxidative metabolism and glycolysis to ATP production in 
hypertrophied hearts. Am J Physiol. 1994;267(742-750). 
111. Opie LH, ed. The Heart: Physiology and metabolism. New York; 1991. 
  
Page 8-257 
 
112. Russel RR, Li J, Coven DL, Pypaert M, Zechner C, Palmeri M, Gioradano FJ. 
AMP-activated protein kinase mediates glucose uptake and prevents post 
ischemic injury. J Clin Invest. 2004;114:495-463. 
113. Baron SJ, Russel RR III, Neuman D, Miller EJ, Tuerk R, Walliman T et al. 
Dual mechanisms regulating AMP Kinase action in the ischemic heart. Circ 
Res. 2005;96:337-343. 
114. Depre C, Wang L, Sui X, Hong C, Hedhli N, Ginion A, Shah A et al. H11 
kinase prevents myocardial infarction by preemptive preconditioning of the 
heart. Circ Res. 2006;98:280-288. 
115. Nishino Y, Miura T, Miki T, Sakamoto J,Ikeda Y, Kobayashi H, Shimamoto K. 
Ischemic preconditioning activates AMPK in a PKC-dependent manner and 
induces GLUT4 upregulation in the late phase of cardioprotection. Cardiovasc 
Res. 2004;61:610-619. 
116. Sukhodub A, Jovanovic S, Du Q, et al. AMP-activated protein kinase 
mediates preconditioning in cardiomyocytes by regulating activity and 
trafficking of sarcolemmal ATP-sensitive K channels. J Cell Physiol. 
2007;210:224-236. 
117. Harper IS, Lochner A. Sarcolemmal integrity during ischemia and reperfusion 
of isolated rat heart. Basic Res Cardiol. 1989;84:208-212. 
118. Bladergroen MR, Takei H, Christopher TD, Cummings RD, Blanchard SM, 
Lowe JE. Accerlerated transmural gradients of energy compound metabolism 
resulting from left ventricular hypertrophy. J Thorac Cardiovasc Surg. 
1990;100:506-512. 
119. Martin AM, Hackel DB. An electron microscopy study of the progression of 
myocardial lesions in the dog after haemorrhage shock. Lab Invest. 
1966;15:243-249. 
120. Ambrosio G, Weisfeldt ML, Jacobus WF, Flaherty JT. Evidence for a 
reversible oxygen radical mediated component of reperfusion injury: 
Reduction by recombinant human superoxide dismutase administered at the 
time of reflow. Circulation. 1987;75:282-289. 
121. Griffiths EJ, Halestrap AP. Mitochondrial non-specific pores remain closed 
during cardiac ischemia but open upon reperfusion. Biochem J. 1995;307:93-
98. 
  
Page 8-258 
 
122. Juhaszova M, Zorov DB, Yaniv Y, Nuss B, Wand S, Sollot SJ. Role of 
Glycogen Synthase Kinase 3B in cardioprotection. Circ Res. 2009;104:1240-
1252. 
123. Brady NR, Elmore SP, van Beck JJ, Krab K et al. Coordinated behaviour of 
mitochondria in both space and time: a reactive oxygen species activated 
wave of mitochondrial depolarization. Biophys J. 2004;87:2022-2034. 
124. Zorov DB, Filburn CR, Klotz LO, Zweier JL, Sollot SJ. Reactive oxygen 
species (ROS) induced ROS release: a new phenomenon accompanying 
induction of the mPTM in cardiac myocytes. J Exp Med. 2000;192:1001-1014. 
125. Akar FG, Aon MA, Tomaselli GF, O'Rourke B. The mitochondrial origin of 
postischemic arrhthymias J Clin Invest. 2005;2005(115):3527-3535. 
126. Aon MA, Cortossa S, Akar FG, O'Rourke B. Mitochondrial criticality: a new 
concept in the turning point of life and death. Biochem Biophys Acta. 
2006;1762:232-240. 
127. Halestrap AP, Clarke SJ, Javadov SA,. Mitochondrial permeability transition 
pore opening during myocardial reperfusion - a target for cardioprotection. 
Cardiovasc Res. 2004;61:372-385. 
128. Murray CE, Jenning RB, Reimer KA. Preconditioning with ischemia: a delay 
of lethal cell injury in ischemic myocardium. Circulation. 1986;74:1124-1136. 
129. Zhao ZQ, Corvera JS, Halkos ME, Kerendi F, Wang NP, Guyton RA, 
Johansen JV. Inhibition of myocardial injury by ischemic post conditioning 
during reperfusion: comparison with preconditioning Am J Physiol Heart Circ 
Physiol. 2003;285:579-588. 
130. Yellon DM, Downey JM. Preconditioning the myocardium: from cellular 
physiology to clinical cardiology. Physiol Rev. 2003;83:113-151. 
131. Cohen MV, Yang XM, Downey JM. The pH hypothesis of postconditioning: 
staccato  reperfusion reintroduces oxygen and perpetuates myocardial 
acidosis. Circulation. 2007;115:1895-1903. 
132. Rylatt DB, Aitken A, Bilham T, Condon GD, Embi N, Cohen P. Glycogen 
synthase from rabbit skeletal muscle. Amino acid sequence at the sites 
phosphorylated by GSK-3. Eur J Biochem. 1980;107:529-537. 
  
Page 8-259 
 
133. Tong H, Imahashi K, Steenbergen C, Murphy E. Phosphorylation of GSK-3B 
during preconditioning through a phosphatidylinositol-3-kinase dependent 
pathway is cardioprotective. Circ Res. 2002;90:377-379. 
134. Kaga S, Zhan L, Altaf E, Maulik N GSK-3B promotes angiogenic and anti-
apoptotic signaling through the induction of VEGF, Bcl-2 and survivin 
expression in rat ischemic preconditioned myocardium. J Mol Cell Cardiol. 
2006;40:138-147. 
135. Nishihara M, Miura T, Miki T, Sakamoto J, Tanno M et al. Erythropoietin 
affords additional cardioprotection to preconditioned hearts by enhancing 
phosphorylation of GSK-3B. Am J Physiol Heart Circ Physiol. 2006;291:748-
755. 
136. Gomez L, Paillard M, Thibault H, Derumeaux G, Ovize M. Inhibition of GSK-
3B by postconditioniong is required to prevent opening of the mitochondrial 
transition pore during reperfusion. Circulation. 2008;117:2761-2768. 
137. Gross ER, Hsu AK, Gross GJ. Opioid-induced cardioprotection occurs via 
GSK beta inhibition during reperfusion. Circ Res. 2004;94:960-966. 
138. Gross ER, Hsu AK, Gross GJ. The JAK/STAT pathway is essential for opiod 
induced cardioprotection: JAK2 as a mediator of STAT3, Akt and GSK-3beta. 
Am J Physiol Heart Circ Physiol. 2006;291:827-834. 
139. Feng J, Lucchinetti E, Ahuja P, Pasch T, Perriard JC, Zaugg M. Isoflurane 
postconditioning prevents opening of the mitochondrial permeability transition 
pore. Anaesthesiology. 2005;103:987-995. 
140. Toth A, Kovacs K, Deres P, Halmosi R, Czopf L et al. Impact of a novel 
cardioprotective agent on the ischemia-reperfusion induced Akt kinase 
activation. Biochem Pharmacol. 2003;66:2263-2272. 
141. Das S, Wong R, Rajapakse N, Murphy E Steenbergen C. Glycogen synthase 
kinase 3 inhibition slows mitochondrial adenine nucleotide transport and 
regulates voltage-dependent anion channel phosphorylation. Circ Res. 
2008;103:983-991. 
142. Marshall S, Bacote V, Traxinger RR. Discovery of a metabolic pathway 
mediating glucose induced desensitization of the glucose transport system.  
Role of hexosamine biosynthesis in the induction of insulin resistance. J Biol 
Chem. 1991;266:4706-4712. 
  
Page 8-260 
 
143. Kreppel LK, Hart GW. Regulation of cytosolic and nuclear O-GlcNAc 
transferase.  Role of the tetratricopeptide repeats. J Biol Chem. 
1999;274:32015-32022. 
144. Whelan SA, Lane MD, Hart GW. Regulation of the O-linked beta-N-
acetylyglucosamine transferase by insulin signalling. J Biol Chem. 
2008;283:21411-21417. 
145. Yang X, Ongusaha PP, Miles PD, Harvstad JD, et al. Phosphoinositide 
signalling links O-GlcNAc transferase to insulin resistance. Nature. 
2008;451:964-969. 
146. Laczy B, Hill BG, Wang K, Paterson AJ, White CR, Xing D, Chen YF, Darley-
Usmar V, Oparil S, Chatham JC. Protein O-GlcNAcylation: a new signalling 
paradigm for the cardiovascular system. Am J Physiol Heart Circ Physiol. 
2009;296:13-28. 
147. Zachara NE, O'Donell N, Cheung WD, Mercer JJ, Marth JD, Hart GW. 
Dynamic O'GlcNAc modifiaction of nucleocytoplasmic proteins in response to 
stress.  A survival response of mammalian cells. J Biol Chem. 
2004;279:30133-30142. 
148. Fulop N, Zhang Z, Marchase RB, Chatham JC. Glucosamine cardioprotection 
in perfused rat hearts associated with increased O-linked N-
acetylyglucosamine protein modification and altered p38 activity. Am J 
Physiol Heart Circ Physiol. 2007;292:H2227-2236. 
149. Liu J, Marchase RB, Chatham JC. Glutamine induced protection of isolated 
rat heart from ischemia/reperfusion injury is mediated via the hexosamine 
biosynthesis pathway and increased protein O-GlcNAc levels. J Mol Cell 
Cardiol. 2007;42:177-185. 
150. Walgren JL, Vincent TS, Schley KL, Bruse MG. High glucose and insulin 
promote O-GlcNAc modification of proteins including alpha tubulin. Am J 
Physiol Endocrinol Metab. 2003;284:424-434. 
151. Jones SP, Zachara NE, Ngoh GA, Hill BG, Teshimay Y, Bhatnagar A, Hart 
GW, Marban E. Cardioprotection by N-acetylglucosamine linkage to cellular 
proteins. Circulation. 2008;117:1172-1182. 
  
Page 8-261 
 
152. Ngoh GA, Watson LJ, Facundo HT, Dillman W, Jones SP Non-canonical 
glycosyltransferase modulates post hypoxic cardiac myocyte death and 
mitochondrial permeability transition. J Mol Cell Cardiol. 2008;45:313-325. 
153. Wells L, Hart GW. Proteomic approaches to analyze the dynamic relationship 
bewteen nuclocytoplasmic protein glycosylation and phosphorylation. Circ 
Res. 2003;93:1047-1058. 
154. Laczy B, Wilson L, Brocks CA, Marchase RB, Chatham JC. Effects of 
ischemia-reperfusion on O-GlcNAcylation of specific proteins in isolated rat 
hearts. FASEB. 2008;22:750-759. 
155. Liu J, Marchase RB, Chatham JC. Increased O-GlcNAc levels during 
reperfusion leads to improved functional recovery and reduced calpain 
proteolysis. Am J Physiol Heart Circ Physiol. 2007;293:H1391-1399. 
156. Du XL, Edelstein D, Dimmler S, Ju Q, Sui C, Brownlee M. Hyperglycaemia 
inhibits endothelial nitic oxide synthase activity by post translational 
modification of the Akt site. J Clin Invest. 2001;108:1341-1348. 
157. Fulop N, Marchase RB, Chatham JC. Role of protein O-linked N-acetyl-
glucosamine in mediating cell function and survival in the cardiovascular 
system. Cardiovasc Res. 2007;73:288-297. 
158. Buckerberg GD, Brazier JR, Nelson RL et al. Studies of the effects of 
hypothermia on regional myocardial blood flow and metabolism during 
cardiopulmonary bypass. I. The adequately perfused beating, fibrillating and 
arrested heart. J Thorac Cardiovasc Surg. 1977;73:87-94. 
159. Melrose DG, Dreyer B, Bentall HH et al. Elective cardiac arrest. Lancet. 
1955;266:21-22. 
160. Sealy WC, Young WG Jr, Brown IR Jr, et al. Potassium, magnesium and 
neostigmine for controlled cardioplegia; studies on the dog using 
extracorporeal circulation and hypothermia. AMA Arch Surch. 1958;77:33-38. 
161. Gay WA, Ebert PA. Functional, metabolic and morphological effects of 
potassium induced cardioplegia. Surgery. 1973;74:284-290. 
162. Hearse DJ, Stewart DA, Baimbridge MV. Cellular protection during 
myocardial ischemia: the development and characterization of a procedure for 
the induction of reversible ischemic arrest. Circulation. 1976;54:193-202. 
  
Page 8-262 
 
163. Follette DM, Mulder DG, Maloney JV et al. Advantages of blood cardioplegia 
over continuous coronary perfusion or intermittent ischemia.  Experimental 
and clinical study. J Thorac Cardiovasc Surg. 1978;58:1200-1209. 
164. Follette DM, Steed DL, Foglia R et al. Advantages of intermittent blood 
cardioplegia over intermittent ischemia during prolonged hypothermic aortic 
clamping. Circulation. 1978;58:I200-209. 
165. Ascione R, Suleiman SM, Angelini GD. Retrograde hot shot cardioplegia in 
patients with left ventricular hypertrophy underoing aortic valve replacement 
Ann Thorac Surg. 2008;85:454-458. 
166. Friehs I, del Nido PJ. Increased susceptibility of hypertrophied hearts to 
iscemic injury. Ann Thorac Surg. 2003;75:678-684. 
167. Gaasch WH, Zile MR, Hoshino PK, Weinberg EO et al. Tolerance of the 
hypertrophic heart to ischemia: studies in compensated and failing dog hearts 
with pressure overload hypertrophy. Circulation. 1990;81:1644-1653. 
168. Taegtmeyer H, Golfman L, Sharma S, Razeghi P. Linking gene expression to 
dunction: metabolic flexibility in the normal and diseased heart. Ann NY Acad 
Sci. 2004;1015:202-213. 
169. Friehs I, Cao-Danh H, Nthan M, McGowan FX, del Nido PJ. Impaired insulin 
signalling in hypertrophied hearts contributes to increased susceptibility to 
ischemic injury Biophys Res Comm. 2005;331:15-22. 
170. Allard MF. Energy substrate metabolism in cardiac hypertrophy. Curr 
Hypertens Rev. 2004;6:430-435. 
171. Allard MF, Henning SL, Wambolt RB, Granleese SR, English DR, Lopaschuk 
GD. Glycogen metabolism in the aerobic hypertrophied rat heart. Circulation. 
1997;96:676-682. 
172. Soldi-Pallares D, Testelli MR, Fishler BL. Effects of intravenous infusion of 
potassium-glucose-insulin solution on the electrocardiographic signs of 
myocardial infarction. Am J Cardiol. 1962;9:166-181. 
173. Iyengar SRK, Charette JP, Iyengar CKS, Wasan S. Myocardial glycogen in 
prevention of perioperative ischemia injury of the heart. Can J Surg. 
1976;19:246-251. 
  
Page 8-263 
 
174. Neely JR, Morgan HE. Relationship between carbohydrate and lipid 
metabolism and the energy balance of heart muscle. Annu Rev Physiol. 
1974;36:413-459. 
175. Kantor PF, Dyck JR, Lopaschuk GD. Fatty acid oxidation in the reperfused 
ischemic heart. Am J Med Sci. 1999;318:3-14. 
176. Lolley DM, Ray JF, Myers WO, Tewsbury DA. Importance of preoperative 
myocardial glycogen levels in human cardiac preservation. J Thorac 
Cardiovasc Surg. 1978;78:678-687. 
177. Boehm EA, Jones BE, Radda GK, Veech RL, Clarke K. Increased uncoupling 
proteins and decreased efficiency in palmitate perfused rat heart. Am J 
Physiol. 2001;280(3):977-983. 
178. Apstein CS, Taegtmeyer H. Glucose-insulin-potassium in acute myocardial 
infarction: the time has come for a large prospective trial. Circulation. 
1997;96:1152-1156. 
179. Gamble J, Lopaschuk GD. Insulin inhibition of 5' adenosine monophosphate 
activated protein kinase in the heart results in activation of acetyl coenzyme A 
carboxylase and inhibition of fatty acid oxidation. Metabolism. 1997;46:1270-
1274. 
180. Jonassen AK, Sack MN, Mjos O, Yellon D. Myocardial protection by insulin at 
reperfusion requires early administration and is mediated via Akt and p70s6 
kinase cell-survival signalling. Circ Res. 2001;89:1191-1198. 
181. Fath-Ordoubadi F, Beatt KJ. Glucose-insulin-potassium therapy for treatment 
of acute myocardial infarction: an overview of randomised placebo-controlled 
trials. Circulation. 1997;96:1152-1156. 
182. Malmeberg K. Prospective randomised study of intensive insulin treatment on 
long term survival after acute myocardial infarction in patients with diabetes 
mellitus. BMJ. 1997;314:1512. 
183. Ceremuzynski L, Budaj A, Czepiel A et al. Low-dose glucose-insulin-
potassium is ineffective in acute myocardial infarction: results of a 
randomised multicentre Pol-GIK trial. Cardiovasc Drugs Ther. 1999;13:191-
200. 
  
Page 8-264 
 
184. Van DH, Trimmer JR, Ottervanger JP et al. Glucose-insulin-potassium and 
reperfusion in acute myocardial infarction: rationale and design of the 
Glucose-insulin-potassium Study 2 (GIPS-2). Am Heart J. 2005;2005(149). 
185. Diaz R, Paolasso EA, Piegas LS, Tajer CD, Moreno MG, Corvalan R, Isea 
JE, Romero G. The ECLA (Estudios Cardiologicos Lationamerica) 
Collaborative group: Metabolic modulation of acute myocardial infarction. 
Circulation. 1998;98:2227-2234. 
186. Malmberg K, Ryden L, Wedel H et al. Intense metabolic control by means of 
insulin in patients with diabetes mellitus and acute myocardial infarction 
(DIGAMI2). Eur Heart J. 2005;26(650-661). 
187. Van DH, Zilastra F, Hof AW et al. Glucose-insulin-potassium infusion in 
patients treated with primary angioplasty for acute myocardial infarction: the 
glucose-insulin-potassium study: a randomized trial. J Am Coll Cardiol. 
2003;42:784-791. 
188. Rasoul S, Ottervanger JP, Timmer JR et al. One year outcomes after 
glucose-insulin-potassium study II. Int J Cardiol. 2007;122:52-55. 
189. Group. TC-ET. Effect of Glucose-Insulin-Potassium Infusion on mortality in 
patients with acute ST-segment elevation myocardial infarction: The 
CREATE-ECLA Randomised controlled Trial. JAMA. 2005;293:437-446. 
190. Bothe W, Olschewaski M, Beyersdorf F, Doenst T. Glucose-insulin-potassium 
in cardiac surgery: A meta-analysis. Ann Thorac Surg. 2004;78:1650-1657. 
191. Lazar HL, Chipkin S, Philippides G et al Glucose-insulin-potassium solutions 
improve outcomes in diabetics who have coronary artery operations. Ann 
Thorac Surg. 2000;70:145-150. 
192. Lazar HL, Chipkin S, Fitzgerald CA et al. Tight glycaemic control in Diabetic 
coronary artery bypass graft patients improves perioperative outcomes and 
decreases recurrent ischemic events. Circulation. 2004;109:1497-1502. 
193. Rao V, Borger MA, Weissel RD et al. The insulin cardioplegia trial: myocardial 
protection for urgent coronary artery bypass grafting. J Thorac Cardiovasc 
Surg. 2002;123:928-935. 
194. Rao V, Borger MA, Weissel RD et al. Insulin cardioplegia for elective coronary 
artery bypass surgery. J Thorac Cardiovasc Surg. 2000;119:1176-1184. 
  
Page 8-265 
 
195. Brodin LA, Dahlgreen G, Ekestrom S et al. Influence of glucose-insulin-
potassium on left ventricular function during coronary artery bypass grafting. 
Scan J Thorac Cardiovasc Surg. 1993;27:27-34. 
196. Quinn DW, Pagano D, Bonser, Rooney SJ, Graham TR, Wilson IC, Keogh 
BE, Townend JN, Lewis ME, Nightingale P. Improved myocardial protection 
during coronary artery surgery with glucose-insulin-potassium:  A randomized 
controlled trial. J Thorac Cardiovasc Surg. 2006;131  34-42. 
197. Ranasinghe AM, McCabe CJ, Quinn DW, et al. How does glucose insulin 
potassium improve hemodynamic performance? Evidence for altered 
expression of beta-adrenergic receptor and calcium handling genes. 
Circulation. 2006;114:I239-244. 
198. Ranasinghe AM, Quinn D, Pagano D, et al. Glucose-insulin-potassium (GIK) 
and tri-iodothyronine individually improve hemodynamic performance and are 
associated with reduced troponin-I release after on-pump coronary artery 
bypass grafting. Circulation. 2006;114:245-250. 
199. Koskenkari JK, Kaukoranta PK, Kiviluoma KT et al. Metabolic and 
hemodynamic effects of high-dose insulin treatment in aortic valve and 
coronary surgery. Ann Thorac Surg. 2005;80:511-517 
 
200. Dunn WB, Bailey NJ, |Johnson HE. Measuring the metabolome: current 
analytical technologies. Analyst. 2005;4:605-625. 
201. Dunn WB, Ellis D. Metabolomics: current analytical platforms and 
methodologies. Trends Anal Chem. 2005;4:285-294. 
202. Bracewell RN. The Fourier transform and its application. 3rd ed. Boston, 
USA: McGraw-Hill; 2000. 
203. Lewis GD, Asnani A, Gerszten RE. Application of metabolomics to 
cardiovascular biomarker and pathway discovery. J Am Coll Cardiol. 
2008;52(2):117-123. 
204. Van der Greef J, Stroobant P, Van der Heijen R. The role of analytical 
science in medical systems biology. Curr Opin Chem Biol. 2004;8:559-565. 
205. Devereaux RB, Reichek N. Echocardiographic determination of LV mass in 
man: anatomic validation of the method. Circulation. 1977;55:613-619. 
  
Page 8-266 
 
206. Devereaux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I. 
Echocardiographic assessment of left ventricular hypertrophy: comparison to 
necropsy findings. Am J Cardiol. 1986;57:450-458. 
207. Keogh BE, Kinsman R. National adult cardiac surgical database report 2003. 
Fifth ed: Henley on Thames: Dendrite Clinical Systems; 2003. 
208. Bridgewater B, Keogh BE, Kinsman R, Walton P. Sixth national adult cardiac 
surgical database report; 2008. 
209. Arnold JMO, Wynne J, Braunwald E et al Response of reperfusion-salvaged 
stunned myocardium to inotropic support. J Am Coll Cardiol. 1984;6:1026-
1034. 
210. Fremes SE, Tamariz MG, Abramov D et al. The influence of non-fatal cardiac 
events on late survival. Circulation. 2000;102:III339-345. 
211. Keogh BE. Society of cardiothoracic surgeons register. J Royal Coll Surg. 
2002;3:14-19. 
212. Muller M, Junger A, Brau M et al. Incidence and risk calculation of inotropic 
support in patients undergoing cardiac surgery with cardiopulmonary bypass. 
B J Anaesth. 2002;89:398-404. 
213. Wallace A, Lam HW, Nose PS, Bellows W, Magano DT. Changes in systolic 
and diastolic ventricular function with cold cardioplegic arrest in man. The 
Multicentre Study of Perioperative Ischeamia (McSPI) Research Group. J 
Cardiac Surg. 1994;9:497-502. 
214. Tulner SA, Klautz RJ, Rijk-Zwikker GL, Engbers FH, Baxx JJ et al. 
Perioperative assessment of left ventricular function by pressure volume 
loops using the conductance catheter method. Anaesth Analg. 2003;97:950-
957. 
215. McCulloch CE, Searle SR, ed. Generalized linear and mixed models. New 
York; 2001. 
216. Southam AD, Payne TG, Cooper HJ, Arvanitis TN, Viant MR. Dynamic Range 
and Mass Accuracy of Wide-Scan Direct Infusion Nanoelectrospray Fourier 
Transform Ion Cyclotron Resonance Mass Spectrometry-Based 
Metabolomics Increased by the Spectral Stitching Method. Anal. Chem. 
2007;79(12):4595-4602. 
  
Page 8-267 
 
217. Parsons HM, Ludwig C, Günther UL, Viant MR. Improved classification 
accuracy in 1- and 2-dimensional NMR metabolomics data using the variance 
stabilising generalised logarithm transformation. BMC Bioinformatics. 
2007;8:234. 
218. Taylor NS, Weber RJM, Southam AD, Payne TG, Hrydziuszko O, Arvanitis 
TN, Viant MR. A new approach to toxicity testing in Daphnia magna: 
application of high throughput FT-ICR mass spectrometry metabolomics. 
Metabolomics. In press. 
219. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, 
Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, 
Sutton MSJ, Stewart WJ. Recommendations for chamber quantification: a 
report from the American Society of Echocardiography's guidelines and 
standards committe and the chamber quantification writing group developed 
in conjunction with the European Association of Echocardiography, a branch 
of the European Society of Cardiology. J Am Soc Echocardiogr. 
2005;18:1440-1463. 
220. Taylor RW, Weber RJM, Southam AD, Viant MR. A new approach to toxicity 
testing: application of high throughput FT-ICR mass spectroscopy 
metabolomics. Metabolomics. 2008:In press. 
221. Finck BN, Kelly DP,. Peroxisome proliferator activated receptor gamma 
coactivator-1 (PGC-1) regulatory cascade in cardiac physiology and disease. 
Circulation. 2007;115:2540-2548. 
222. Ventura-Clapier R, Garnier A, Vekser V. Transcriptional control of 
mitochondrial biogenesis: the central role of PGC-1a. Cardiovasc Res. 
2008;79:208-217. 
223. Sihag S, Li AY, Cresci S, Lehman JJ, . PGC-1a and ERRa target gene 
downregulation is a signature of the failing heart. J Mol Cell Cardiol. 2008. 
224. Weiss RG, Gerstenlith G, Bottomley PA. ATP flux through creatinine kinase in 
the normal, stressed and failing human heart. Proc Natl Acad Sci USA. 
2005;102:808-813. 
225. Van BM, Smeets PJ, Gilde AJ. Metabolic remodelling of the failing human 
heart: the cardiac burn out syndrome? Cardiovasc Res. 2004;61:218-226. 
  
Page 8-268 
 
226. Degens H, de Brouwer KF, Gilde AJ et al. Cardiac fatty acid metabolism is 
preserved in the compensated hypertrophied rat heart. Basic Res Cardiol. 
2006;101:17-26. 
227. Leong HS, Browney RW, Kulpa JE, Allard MF. Glycolysis and pyruvate 
oxidation in cardiac hypertrophy - why so unbalanced? Comp Biochem 
Physiol A Mol Integr Physiol. 2003 135:499-513. 
228. Sorokina N, O'Donnell JM, McKinely RD, Pound KM, Wolderiorgis G. 
Recruitment of compensatory pathways to sustain oxidative flux with reduced 
APT-1 activity characterises inefficiency in energy metabolism in 
hypertrophied hearts. Circulation. 2007. 
229. Paternosto G, Clarke K, Heath J, Seymour AM, Radda GK. Decreased 
GLUT-4 mRNA content and insulin sensitive deoxyglucose uptake show 
insulin resistance in the hypertensive rat heart. Cardiovasc Res. 1995;30:205-
211. 
230. Debl K, Djavidani B, Bucner S et al. Delayed hyper-enhancment in magnetic 
resonance imaging of left ventricular hypertrophy caused by aortic stenosis 
and hypertrophic cardiomyopathy. Heart. 2006;92:1447-1451. 
231. Mervaala E, Biala A, Merasto S, Lempiainen, Mattila I, Martonen E, Eriksson 
O, Louhelainen M, Finckenberg P, Kaheinen P, Muller DN, Luft FC, Lapatto 
R, Oresic M Metabolomics in angiotensin II-induced cardiac hypertrophy. 
Hypertension. 2010;55:508-515. 
232. Kato T, Niizuma A, Inuzuka Y, et al. Analysis of metabolic remodelling in 
compensated left ventricular hypertrophy and heart failure. Circ Heart Fail. 
2010;3:420-430. 
233. Kloner RA, Przyklenk K, Kay GL. Clinical evidence for stunned myocardium 
after coronary artery bypass surgery. J Cardiac Surg. 1994;9:397-402. 
234. Stamm C, Friehs I, Cowan DB, Cao-Danh H, Choi YH, et al. Dopamine 
treatment of post-ischemic contractile dysfunction rapidly induces calcium 
dependent pro-apopotic signalling. Circulation. 2002;106:290-298. 
235. Nesher N, Alghamdi AA, Singh SK, Sever JY, Christakis GT, Goldman BS, 
Cohen GN, Moussa F, Fremes SE. Troponin after cardiac surgery: a predictor 
or phenomenon? Ann Thorac Surg. 2008;85:1348-1354. 
  
Page 8-269 
 
236. Fincke R, Hochman JS, Lowe A, Menon V, Slater JN, Webb JG, LeJemtel 
TH, Gotter G. Cardiac power is the strongest correlate of mortality: A report 
from the SHOCK trial registry. J Am Coll Cardiol. 2004;44:340-348. 
237. Bertrand L, Horman S, Beauloye, Vanoverschelde JL. Insulin signalling in the 
heart. Cardiovasc Res. 2008;79:238-248. 
238. Hausenloy DJ, Yellon DM. Reperfusion injury salvage kinase signalling: 
taking a RISK for cardioprotection. Heart Failure Reviews. 2007;12(3-4):1382-
4147. 
239. Oates A, Nubani R, Kistler L, Hughey S, Theiss P, Perez-TamayoRA, 
Eiferman D, Lonychyna V, Higgins RS. Myocardial protection of insulin and 
potassium in porcine ischemia-reperfusion model. Surgery. 2009;146:23-30. 
240. Wang Y, Gao E, Tao L,  Lau WB, Yuan Y, Goldstein BJ, Lopez BL, 
Christopher TA, Tian R, Koch W, Ma XL AMP-activated protein kinase 
deficiency enhances myocardial ischaemia/reperfusion injury but has minimal 
effect on the antioxidant/antinitrative protection of adiponectin. Circulation. 
2009;119:835-844. 
241. Beauloye C, Marsin AS, Bertrand L, Krause U, Hardie DG, Vanoverschelde 
JL, Hue L. Insulin antagonizes AMP-activated protein kinase activation by 
ischemia or anoxia in rat hearts, without affecting total adenine nucleotides. 
FEBS Lett. 2001;505:348-352. 
242. Kovacic S, Soltys CL, Barr AJ, Shiojima I, Walsh K,  Dyck JR. Akt activity 
negatively regulates phosphorylation of AMP-activated protein kinase in the 
heart. J Biol Chem. 2003;278:39422-39427. 
243. Horman S, Vertommen D, Heath R, Neuman D,  Mouton V, Woods A, 
Schlattner U, Walliman T, Carling D, Hue L, Rider MH. Insulin antagonizes 
ischemia-induced Thr172 phosphorylation of Ser485/491. J Biol Chem. 
2006;281:5335-5340. 
244. Folmes CD, Clanachan AS, Lopaschuk GD. Fatty acids attenuate insulin 
regulation of 5'-AMP-activated protein kinase and insulin cardioprotection 
after ischemia. Circ Res. 2006;99:61-68. 
245. Tian R, Balschi JA. Interaction of insulin and AMPK in the ischemic heart: 
another chapter in the book of metabolic therapy? Circ Res. 2006;99:3-5. 
  
Page 8-270 
 
246. Attarian DE, Jones RN, Currie WD, Hill RC, Sink JD, Chitwood WR, Wechsler 
AS. Characteristics of chronic left ventricular hypertrophy induced by 
subcoronary vavular aortic stenosis. II. Response to ischemia. J Thorac 
Cardiovasc Surg. 1981;81:389-395. 
247. Orsinelli DA, Aurigemma GP, Batista S, Kendel S, Gaasch WH. Left 
ventricular hypertrophy and mortality after aortic valve replacement for aortic 
stenosis: a high risk subgroup identified by preoperative wall thickness. J Am 
Coll Cardiol. 1993;5:811-826. 
248. Mehta RH, Ruckman D, Das S, Tsai T, Russman P, Karavite D, Monaghan H, 
Sonnad S, Shea MJ, Eagle KA, Deeb GM. Implications of increased left 
ventricular mass index on in-hospital outcomes in patients undergoing aortic 
valve surgery. J Thorac Cardiovasc Surg. 2001;122:919-928. 
249. Tomanek RJ, Palmer PJ, Peiffer GL, Schreiber KL, Eastham CL, Marcus ML. 
Morphometry of canine coronary arteries, arterioles, and capillaries during 
hypertension and left ventricular hypertrophy. Circ Res. 1986;58:38-46. 
250. Bache RJ, Vrobel TR, Ring WS, Emery RW, Anderson RW. Regional 
myocardial blood flow during exercise in dogs with chronic left ventricular 
hypertrophy. Circ Res. 1981;48:76-87. 
251. Murray AJ, Anderson RE, Watson GC, Radda GK, Clarke K. Uncoupling 
proteins in human heart. Lancet. 2004;364:1786-1788. 
252. Maganti M, Rao V, Borger MA, Ivanov J, David TE. Predictors of low cardiac 
ouput syndrome after isolated aortic valve surgery. Circulation. 
2005;112:I448-I452. 
253. Cohen G, Feder-Elituv R, Iazetta J, Bunting P, Mallidi H, Bozinovski J, 
Deemar C, Christakis GT, Cohen EA, Wong BI, McLean RD, Myers M, 
Morgan CD, Mazer CD, Smith TS, Goldman BS, Naylor CD, Fremes SE. 
Phase 2 studies of adenosine cardioplegia. Circulation. 1998;98:I225-233. 
254. Gradinac S, Coleman GM, Taegtmeyer H, Sweeny MS, Frazier OH. Improved 
cardiac function with GIK after aorto-coronary bypass grafting. Ann Thorac 
Surg. 1989;48:284-289. 
255. Feng J, Schaus BJ, Fallavollita JA, Lee TC, Canty J. Preload induces 
Troponin I degradation independently of myocardial ischemia. Circulation. 
2001;103:2035-2037. 
  
Page 8-271 
 
256. Ishihara M, Inoue I, Kawagoe T, Shimatani Y, Kurisu S, Nishioka K, Umemura 
T, Nakamura S, Yoshida M. Impact of acute hyperglycaemia on left 
ventricular function after reperfusion therapy in patients with a first anterior 
wall acute myocardial infarction. AHJ. 2003;146:674-678. 
257. Ishihara M, Kojima S, Sakamoto T, Asada Y, Tei C, Kimura K, Miyazaki S, 
Sonoda M, Tsuchihashi K, Yamagishi M, Ikeda Y, Shirai M, Hiraoka H, Inoue 
T, Saito F, Ogawa H. Acute hyperglycaemia is associated with adverse 
outcomes after acute myocardial infarction in the coronary intervention era. 
AHJ. 2005;150:814-820. 
258. Doenst T, Wijeysundera D, Karkouti K, Zechner C, Maganti M, Rao V, Borger 
MA. Hyperglycaemia during cardiopulmonary bypass is an independent risk 
factor for mortality in patients undergoing cardiac surgery. J Thorac 
Cardiovasc Surg. 2005;130:1144.e1141-e1148. 
259. Su H, Sun X, Zhang HF, Yu QJ, Huang C, Wang XM, Luan RH, Wang HC, 
Gao F. Acute hyperglycaemia exacerbates myocardial ischemia/ reperfusion 
injury and blunts cardioprotective effect of GIK. Am J Phsyiol Endocrinol 
Metab. 2007;293:E629-635. 
 
 
